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Day-case surgery has its origin more than 100 years ago. James H. Nicoll was the first 
surgeon who operated patients – i.c. children – on a day-case base.1 In 1909 he published 
his promising results on nearly 9,000 day-case surgical procedures.2 It took almost 50 
years before other results supported day-case surgery.3 From that point on, the use of 
day-case surgery gradually increased. In the USA elective surgery performed in a day-
case setting increased from 34% to 61% (1985 – 1994), while in the UK the increase 
was from 15% to 70% (1989 – 2003).4 Today, modern day-case surgery is continuously 
increasing worldwide because – among others – safety has further increased with 
anaesthetic and surgical advancements – even craniotomies for brain tumour resection 
have recently been performed in a day-case setting.5,6 
In day-case surgery patients are admitted and discharged on the day of surgery. A co-
founder of the International Association of Ambulatory Surgery proposed an internal 
definition of a surgical day case as follows: “A surgical day case is a patient who is 
admitted for investigation or operation on a planned non-residential basis and who 
nonetheless requires facilities for recovery. The whole procedure should not require an 
overnight stay in a hospital bed.”7
Day-case surgery is beneficial is many ways.4 A couple of them are outlined. From a 
financial point of view, day-case surgery is cost saving as patients are admitted and 
discharged on the day of surgery.4,8,9 As sooner recovery is normally achieved when 
compared to inpatient surgery, patient's return to normal activities including work will 
be sooner.4 From a health care point of view, day-case surgery is safe and reduction 
in surgical waiting lists may be achieved by the higher turnover.10,11 In addition, the 
scheduling can be more efficient as cancellation of surgical procedure due to for 
example an emergency procedure is rare.4 From a patient’s perspective, the disruption 
of normal daily living is minimised which is preferred by most patients.4 Furthermore, 
hospitalisation is avoided which reduces, for example, the risk of infection and 
thromboembolism as a result of bedridden.12,13 Besides these advantages, patients 
have less contact with health care professionals. Consequently, they have to manage 
a substantial part of their postoperative recovery in their home situation together with 
their social network. Therefore, selecting the right patient for day-case surgery requires 
a proper preoperative evaluation.
1.1. Preoperative evaluation
The preoperative evaluation of the patient is one of the main tasks of anesthesiologists. 
Adequate evaluation will lead to an appropriate selection of patients and preparation 
for the surgical procedure. Generally, the preoperative evaluation includes evaluation 
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of the physical status and evaluation of the psychological status.14 In day-case surgery, 
patients are normally physically well, and the evaluation of the psychological status is 
therefore of substantial interest. The psychological status could be influenced in either 
a psychologically or pharmacologically way which will be outlined below.
1.1.1. Psychological preparation
Psychological preparation is performed by nursing staff as well as by physicians. At nurs-
ing level, psychological preparation may include charts, videos, written and verbal in-
formation but should ensure the whole patient experience of the surgical episode.15 At 
physician level, psychological preparation is achieved by means of the preoperative visit 
and interview, and should include an explanation of the anticipated events together 
with the planned anesthetic regime.14 The preoperative interview is a powerful method 
that could enhance the apprehensive attitude of patients and reduction of anxiety.14 
However, unfortunately, psychological preparation is not always sufficient and anesthe-
siologists necessarily make use of pharmacological preparation.
1.1.2. Pharmacological preparation
Preoperative pharmacological preparation is usually referred as ‘premedication’. The 
main goal of premedication is to relief patients’ level of anxiety. In day-case surgery, 
premedication seems to be a suitable choice for preoperative preparation as patients 
are normally physically well and contraindications based on physiological reasons or 
morbidity reasons are rare. Utility of premedication is still inconclusive, however, and 
can even differ in an institution.16
The development of premedication has his roots in the early fifties. Laborit and 
Huguenard found that chlorpromazine depressed the central nervous system and 
it was therefore proposed as premedication. Accordingly, other psychopharmaca 
were introduced over the years. Although several preoperative drugs could serve as 
an appropriate premedication, the benzodiazepines have been generally used as 
premedication.14
The benzodiazepine history starts with the work done by Leo H Sternbach. In the early 
1930s, Sternbach worked with benzheptoxdiazines in order to find new dyestuffs at the 
University of Cracow, Poland. Although this was an unsuccessful story, he continued 
working with these compounds in the mid 1950s in order to find better tranquilizers.17 By 
chance, Sternbach and his coworkers found a compound that was superior to the existing 
tranquilizers. This compound had promising anxiolytic properties and was therefore 
introduced in 1960 under the trademark Librium, generic name Chlordiazepoxide, a 
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benzodiazepine nowadays.18 Accordingly, other benzodiazepines were introduced over 
the years. The benzodiazepine lorazepam was introduced in 1977.17
The clinical eff ects of benzodiazepines are predominantly a consequence of its action 
in the central nervous system (CNS). Specifi cally, they cause neural inhibition as they 
reinforce the eff ects performed by ɣ-aminobutyric acid (GABA).19 GABA is a prominent 
inhibitory neurotransmitter in the brain.20 Among others, GABA interacts with the GABAA 
receptor.20 The attachment of GABA to the GABAA receptor leads to an inward fl ow of 
chloride (Cl-) into the neuron inducing hyperpolarization of the neuronal membrane.20 
Consequently, the cell is robust for excitatory neurotransmitters.20 
Benzodiazepines attach to the GABAA receptor complex too, but need GABA for its 
performance – without GABA they cannot open the Cl- channel.21 Attachment of 
a benzodiazepine will lead to an increase of the chloride ion conductance of the 
postsynaptic membrane which will lead to inhibition of neuronal fi ring,19,22 Figure 
1. As benzodiazepines act predominantly on the GABAA receptor, they are barely 
toxic for other organs outside the CNS, e.g. respiratory and cardiovascular system, 
especially with dosages used for premedication purposes.14 This is one of the reasons 
why benzodiazepines are among the most popular drugs used for premedication.14 
Therefore, this thesis focuses on benzodiazepines.
FIGURE 1 | Schematic illustration of the eff ect of the attachment of benzodiazepines to the 
GABAA receptor complex
Abbreviations: Cl- = chloride; BZD = benzodiazepine; GABA = gamma-aminobutyric acid.
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Among the most commonly used benzodiazepines (i.e. midazolam, diazepam and 
lorazepam), lorazepam is the most anxiolytic, and the most potent.14,19 This makes 
lorazepam suitable for premedication in day-case surgery, although some criticisers do 
not agree because the relatively long half-life of lorazepam can be disadvantageous in 
day-case surgery. Others even think it is unnecessary to administer benzodiazepines 
as premedication in day-case surgery due to the nature of the procedure and for 
concerns of delayed recovery. Almost half of the day-case surgery patients request 
for premedication nonetheless.23 Pharmacologically, this thesis focuses on the potent 
lorazepam. Further details of lorazepam are therefore outlined below.
1.1.2.1 Pharmacokinetics
Absorption—Orally, lorazepam is absorbed from the gastrointestinal tract with peak 
plasma levels attained within 2 hours.24 Intramuscularly, absorption of lorazepam is 
dependent on the blood flow velocity with peak plasma levels attained within 1.5 hour 
with regards to the deltoid muscle.24 Intravenously, absorption is redundant; the clinical 
effects can be observed within several minutes after injection.25,26
Elimination—the biotransformation of lorazepam is different from the other 
benzodiazepines. Lorazepam is biotransformed by direct glucuronide conjugation 
followed by predominantly renal excretion of the conjugation metabolite,25 whereas 
other benzodiazepines also have to undergo phase I reactions.19 In contrast to other 
benzodiazepines, the elimination of lorazepam does not involve pharmacologically 
active metabolic products.19 Therefore, liver and renal failure have only a minor effect 
on the pharmacokinects of lorazepam. Also, interactions with other drugs are less likely, 
but may occur, for example, in the case of rifampicine, valproic acid and clozapine.27-29 
The mean half-life of lorazepam elimination is 14-15 hours with a range of 8 to 25 
hours.24,30 Other kinetic data with regards to lorazepam include volume of distribution, 
1.0 to 1.3 L/kg; and clearance, 0.7 to 1.2 ml/min/kg.30
1.1.2.2 Pharmacodynamics
As lorazepam induces depression of the central nervous system, among its 
pharmacodynamic effects (i.e. clinical effects) are sedation, hypnosis, reduction of 
anxiety, muscle relaxation, impairment of psychomotor function and anti-convulsant 
activity.19,25 From a respiratory and cardiovascular point of view, lorazepam may induce 
repiratory depression and a depression of the systemic vascular resistance (which results 
in a lowering of the arterial blood pressure and an increase in heart rate), respectively.19,25 
Furthermore, a small reduction of cardiac output has been reported.19
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As a premedication, the endeavoured pharmacodynamic actions of lorazepam include 
reduction of anxiety, anterograde amnesia and (maintenance of ) sedation.25 The 
pharmacodynamic effects are dose-dependent, and are therefore reversible upon 
reduction of dosage. Side effects are usually a result of over-dosing and can be derived 
easily from the pharmacodynamic effects of lorazepam; for example, oversedation, 
hangover, impaired psychomotor function and drowsiness.
1.1.2.3 Pharmacogenetics
Pharmacogenetics have been defined as the study of genetic variations that cause a 
variable drug response and includes the genetic polymorphism of drug metabolizing 
enzymes, drug transporter proteins, and drug receptors.31 These three aspects will be 
introduced below together with clinical applications with respect to lorazepam.
1.1.2.3.1 Drug metabolizing enzymes
Important routes of drug metabolism include phase 1 and phase 2 reactions (Figure 
2), each utilized with its own specific enzymes. As phase 1 reactions do not apply in 
the case of lorazepam it is not outlined in further detail. Phase 2 reactions facilitate 
glucuronidation. Enzymes of interest in our field include uridine 5’-diphosphate-
glucuronosyltransferases (UGTs), glutathione S-transferase, N-Acetyltransferase 2 and 
sulfotransferases.31 Among the enzymes of interest, the UGTs are of importance with 
respect to lorazepam. UGTs are generally divided into two families: the UGT1 family and 
the UGT2 family.32 The UGT2B15 genotype is one of the members of the UGT2 family. 
Polymorphisms in this genotype have been shown to be of clinical interest, accounting 
for more than half of the total clearance of lorazepam.33 Pharmacodynamics, such as 
sedation and psychomotor function, are also affected by UGT2B15 polymorphism.33 The 
effects on one of the main goals of premedication (i.e. reduction in anxiety) have not 
been evaluated yet however. Lorazepam is also glucuronidated by UGT2B7. However, 
this genotype has shown to be insufficient to affect the systemic clearance of lorazepam 
substantially.34
1.1.2.3.2 Drug transporters proteins
Another way that could influence drug activity is the velocity of drug absorption. 
Drug absorption can roughly be either passively (i.e. via diffusion) and actively (i.e. via 
transporter proteins). Among transporter proteins, membrane transporters play a vital 
role. Most ABC (adenosine triphosphate (ATP) binding cassette) proteins, one of the 
largest protein families known, are membrane transporters.35  Among these membrane 
transporters, P-glycoprotein is probably the most studied member of the family. 
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FIGURE 2 | Important routes of drug metabolism
The route of lorazepam is primarily via glucuronidation (bold face). Adapted with permission from de Wildt SN, et al. Glucu-
ronidation in Humans. Pharmacogenetic and developmental aspects. Clin Pharmacokinet. 1999;36:439-452.
P-glycoprotein is expressed, for example, on the membrane of the intestine and tubules 
of the kidney but also at the blood-brain barrier (BBB),35 and is responsible for transport 
of many substrates out of cells.36 The BBB has to protect the brain and CNS from toxic 
substances, like drugs. P-glycoprotein therefore plays an essential role in maintaining 
the homoeostasis in the CNS: high and low P-glycoprotein levels at the BBB may 
result into too low or too high concentrations of the drug in the brain, respectively.37 
Concerning lorazepam the infl uence of P-glycoprotein levels is not intensively studied, 
although some reports suggest clinical signifi cance.38,39 Another member of the ABC 
family that might be of interest in our fi eld is the multi-drug resistance-associated 
proteins (MRPs).31,40
1.1.2.3.3 Drug receptors
Pharmacogenetically, a third way to explain some of the diversity in drug activity is by 
polymorphisms that modify drug receptors. Lorazepam attaches to the GABAA receptor 
complex. Although there are no reports that describe specifi c polymorphisms in the 
GABAA that aff ect the activity of lorazepam, there is literature that covers this issue 
more generally. For example, it is known that, polymorphisms in the GABAA receptor 
may result in impaired benzodiazepine insensitivity.41,42 The clinical signifi cance is 
inconclusive as other literature does not fi nd such relation.43
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1.2 Postoperative evaluation in day-case surgery
Although day-case surgery is beneficial in multiple ways, we need to take into account 
new outcomes where patients may be suffering from when we analyse the quality of 
day-case surgery. Perioperative morbidity and mortality are extremely low.44 The actual 
recovery time in hospital is relatively short and the necessary postoperative care is 
transferred from health care professionals to the patients themselves together with 
their social network. The colorally is that postoperative evaluation in day-case surgery 
has been shifted towards predominantly psychological outcomes including anxiety, 
depressive moods, aggression and feelings of fatigue. Nevertheless, somatic outcomes 
should not be ignored. Vulnerable patients according to these outcome parameters 
should be identified and treatments adapted to the patient’s needs should be evaluated. 
Statistical models could help to achieve these aims.
1.3 Statistical modeling in day-case surgery
Next to the biomedical profession, the profession of biostatistics has made significant 
progress. Biostatistically, a valuable innovation is the application of Structural Equation 
Modeling (SEM). Although previously mentioned as an approach that should be further 
established in anesthesiology,45 application of this statistical methodology is very rare 
in this field. With the shift towards predominantly psychological outcomes in day-case 
surgery, multiple outcomes became of interest that ideally should be analysed jointly. 
Accordingly, analysis by means of SEM is a powerful and suitable strategy to apply.46
1.3.1 Structural Equation Modeling
SEM includes a family of several traditional multivariate statistical analysis techniques.47 
SEM is a statistical methodology that specifies, estimates, and evaluates models of (non) 
linear relationships among determinants and outcome variables. SEM makes use of 
observed variables (i.e. variables directly measured) and/or latent variables (i.e. variables 
indirectly measured). In contrast with multiple regression analysis for observed variables, 
SEM models could contain many dependent and independent variables that could be 
either observed or latent variables.47 An additional advantage of SEM is the possibility to 
estimate indirect effects (i.e. from variable to mediation variable(s) to another variable) 
next to direct effects (i.e. from variable to variable). To visualize structural equation 
models, researchers usually make use of graphical path diagrams. To properly make use 
of SEM, the statistical assumptions should be taken into account and large sample sizes 
are desired.47 Although SEM could be used for many research purposes, SEM is typically 
useful for testing theories, hypothesis-generating purposes, exploration and when we 
are interested in several different effects among a set of variables for several different 
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outcome parameters.47,48
1.4 Outline of this thesis
The aim of this thesis was to investigate, in a multidisciplinary way, the effects of 
premedication on predominantly psychological outcome variables after day-case 
surgery. Furthermore, the aim was to identify vulnerable patients in the postoperative 
period by means of prognostic modeling including SEM.
1.4.1 Part 1: Premedication with lorazepam and other benzodiazepines
Part 1 evaluates the preoperative pharmacological preparation (i.e. premedication) 
provided by the anesthesiologist. Chapter 2 presents the results of a randomized 
placebo-controlled clinical trial assessing the effects of lorazepam premedication on 
the  quality of recovery after day-case surgery with specific attention for psychological 
phenomena. The influence of pharmacogenetic polymorphisms on the most prominent 
pharmacodynamic action of lorazepam (i.e. anxiety reduction) is investigated in Chapter 
3. Chapter 4 comprises (1) a systematic review of the relevant literature assessing the 
effectiveness of benzodiazepine premedication on postoperative psychological- and 
somatic outcomes, and (2) a meta-analysis of studies that report on these outcomes. 
1.4.2 Part 2: Identifying vulnerable patients
Chapters 5 and 6 show studies using preoperative data in order to identify patients 
preoperatively that are likely to be vulnerable in the postoperative period. Chapter 5 
shows a prognostic model that enables predicting multiple psychological outcomes 
simultaneously one week after day-case surgery. The proposed model provides 
an evidence-based tool for anesthesiologist to determine which patients are likely 
vulnerable one week after the surgical procedure. In Chapter 6, three categories of 
psychological vulnerability are constructed according to normative data. Subsequently, 
using preoperative data of the patients, a prediction model was build to identify these 
postoperative vulnerability categories.
Postoperative fatigue emerges substantially following surgery and is closely related 
to anxiety and depression. In Chapter 7, therefore, a specific feature of SEM (i.c. path 
modeling) is applied in order to unravel the potential pathways between these variables 
preoperatively and postoperatively. Consequently, possible tailored preoperative 
treatment that could affect postoperative fatigue is discussed.
Mijderwijk.indd   20 28-10-2016   07:01:07
21 |
Introduction | 
1
The main findings of this thesis and interpretation of the results are discussed in Chapter 
8. In addition, future perspectives on the improvement of quality of the convalescence 
period will be discussed.
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ABSTRACT
In day-case surgery, the effects of the anxiolytic lorazepam as premedication on the 
quality of postoperative recovery are unknown. The objective was to evaluate whether 
lorazepam as a premedication beneficially affects quality of recovery (primary outcome) 
and psychological manifestations (secondary outcome) after day-case surgery. A 
randomised, double-blind, placebo-controlled clinical trial was executed in a single 
tertiary centre. Inclusion criteria included patients admitted for day-case surgery and age 
at least 18 years. Exclusion criteria were insufficient knowledge of the Dutch language; 
intellectual disability; ophthalmology surgery; extracorporeal shock wave lithotripsy; 
endoscopy; botulinum toxin A treatment; abortion; chronic pain treatment; preceding 
use of psychopharmaceuticals; contraindication to lorazepam. The intervention 
consisted of lorazepam (1 to 1.5 mg) intravenously vs. NaCl 0.9% as a premedication 
prior to surgery. The main outcome measure was the Quality of Recovery-40 (QoR-40) 
score. Secondary outcomes included State-Trait Anxiety Inventory (STAI-State/Trait); 
State-Trait Anger Scale (STAS-State/Trait); Multidimensional Fatigue Inventory (MFI); 
Hospital Anxiety and Depression Scale (HADS). Timing of evaluation: T0: preoperatively 
(all scales); T1: before discharge (STAI-State/Trait); T2: first postoperative working day 
(QoR-40); T3: 7th day after surgery (all scales). Robust regression analysis was applied. 
Statistical analyses were adjusted for the corresponding baseline value and sex. Four 
hundred patients were randomised; 398 patients were analysed. Postoperative mean 
QoR-40 scores were similar in both groups at T2 (174.5 vs. 176.4, P = 0.34) and T3 (172.8 
vs.176.3, P = 0.38). Postoperative mean STAI-State/Trait scores decreased less in the 
group with lorazepam at T1 (32.3 vs. 29.3, P < 0.0001; 32.7 vs. 30.8, P = 0.0002). STAI-
Trait and HADS-Anxiety decreased less in the group with lorazepam at T3 (31.1 vs. 30.0; 
P = 0.03, 3.3 vs. 2.5, P = 0.003). STAS-State increased in the group with lorazepam at 
T3 (10.8 vs. 10.3, P = 0.04). In day-case surgery, lorazepam as a premedication did not 
improve quality of recovery. Furthermore, this premedication may delay the decrease in 
postoperative anxiety and aggression.
TRIAL REGISTRATION ClinicalTrials.gov identifier: NCT01441843.
Mijderwijk.indd   30 28-10-2016   07:01:08
31 |
Lorazepam and Quality of Recovery  | 
2
INTRODUCTION
The use of day-case surgery is increasing,1,2 and even complex surgical procedures are 
now performed in a day-case setting.3,4 Along with this increase, the psychological 
aspects of perioperative care have received greater attention in recent years.5,6 Many 
patients have negative feelings about surgical procedures, a range of emotions covered 
by the term ‘resistance’. The most prominent manifestation of resistance is anxiety, which 
in the preoperative period can affect the perioperative course. Induction of anaesthesia 
is more difficult in anxious patients,7,8 and if the patient is anxious, more analgesics are 
needed postoperatively.9 In addition, postoperative anxiety often follows preoperative 
anxiety, and patients are less satisfied with the perioperative experience.9 Nevertheless, 
some healthcare professionals are reluctant to administer anxiolytic premedication 
because of concerns about delayed recovery.
A recent Cochrane review, however, concluded that because the use of anxiolytic 
premedication in day-case surgery does not negatively affect recovery duration; 
withholding anxiolytic premedication for that reason is not justified.2 In addition, 
benzodiazepines for premedication in day-case surgery are reported to reduce anxiety 
preoperatively.10
In spite of these findings, whether benzodiazepines really improve the quality of 
postoperative recovery remains an unanswered question. For example, midazolam is 
the most prescribed premedication in day-case surgery; however, it has no beneficial 
effects on clinical recovery after surgery.11 Lorazepam is less commonly used than 
midazolam but also serves as a premedication in day-case surgery.12 Due to its greater 
anxiolytic effect and relatively long duration of action, lorazepam might be superior 
to midazolam in enhancing the quality of recovery. We hypothesised that a stronger 
anxiolytic drug with a prolonged effect such as lorazepam applied to a much larger 
study population might show more pronounced results in terms of improved quality 
of recovery.
The primary objective of this study, therefore, was to evaluate the effects of lorazepam 
on the quality of recovery in day-case surgery patients in a large-scale, randomised, 
parallel group trial. The secondary objective was to assess the effects of lorazepam 
on resistance in the postoperative period, including related manifestations of anxiety, 
aggression, feelings of fatigue and depressive mood.
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METHODS
The study protocol was approved by the Medical Ethical Committee of Erasmus 
University Medical Centre, Rotterdam, The Netherlands (Chairperson Prof. dr. H.W. 
Tilanus) on 23 August, 2010, and by the Netherlands Central Committee on Research 
involving Human Subjects (CCMO) and registered with EudraCT number 2010-020332-
19. The trial was also registered under identification number NCT01441843 in the 
ClinicalTrials.gov protocol registration system. Written informed consent was obtained 
from all participants.
Study population
Between October 2010 and September 2011, 400 patients were recruited from our day-
case surgery department. Inclusion criteria were referral for day-case surgery and age 
at least 18 years. Patients were excluded if they exhibited clearly insufficient command 
of the Dutch language or intellectual disability, or were undergoing ophthalmology 
surgery, extracorporeal shock wave lithotripsy, endoscopy, botulinum toxin A 
treatment, abortion or chronic pain treatment. The latter procedures are generally 
considered as being minimally invasive, some cooperation of the patient is required 
and most practitioners are of the opinion that these do not require premedication. 
Additional exclusion criteria were the preceding use of psychopharmaceuticals and any 
contraindication to lorazepam use.
Study design
We conducted a randomised, parallel group design, with varying block sizes (8–10–12) 
across time. The ratio of allocation to either verum condition (lorazepam) or placebo 
condition (NaCl 0.9%) was 1 : 1. Randomisation was done by a computer-generated 
table, and patients were assigned subsequent numbers upon inclusion. Nurses who 
were not further involved in the care of these patients prepared the study medication 
according to the randomisation table. The study was double-blinded; the researchers, 
patients and all healthcare professionals involved in patient care were blinded to the 
treatment allocation.
Procedure and intervention
Figure 1 provides a timeline of the study procedure. All patients scheduled for day-case 
surgery received written information about the trial at least 1 week before surgery. A 
member of the research group enrolled patients after admission to the day-surgery 
centre. After giving written informed consent, patients completed a set of online
Mijderwijk.indd   32 28-10-2016   07:01:08
33 |
Lorazepam and Quality of Recovery  | 
2
A
dm
is
si
on
 
to
 th
e 
w
ar
d
Pr
eo
pe
ra
ti
ve
 
ho
ld
in
g
Po
st
op
er
at
iv
e 
ho
ld
in
g
T3
D
is
ch
ar
ge
 
ho
m
e
W
ar
d
O
pe
ra
tio
n 
ar
ea
W
ar
d
T2
H
om
e
 In
je
ct
io
n 
of
 
lo
ra
ze
pa
m
 o
r 
N
aC
l 0
.9
%
ST
A
I
Q
oR
-4
0
Q
oR
-4
0,
 
ST
A
I, 
M
FI
, 
H
A
D
S,
 S
TA
S
T0
Su
rg
er
y
T1
D
em
og
ra
ph
ic
 
an
d 
cl
in
ic
al
 
fe
at
ur
es
, Q
oR
-
40
, S
TA
I, 
M
FI
, 
H
A
D
S,
 S
TA
S
questionnaires while waiting for surgery (T0). Next, in the preoperative holding area, 
the independent recovery nurses, who had access to the group assignment document, 
prepared the medication. Blinding was achieved by preparation of the transparent flu-
ids in identical syringes. Lorazepam was diluted in NaCl 0.9% to 4mg/4ml. Following our 
clinical routine depending on the patient’s body weight (<75 and ≥75kg, respectively), 
FI
G
U
RE
 1
 | T
im
el
in
e 
of
 th
e 
st
ud
y
T0
: b
as
el
in
e 
as
se
ss
m
en
t o
n 
th
e 
da
y 
of
 s
ur
ge
ry
 (s
el
f-r
ep
or
te
d 
qu
es
tio
nn
ai
re
); 
T1
: a
ss
es
sm
en
t a
ft
er
 s
ur
ge
ry
, b
ef
or
e 
di
sc
ha
rg
e 
(s
el
f-r
ep
or
te
d 
qu
es
tio
nn
ai
re
); 
T2
: fi
rs
t p
os
to
pe
ra
tiv
e 
w
or
ki
ng
 d
ay
 (a
dm
in
is
te
re
d 
by
 a
 h
ea
lth
ca
re
 p
ro
fe
ss
io
na
l);
 T
3:
 s
ev
en
th
 p
os
to
pe
ra
tiv
e 
da
y 
(s
el
f-r
ep
or
te
d 
qu
es
tio
nn
ai
re
); 
H
A
D
S,
 H
os
pi
ta
l 
A
nx
ie
ty
 a
nd
 D
ep
re
ss
io
n 
Sc
al
e;
 M
FI
, M
ul
tid
im
en
si
on
al
 F
at
ig
ue
 In
ve
nt
or
y;
 Q
oR
-4
0:
 Q
ua
lit
y 
of
 R
ec
ov
er
y 
Sc
or
e-
40
; S
TA
I, 
St
at
e-
Tr
ai
t A
nx
ie
ty
 In
ve
nt
or
y;
 S
TA
S,
 
St
at
e-
Tr
ai
t A
ng
er
 S
ca
le
.
Mijderwijk.indd   33 28-10-2016   07:01:08
| 34 
| Chapter 2
another nurse blinded to the treatment condition injected the single dosage of 1 or 1.5ml 
lorazepam/NaCl 0.9% by peripheral infusion 30 min before induction of anaesthesia. 
After the surgical procedure, patients completed another online questionnaire before 
discharge. On the first postoperative working day, a telephonic interview was done. On 
the sixth day after surgery, one of the researchers reminded the patients in a telephonic 
call to complete the last set of online questionnaires the next day (postoperative day 7).
Assessment of outcomes
Primary outcome
Quality of recovery after surgery was routinely assessed by a Dutch-translated version of 
the well validated 40-item Quality of Recovery Score-40 (QoR-40).13,14 This questionnaire 
comprises five scales: physical comfort (12 items); emotional state (nine items); physical 
independence (five items); psychological support (seven items); and pain (seven items). 
Each item is rated on a five-point Likert scale, and the QoR-40 score is calculated as the 
sum of the scores on these scales. The higher is the score, the higher is the quality of 
recovery. QoR-40 has a good internal consistency, with Cronbach’s α equal to 0.93.14
Secondary outcomes
Anxiety was measured using the Dutch version of the State-Trait Anxiety questionnaire 
(STAI).15 The STAI consists of two 20-item scales; one measures how one generally feels 
(trait anxiety), and the other measures how one feels at the present moment (state 
anxiety). All items are rated on a four-point Likert scale. Scores for both scales are 
calculated by summing the scores on the items, and a higher score indicates a higher 
level of anxiety. STAI-State and STAI-Trait show similar internal consistencies (Cronbach’s 
α >0.80, respectively15).
Fatigue was measured with the Dutch version of the Multidimensional Fatigue Inventory 
(MFI),16 a 20-item questionnaire covering five scales (four items per scale): general 
fatigue; physical fatigue; mental fatigue; reduced motivation; and reduced activity. Each 
item is rated on a five-point Likert scale, and a higher score indicates a higher degree of 
fatigue. In general, MFI has a strong internal consistency, with Cronbach’s α more than 
0.80.16
Depressive moods were measured using a Dutch-translated version of the Hospital 
Anxiety and Depression Scale (HADS),17 which consists of two seven-item scales, one for 
anxiety and one for depression. A higher score indicates a higher degree of depressive 
mood. For the Dutch general population, internal consistency (i.e. Cronbach’s α) of 
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HADS equals 0.88.18 
Aggression regulation was assessed with the Dutch-translated version of the State-
Trait Anger Scale (STAS),19 which consists of two 10-item scales, one covering the State 
aggression (how angry one feels at the moment) and one covering the Trait aggression 
(how angry one feels in general). Each item is rated on a four-point Likert scale, and a 
higher score indicates a higher degree of aggression. The internal consistency of STAS-
State and STAS-Trait equals Cronbach’s α of 0.93 and 0.88, respectively.19
The following demographic characteristics were assessed: sex; age; educational level; 
marital status; religion; and employment. At baseline, we also measured some clinical 
features: weight; height; heart rate; type of surgery; history of surgery; anaesthetic 
technique; and American Society of Anaesthesiologists (ASA) physical status 
classification.
Statistical analysis
To evaluate the possible beneficial effects of lorazepam, the following outcome variables 
were used: QoR-40 (five scales); STAI (both State and Trait scales); STAS (both State and 
Trait scales); MFI (five scales); and HADS (anxiety and depression scales). The expected 
clinical effect equals 0.50 in terms of standardised mean difference. For example, 
following Myles et al.,14 the average score in the lorazepam and placebo conditions 
before surgery equals 183 (SD = 17). Then, we consider a positive difference of at least 
8.5 in lorazepam compared with placebo to be clinically relevant. The nominal alpha is 
fixed at 0.05 (two sided). As the (scales of the) outcome variables were expected to be 
related, the number of independent scales (dimensions) of the outcome variables was 
estimated to be nine. Therefore, the real two-sided alpha had to be 0.05/9, whereas beta 
was fixed at 0.20. Consequently, a minimum number of 208 patients was required, 104 
in each group. We expected that the percentage of dropouts would be 20%, meaning 
that the minimum number of patients required was 260, 130 in each group.
An intention-to-treat analysis was applied. Categorical data were tested with the 
Pearson chi-square test and continuous data with the Student’s t-test for independent 
observations.
We applied robust regression analysis to test for differences in the primary and secondary 
outcome variables between the two groups. This approach can account for non-normal 
distribution of the outcome variables and also for heteroskedasticity.20 In particular, we 
used MM estimation, which is a combination of least-trimmed squares estimator and 
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scale estimator, by which the variance of the estimator is minimised. To detect possible 
differences between verum and placebo on the outcome variables without bias, we 
adjusted for the baseline imbalance of the corresponding outcome variable and sex.
P-values (two-tailed) were estimated for all parameters. The regression analyses were 
done with SAS version 9.2 (SAS Institute Inc, Cary, NC, USA);21 all other analyses were 
performed with SPSS software version 17.0 (SPSS Institute, Chicago, IL, USA).
RESULTS
Study population
A total of 3820 patients were assessed for eligibility; 3420 were excluded and conse-
quently, 400 patients were randomised to either lorazepam or NaCl 0.9%.
Twelve patients in the lorazepam group and six in the NaCl 0.9% group were lost to 
follow-up for at least one of the measurement periods. For detailed information, see 
Figure 2.
FIGURE 2 | A flowchart showing patient flow according to the study protocol
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In retrospect, two patients in the lorazepam group should not have been included; one 
could not complete the baseline measurements for technical reasons and the other 
admitted afterwards to using psychoactive drugs. Data for these two patients were, 
therefore, excluded from analysis. In total, 14 patients from the lorazepam group and 
six patients from the NaCl 0.9% group were lost to follow-up for at least one of the 
measurement points. This difference was not significant (P = 0.11, two tailed).
General characteristics
Overall, general patient characteristics did not significantly differ between the two 
groups (Table 1).
Primary outcome
Table 2 shows the mean QoR-40 scores for both groups at T0, T2 and T3. In both groups, 
the mean scores were high at all time points. Regarding the lorazepam group, mean 
values were 177.2 at T0, 174.5 at T2 and 172.8 at T3. With respect to the NaCl 0.9% 
group, mean values were 180.4 at T0, 176.4 at T2 and 176.3 at T3. Although the mean 
scores slightly decreased after surgery, the differences between the groups were not 
significant after adjustment for the baseline QoR-40 score and sex at T2 (Χ2 = 0.93; P = 
0.34) or at T3 (Χ2 = 0.77; P = 0.38). Lorazepam showed no statistically significant effect on 
the quality of recovery after surgery.
Secondary outcomes
Anxiety measured at T1 was statistically significantly higher in the lorazepam group. The 
two groups also differed on STAI-State (Χ2 = 18.50; P < 0.0001) and STAI-Trait (Χ2 = 14.26; 
P = 0.0002), with the effect that the postoperative decrease in anxiety was smallest in 
the lorazepam group (Table 3). The decrease in STAI-State scores was greater in the 
placebo group (from 37.6 to 29.3 at T1) than in the lorazepam group (from 38.6 to 32.3 
at T1). STAI-Trait scores in the placebo group also dropped significantly more (from 33.4 
to 30.8 at T1) than in the lorazepam group (from 33.6 to 32.7 at T1).
The two groups differed significantly on three outcome variables (Table 4): STAI-Trait (Χ2 
= 5.27; P = 0.03); HADS-Anxiety (Χ2 = 9.26; P = 0.003); and STAS-State (Χ2 = 4.45; P = 0.04) 
at T3. The postoperative decrease in STAI-Trait scores was greater in the placebo group 
(from 33.4 to 30.0 at T3) than in the lorazepam group (from 33.6 to 31.1 at T3). HADS-
Anxiety scores in the placebo group also dropped significantly more (from 4.7 to 2.5 at 
T3) than in the lorazepam group (from 4.6 to 3.3 at T3). STAS-State scores slightly (but 
significantly) increased more in the lorazepam group (from 10.1 at T0 to 10.8 at T3) than 
in the placebo group from (10.3 at T0 to 10.3 at T3).
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TABLE 1 | Patient characteristics at baseline
                                                  Intervention  
  Lorazepam, n=198 NaCl 0.9%, n=200 P*
  (%) (%)  
Demographic      
Sex     0.63
   Female 89 (44.9) 85 (42.5)  
   Male 109 (55.1) 115 (57.5)  
Age (mean; SD) 39.5; 13.7 39.3; 13.6 0.88
Educational levela     0.12
   Low 26 (13.1) 37 (18.5)  
   Mid-level 144 (72.7) 126 (63.0)  
   High 28 (14.1) 37 (18.5)  
Marital statusb     0.94
   Single 79 (39.9) 79 (39.5)  
   Together 119 (60.1) 121 (60.5)  
Religion     0.23
   Yes 58 (29.3) 70 (35.0)  
   No 140 (70.7) 130 (65.0)  
Employment     0.77
   Yes 151 (76.3) 150 (75.0)  
   No 47 (23.7) 50 (25.0)  
Clinical      
Weight (mean; SD)c 78.8; 15.6 79.6; 15.2 0.64
Height (mean; SD)d 176.5; 10.1 176.9; 10.1 0.68
Heart rate (mean; SD)e 69.9; 12.8 70.9; 13.5 0.44
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                                                  Intervention  
  Lorazepam, n=198 NaCl 0.9%, n=200 P*
  (%) (%)  
Type of surgery   0.51
   General 60 (30.3) 44 (22.0)  
   Otorhinolaryngologic 8 (4.0) 12 (6.0)  
   Gynaecologic 25 (12.6) 32 (16.0)  
   Urologic 20 (10.1) 26 (13.0)  
   Orthopedic 46 (23.2) 46 (23.0)  
   Plastic 31 (15.7) 34 (17.0)  
   Dental/faciomaxillary 8 (4.0) 6 (3.0)  
Had surgery before   0.28
   Yes 159 (80.3) 169 (84.5)  
   No 39 (19.7) 31 (15.5)  
Anaesthesia techniquef   0.09
   General 167 (85.2) 182 (91.5)  
   Peripheral regional 14 (7.1) 11 (5.5)  
   Neuraxial 15 (7.7) 6 (3.0)  
ASAg   0.32
   ASA I 133 (67.2) 125 (62.5)  
   ASA II 62 (31.3) 74 (37.0)  
   ASA III 3 (1.5) 1 (0.5)  
*)P-values are rounded upwards; a)Low: no education, elementary school, preparatory middle-level vocational education; 
Mid-level: middle-level vocational education, higher general continued education, higher vocational education; High: 
preparatory university education, university education; b)Single: unmarried, divorced, widow(er); Together: married, living 
together; c)Weight: body weight in kilograms; d)Height: body length in centimeters; e)Heart rate: beats per minute, n ver-
um=197 and n placebo=199 due to cancelling surgical procedure; f )n verum=196 and n placebo=199 due to cancelling 
surgical procedure; g)risk classification according to the American Society of Anesthesiology.
TABLE 1 | Patient characteristics at baseline (continued)
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DISCUSSION
This study is the first randomised controlled trial with a strong methodological framework 
to address the effects of intravenous premedication with lorazepam on the quality of 
recovery. The principal finding is the lack of any beneficial effect of premedication with 
lorazepam on the quality of recovery in the day-case surgery setting. In addition, we 
found that the postoperative decrease in anxiety was lower in the lorazepam group 
and that aggression scores had increased in this group, both to a statistically significant 
level. Our results support the reluctance of some healthcare professionals to routinely 
administer anxiolytic premedication in day-case surgery.22
We chose lorazepam for its proven anxiolytic properties.23 Furthermore, it has been used 
as a reference anxiolytic medication.24 Schunck et al.25 recently showed that a single 
intravenous dosage (as we used) reduced anxiety for patients at a moderate level, 
although it was not strong enough to suppress a panic attack. The more commonly 
used midazolam has unpredictable effects and a relatively high risk of paradoxical 
reactions, although this risk is much lower with lorazepam.26 Moreover, Kain et al.11 
showed that despite a reduction in anxiety, midazolam did not improve clinical recovery 
in day-case surgery. According to their study, we expected that an alternative anxiolytic 
administered on a different schedule in relation to surgery might result in different 
findings.
We found that even lorazepam, which is considered the most potent anxiolytic 
benzodiazepine, had no beneficial effects on the quality of recovery or on the 
manifestations of resistance. This may be due to the low preoperative anxiety levels, 
as the effects of lorazepam could differ depending on the perceived level of threat.24 
In our population, baseline scores of anxiety were not high, fitting with our high score 
of quality of recovery, which is in line with the literature in patients undergoing minor/
day-case surgery.27,28
Our second finding was a minor, unwanted, adverse reaction to lorazepam. The lower 
decrease in anxiety and increase in aggression in the lorazepam group was statistically 
significant because of our large sample size; however, this might also be clinically 
relevant, as administration of a drug with a risk of side effects and without a proven 
beneficial effect should be avoided.
A rebound effect after lorazepam use might be a possible explanation for our findings. 
The rebound phenomenon is well described with benzodiazepine use; it may occur 
when the treatment is stopped after a certain (longer) time period.29,30 Kales et al.,31,32 
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however, also found a rebound effect after low dosages of benzodiazepines. The 
molecular mechanisms behind the rebound phenomenon following acute treatment 
are not yet completely understood.33 As Huopaniemi et al.33 showed that a single dosage 
of a benzodiazepine can change genetic transcription processes, our findings in this 
study might fit with the idea of a rebound effect even after the administration of a single 
dosage of lorazepam.
Although a rebound phenomenon points to a (too) short action of the drug, a more 
obvious explanation might simply lie in the fact that patients with a low preoperative 
anxiety score might experience a prolonged decrease in their level of awareness 
secondary to lorazepam as an unwanted side effect. The day-case setting relies on the 
‘patient in control’, and the prolonged effects of lorazepam might be disadvantageous 
in that setting. The relatively long half-life of lorazepam supports this explanation. It is 
unclear whether this phenomenon is present after the administration of benzodiazepines 
with a shorter duration of action.
Due to the lack of a positive postoperative effect (in addition to these negative effects), 
together with the results from Kain et al.11 and the potential risk of delirium,34,35 we 
cannot support the routine administration of benzodiazepines as a premedication in 
perioperative care.
It is worthwhile mentioning that we found significant differences regarding STAI-Trait 
throughout the follow-up period. This was unexpected, as STAI-Trait measures how 
one feels in general, and, therefore, should be stable in the follow-up period. However, 
literature shows that STAI-Trait does not only measure trait anxiety but also assesses 
negative affect.36 Therefore, the changes on STAI-Trait might be interpreted as the 
reflection of negative feelings, rather than trait anxiety. These findings have lead to the 
proposal of a revision of the questionnaire.36 The version we used in our study, however, 
is validated, but we are aware of these concerns.
Our findings should be interpreted in the context of our study methodology and its 
limitations. Ideally, lorazepam administration should be exactly weight dependent; 
however, the dosages used in the current work are standard dosages in our daily 
clinical routine. Higher dosages are believed to provoke unwanted side effects such as 
respiratory depression, drowsiness and amnesia and are, therefore, not indicated for 
patients in day-case surgery, and might also have led to an unblinding of the study.
Premedication for surgical patients is normally given per os. The pharmacokinetics 
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of oral lorazepam show a broad variation with a maximum effect at around 2h after 
administration,37 and we wanted to avoid the influence of circadian rhythm on drug 
absorption.38 Furthermore, in clinical practice, especially in a day-case surgery setting, 
oral administration of premedication is not always in time for all patients. Overall, 
the timing of drug administration and the measuring time points in our study reflect 
common practice in research performed in day-case surgery.11,29,39,40 The time to onset 
of effect after intravenous injection of lorazepam is less than 5 min.41
The study design might also have been more streamlined with a consistent anaesthetic 
technique, but some patients had neuraxial or peripheral regional anaesthesia rather 
than general anaesthesia. Nevertheless, this study reflects daily clinical practice, and 
because of our randomised design, there is no reason to think that possible unmeasured 
confounders differed between the two conditions.
We excluded 459 patients for logistical reasons, due to the interval between eligibility 
assessment and the beginning of the surgical procedure being too short. A much 
smaller group of patients (245) refused to participate. We were unable to detect any 
selection bias.
In our opinion, this study should be repeated in hospitalised patients undergoing 
major surgery who may be facing a longer stay in the hospital, resulting in higher 
preoperative anxiety levels, and probably more pronounced effect sizes regarding 
fatigue and depression. Such a study could well yield findings that differ from ours, 
particularly when ethnic and sociocultural aspects are taken into account. In addition, 
we have described the effects of lorazepam for a whole study population. We believe, 
however, that it might be possible to identify subgroups of patients who could benefit 
from premedication. Future studies should be tailored to identifying these vulnerable 
patients.
CONCLUSION
In this randomised controlled trial, with a strong methodological framework, we 
addressed the effects of routine intravenous premedication with lorazepam on the 
quality of recovery in the day-case surgery setting. We found no improvement in the 
quality of recovery in adult day-case surgery patients, but observed that the use of 
lorazepam as a premedication may delay the decrease in postoperative anxiety and 
aggression. The routine use of lorazepam for premedication in adult day-case surgery 
patients should, therefore, be questioned. Further research is needed to establish 
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whether these findings can be generalised to other benzodiazepines and/or other 
patient groups. 
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ABSTRACT
Lorazepam is used as premedication for its anxiolytic properties. The UGT2B15 genotype 
is of importance for the metabolism of lorazepam. The clinical effect of genetic 
polymorphisms in UGT2B15 genotype on the treatment of anxiety levels in same-day 
surgery patients receiving lorazepam, however, is unknown. Three hundred ninety-eight 
same-day surgery patients of mixed sex (from a previous double-blinded randomized 
controlled trial who were assigned to either lorazepam [n = 198] or placebo [n = 200]) 
were assessed for the UGT2B15*2 variant allele. Anxiety was measured preoperatively 
and postoperatively by the State part of the State-Trait Anxiety Inventory. The difference 
between these 2 measurements served as outcome of the study. Analysis of variance 
was used to assess the State part of the State-Trait Anxiety Inventory difference 
for interactions among the following factors: UGT2B15 genotype status, treatment 
condition (lorazepam or placebo), patient sex, and preoperative anxiety score. The 
anxiety difference was complex in that the interaction of lorazepam and UGT2B15 
genotype status also was dependent on the joint effect of patient sex and preoperative 
anxiety score (F = 7.15, P = .008). Further exploration showed clinical relevant results 
in patients with high preoperative anxiety scores. Striking was that females with high 
preoperative anxiety scores and genetically reduced lorazepam glucuronidation 
(UGT2B15*2 homozygotes) showed more postoperative anxiety reduction than males 
with the same genotype. UGT2B15 genotype contributes to postoperative anxiety 
reduction after lorazepam premedication. Future research that focuses on patients 
with high preoperative anxiety scores could help to gain a deeper understanding in 
the clinical relevance of the interaction between lorazepam and UGT2B15 genotype on 
postoperative anxiety levels.
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INTRODUCTION
Uridine 5′-diphosphate-glucuronosyltransferases (UGTs) are phase II enzymes that have 
a prominent role in biotransformation of endogenous and exogenous substrates.1 UGTs 
primarily facilitate glucuronidation. Glucuronidation is the process in which glucuronic 
acid is linked to a substrate by means of a catalyzing UGT enzyme.2 Consequently, the 
substrate can be eliminated.2 UGTs generally are grouped into the UGT1 and UGT2 
families.3 UGT2B15 is one of the UGT enzymes. The major drug substrate for UGT2B15 
is lorazepam.2 Lorazepam clearance is executed primarily by direct glucuronidation 
followed by mainly renal excreation.4
It is known that the UGT2B15 genotype has a strong influence on the pharmacokinetics of 
lorazepam: 61% of the total variance in lorazepam clearance is explained by this UGT2B15 
genotype in healthy subjects.5 Lévesque et al.6 showed that a guanine-to-thymine 
change in UGT2B15 genotype leads to an amino acid substitution at position 85 from 
aspartic acid (D) to tyrosine (Y), resulting in the UGT2B15(D85Y) genetic polymorphism 
(ie, UGT2B15*2). As a consequence, homozygous subjects have reduced glucuronidation 
compared with wild-type and heterozygous carriers. Therefore, homozygous subjects 
have been shown to have significantly greater lorazepam concentrations.5 Without 
a change in the general pharmacodynamics (which is the S-shaped dosage-effect 
relationship) of lorazepam, these greater plasma levels will induce more pronounced 
clinical effects in patients with UGT2B15*2 polymorphism.
Clinical effects of lorazepam (sedation, psychomotor performance, alertness, motor 
function and coordination) show a large variability in humans according to the UGT2B15 
genotype.5 However, the effect of lorazepam on anxiety according to genotype is of 
clinical importance—as it is widely used for its anxiolytic properties,7 such as anxiolytic 
premedication8—but it is still unknown.
If the anxiolytic effect of lorazepam differs significantly according to the UGT2B15 
genotype, this may in part explain patient variability in anxiolytic effect. Therefore, 
we evaluated interactions between lorazepam and UGT2B15 genotype. In addition, 
we assessed interactions with patient sex and preoperative anxiety score because 
these determinants are relevant in studies with lorazepam and perioperative patient 
anxiety.9,10
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METHODS
This study is a derivative of a larger completed randomized controlled clinical trial (RCT) 
conducted and completed at the Erasmus University Medical Center with the same 
study population, study design, procedure and assessments of outcomes. Therefore 
these sections of the methods in this study are in line with our previous publication.9 
The primary and secondary objectives of the original RCT were to evaluate the effects of 
lorazepam (versus placebo) on the quality of recovery and psychological phenomena, 
including anxiety, in same-day surgery respectively.9 The RCT showed that, among 
others, lorazepam did not improve quality of recovery and that the expected decrease 
in postoperative anxiety was lower in the lorazepam group.9
This study protocol was approved by the Medical Ethical Committee of Erasmus 
MC and by the Netherlands Central Committee on Research involving Human 
Subjects (CCMO) and registered with EudraCT number 2010-020332-19. The trial 
is also registered under identification number NCT01441843 in the ClinicalTrials.gov 
protocol registration system. Signed written informed consent was obtained from all 
patients including whether they consented to genotyping (see also Table 1).
Study population
Between October 2010 and September 2011, 400 patients were recruited from our 
same-day surgery department.9 Inclusion criteria were as follows: all patients who were 
referred for same-day surgery and at least 18 years of age. Patients were excluded if they 
met one or more of the following criteria: clearly insufficient command of the Dutch 
language, mental retardation, undergoing eye surgery, extracorporeal shock wave 
lithotripsy (ESWL), endoscopy, Botox treatment, abortion, or chronic pain treatment. 
The latter procedures are generally considered as low invasive, some cooperation 
of the patient is required, and most practitioners agree that these do not require 
premedication. Finally, preceding use of psychopharmaceuticals and contraindication 
to lorazepam use were exclusion criteria as well.
Study design 
This study was a randomized, double blinded, placebo-controlled clinical trial 
with a parallel group design, with varying block sizes (8-10-12) across time. The 
ratio of allocation to the treatment conditions (lorazepam or placebo) was 1:1. 
Randomization was performed by a computer-generated table, and the patients 
were assigned subsequent numbers on inclusion. Health care professionals, 
patients, and researchers were blinded to the treatment condition; however nurses 
Mijderwijk.indd   54 28-10-2016   07:01:09
55 |
UGT2B15 Genotype and Lorazepam  | 
3
who were not involved directly in the care of these patients, prepared the study 
medication according to the randomization table. A flowchart from this study has 
been published.9
Procedure
Figure 1 provides a timeline of the study procedure. All patients scheduled for 
same-day surgery received written information about the trial at least 1 week 
before surgery. A member of the research group enrolled patients after admission 
to the day-surgery center and sought written informed consent. Patients who 
consented to participate completed a set of online questionnaires when waiting 
for surgery (T0). Next, in the preoperative holding, the independent recovery nurses, 
who had access to the group assignment document, prepared the medication. Blinding 
was achieved by preparing the transparent fluids in identical syringes. Depending on 
the patient’s body weight, respectively < 75kg and ≥ 75kg, another nurse blinded 
to treatment condition injected the single dosage of 1mg or 1.5mg lorazepam by 
peripheral infusion 30 minutes before induction of anesthesia. The placebo group 
received an equal volume of NaCl 0.9%. The recovery nurses obtained 8ml venous blood 
from the peripheral infusion. After the surgical procedure, patients completed an online 
questionnaire before discharge (T1). Because of the long duration of action with known 
therapeutic concentrations even after a single intravenous dosage,11 the preoperative 
injected lorazepam was considered to be active at the moment of postoperative anxiety 
testing.    
FIGURE 1 | Timeline of the study
STAI-State, State-Trait Anxiety Inventory, State part; T0 = preoperative assessment; T1 = postoperative assessment.
Preparing and 
injection 
Lorazepam or 
NaCl 0.9%; 
obtaining 8ml 
bloodSTAI-State STAI-State
Admission to the 
ward
Preoperative 
holding
Surgery Discharge home
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Genotype determination
UGT2B15 genotyping was done using the Taqman allelic discrimination assay on an 
ABI PRISM 7500 FAST sequence detection system. The assay consisted of a master 
mix (TaqMan® GTXpress™ Master Mix, Applied Biosystems, Nieuwerkerk a/d IJssel, 
the Netherlands) and two-specific minor groove binding (MGB) probes, labelled with 
the fluorescent dyes VIC and FAM. For the UGT2B15*2 (253G>T) variant, we used a 
commercial available Drug Metabolizing Enzyme (DME) assay mix: C__27028164, 
rs1902023 (Applied Biosystems). Each reaction was performed in a 10 µL reaction mix 
containing 2 µL of DNA template (10ng/ µL). The thermal profile consisted of an initial 
pre-read step at 60°C for 1 minute, denaturation at 95°C for 20 seconds, followed by 45 
cycles of denaturation at 92°C for 3 seconds, and an annealing and extension step at 
60°C for 30 seconds, followed by a post-read step at 60°C for 1 minute. Genotypes were 
scored by measuring allelic-specific fluorescence using the 7500 software version 2.0.5 
for Allelic Discrimination (Applied Biosystems).
Outcome
Anxiety was measured by the Dutch version of the State-Trait Anxiety questionnaire 
(STAI).12 STAI consists of two scales, each containing 20 items. We used the State 
scale (STAI-State) in this study because this scale measures how the patient feels at 
the moment of completing the questionnaire.12 Conversely, the Trait scale measures 
how one generally feels.12 Theoretically, the latter is not expected to be affected 
by a stressful situation like surgery. We calculated the sum score by summing the 
scores on the items, theoretically ranging from 20 to 80. Greater scores indicate a 
higher level of anxiety. In this study, differences in STAI-State levels relative to the 
preoperative score served as outcome. Thus, anxiety difference was calculated by 
subtracting the postoperative anxiety score from the preoperative anxiety score. 
Consequently, a positive difference indicates that the postoperative anxiety score 
is lower than the preoperative anxiety scores, and a negative difference indicates 
an increase in anxiety in the postoperative period. The median score of these anxiety 
differences are called ‘median differences’ in this work.
Determinants
We used a recessive genetic model for analyzing UGT2B15 genotype because previous 
literature suggests pharmacodynamic differences according to such a model.13 This 
means that only patients who were homozygous for the UGT2B15*2 variant were 
scored as deviant UGT2B15 genotype. As a result, wild type UGT2B15 and heterozygous 
UGT2B15*2 were scored as normal UGT2B15 genotype. In addition, treatment condition 
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(lorazepam or placebo), patient sex, preoperative anxiety score were also used as a 
determinants.
Statistical analysis
Four-way analysis of variance was used to assess anxiety scores for interaction between 
the following factors: UGT2B15 genotype status, treatment condition, patient sex and 
preoperative anxiety score. The effects were evaluated by F-tests and the corresponding 
P values. The model was adjusted for type of surgery (ie, surgical speciality) and type of 
anesthesia (ie, general anesthesia, peripheral regional, and neuraxial). The distribution 
of the constructed outcome (ie, anxiety difference) was considered normal according 
to the obtained histogram and Q-Q plot. The Kolmogorov-Smirnov test and Shapiro-
Wilk test turned out to be statistical significant nonetheless. Neither the square root 
transformation nor the log transformation was adequate to achieve a normal distribution 
for the anxiety score including the residuals. Therefore, analysis of variance was still 
performed because this method has been shown to be resilient for nonnormality.14-17 
It was checked whether there were influential observations (standardized residuals ≥ 
±3.0). There was 1 influential observation. The equality of error variances was evaluated 
by the Levene’s test, which was non-significant (P = .34). The percentage of variance 
explained by the model was based on the coefficient of determination (R2).
To get a full understanding of the anxiety difference, we analyzed the effect of UGT2B15 
genotype in combination with treatment condition, patient sex and preoperative 
anxiety score. Therefore, we had to test for higher order interactions. Significant statistical 
interaction implies that the used variables act dependently on the outcome variable.18 
All possible interactions with either UGT2B15 genotype or treatment condition were 
tested simultaneously for significance and all main terms. Interaction between variables 
means that the effect of variable x1 is modified by the value of variable x2, and x3, etc. 
When a higher-order interaction appeared to be statistical significant, the outcome is 
explained by the combination of multiple variables. Consequently, possible significant 
effects of lower order interactions are less relevant if a higher order interaction turned 
out to be significant.19 Therefore, we only presented and described the results of the 
statistically significant highest order interaction for STAI-State.
All statistical testing took place at .05 level of statistical significance (two-sided). All 
analyses were done with SPSS software 20.0 (IBM Corp. Armonk, NY). 
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RESULTS
Patients
In the original study, 400 eligible patients were randomized to either lorazepam or 
placebo. Three hundred ninety-eight patients were analyzed.9 The number of missing 
values on the outcome variable did not appear to be significantly different between 
the lorazepam or placebo group (Fisher’s exact test 0.22). Furthermore, the number of 
missing values of UGT2B15 genotype did not differ between these 2 groups (Fisher’s 
exact test 0.84).
The study population included 224 males (56%) and had a mean age of 39.4 years 
(standard deviation, 13.6). The groups made by randomization have an equally 
distributed number of patients. For UGT2B15*2 polymorphism, 185 patients (50%) were 
heterozygous and 102 patients (27%) were homozygous deviant. The wild type group 
comprised 85 patients (23%). These frequencies are consistent with Hardy-Weinberg 
equilibrium (P = .95, Pearson Χ2 square). Overall, the level of anxiety was reduced 
postoperatively (Table 1 and Table 2).
All main terms together with all possible interactions including UGT2B15 genotype and 
treatment condition are presented in Table 3. The highest order interaction that was 
statistically significant comprised the following variables: UGT2B15 genotype, treatment 
condition, patient sex, and preoperative anxiety score (F = 7.15; df = 1, 339; P = .008).
Interpretation of higher order interactions can be complex.19 For a more detailed 
understanding of this interaction and its clinical meaning and significance, the median 
differences and other descriptive statistics of patient categories on STAI-State according 
to the used determinants are presented and visualized in Appendix 1 and Figure 2, 
respectively. Because the preoperative measurement of STAI-State is continuous, we 
dichotomized the scores at the overall mean level of STAI-State to make visualization 
feasible. Anyway, this did not affect the results. 
According to STAI-State descriptive statistics (Appendix 1), median differences range 
from -0.50 to 18.00. As mentioned previously, positive median differences represent a 
decrease of anxiety postoperatively. 
Patients with low preoperative anxiety scores
Median differences of patients with low preoperative anxiety scores showed a range 
from -0.50 to 7.00. All female groups together with males in the placebo condition 
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TABLE 1 | Descriptive analysis of used variables
n %
Sex
Male 224 56.3
Female 174 43.7
Treatment condition
Lorazepam 198 49.7
Placebo 200 50.3
UGT2B15 Genotype Polymorphism
Wild type 85 22.8
Heterozygous 185 49.7
Homozygous 102 27.4
Median                                                        IQR, percentiles
25 75
Anxiety (STAI-State)
Preoperative (n=398) 37.0 31.75 44.00
Postoperative (n=388) 30.0 26.00 35.00
TABLE 2 | Pre- and postoperative anxiety scores
        Preoperative median STAI-score          Postoperative median STAI-score 
UGT2B15 wt/ht UGT2B15 hz UGT2B15 wt/ht UGT2B15 hz
Lorazepam 36.00 39.00 32.00 30.00
Placebo 36.00 35.00 29.00 27.50
n= number of patients; % = percentage; IQR = interquartile range; STAI-State = State-Trait Anxiety Inventory, State part; 
Minimum-maximum score STAI-State = 20-80.
STAI-State = State-Trait Anxiety Inventory, State part; UGT2B15 wt/ht = wild type and heterozygous UGT2B15*2; UGT2B15 hz 
= homozygous UGT2B15*2.
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TABLE 3 | Significance testing of anxiety difference
Source of variation F-test † P value 
UGT2B15 (U) 0.06 .80
Treatment Condition (C) 1.09 .30
Sex (S) 2.11 .15
Preoperative Anxiety Score (P) 225.29 <.0001
U*C*S 8.00 .005
U*C*P 0.71 .40
U*C*S*P 7.15 .008
showed anxiety reduction in the postoperative period independently of UGT2B15 
genotype. This was not observed for males in the lorazepam condition: males with 
normal UGT2B15 genotype showed no anxiety reduction, whereas males with deviant 
UGT2B15 genotype did show anxiety reduction (Figure 2).
Patients with high preoperative anxiety scores
Median differences of patients with high preoperative anxiety scores showed a range 
from 9.00 to 18.00. Thus, all patient categories showed anxiety reduction in the 
postoperative period. Males in the lorazepam condition with normal UGT2B15 genotype 
showed greater anxiety reduction than males with deviant UGT2B15 genotype. In 
contrast, females in the lorazepam condition showed opposite results (Figure 2, 
Appendix 1).
Males in the placebo condition with normal UGT2B15 genotype showed less anxiety 
reduction than males with deviant UGT2B15 genotype. In contrast, females in the 
placebo condition showed opposite results (Figure 2, Appendix 1). 
DISCUSSION
The principal finding of this study is that the UGT2B15 genotype has an influence on 
postoperative anxiety levels in same-day surgery patients receiving a single dosage 
of lorazepam as premedication. This clinical effect also depends on patient sex and 
preoperative anxiety score. Our finding supports data from previous research showing 
a large variability in clinical effects of lorazepam in healthy volunteers.5
For the anxiety median differences, most clinical significant results were seen in patients 
 † Corresponding degrees of freedom 1, 339; * = interaction; STAI-State = State-Trait Anxiety Inventory, State part; Sex was 
coded as 1 for females and 0 for males. Treatment condition was coded as 1 for lorazepam and 0 for placebo. UGT2B15 was 
coded as 1 for homozygous UGT2B15*2 and 0 for wild type UGT2B15 and heterozygous UGT2B15*2. Analysis adjusted for 
surgical speciality and type of anesthesia. Model R Squared = 0.72 (Adjusted R Squared = 0.70). 
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with high preoperative anxiety scores (Figure 2). They showed more reduction in anxiety 
compared with patients with low preoperative anxiety scores. Therefore, we believe 
that the signifi cant highest-order interaction is predominately driven by patients with 
high preoperative anxiety scores. In light of clinical signifi cance (i.e. median diff erences 
≥9.0 on a 20 – 80 point scale),20 we discuss these patient categories only.
The fi gures show that anxiety reduction in patients treated with placebo is likely because 
of the well-known placebo eff ect, because pharmacologic interaction between placebo 
and UGT2B15 genotype is not known. Preoperative administration of placebo is known 
to reduce postoperative anxiety.9
FIGURE 2 | STAI-State median diff erence for each patient category 
The y-axis shows the median diff erences of the anxiety diff erences (i.e. preoperative anxiety score minus postoperative 
anxiety score). Positive median diff erences represent a decrease in anxiety postoperatively. Vertical bars represent standard 
errors according to that particular patient category.
0 
5 
10 
15 
20 
Lorazepam Placebo Lorazepam Placebo 
Pr
eo
pe
ra
ti
ve
 - 
po
st
op
er
at
iv
e 
an
xi
et
y 
sc
or
e 
Males                                 Females 
State anxiety 
Patients with low preoperative anxiety scores 
Wild type, heterozygous UGT2B15*2 
Homozygous UGT2B15*2 
0 
5 
10 
15 
20 
Lorazepam Placebo Lorazepam Placebo 
Pr
eo
pe
ra
ti
ve
 - 
po
st
op
er
at
iv
e 
an
xi
et
y 
sc
or
e 
Males                                 Females 
State anxiety 
Patients with high preoperative anxiety scores 
Wild type, heterozygous UGT2B15*2 
Homozygous UGT2B15*2 
Mijderwijk.indd   61 28-10-2016   07:01:10
| 62 
| Chapter 3
Concerning postoperative anxiety reduction in patients treated with lorazepam, we 
expected more anxiety reduction in homozygous carriers of the UGT2B15*2 genotype.5 
Therefore, of interest was the finding that anxiety reduction in females was almost 2 
times greater compared with males with this genotype. Jackson et al10 showed that sex 
differences after a single dosage of lorazepam is not likely because of pharmacokinetic 
differences and suggested that endogenous levels of neurosteroid hormones is a 
feasible explanation for the greater clinical effect of lorazepam in females. Moreover, 
one must take into account that levels of endogenous neurosteroid hormones, such 
as allopregnanolone, increase in stressful situations.21 Allopregnanolone – a metabolite 
of the ovarian hormone progesterone – is one of the most potent endogenous 
neurosteroid hormones having the ability to positively modulate the γ-aminobutyric 
acid receptor type A.22 Furthermore, it has been shown that allopregnanolone enhances 
the effects of benzodiazepine receptor agonists.23-25
Although explorative, this result may be of clinical relevance. It has been reported that 
almost half (49%) of the same-day surgery patients request preoperative anxiolytic 
premedication.26 Administration of anxiolytic premedication traditionally focuses on the 
preoperative stress of a patient, but postoperative recovery has become of increasing 
importance, which has to be considered when the anesthesiologist decides to prescribe 
premedication. On the basis of recent randomized clinical trials,9,27 anesthesiologists 
could negatively counsel patients in their preoperative assessment with respect to 
administration of premedication with lorazepam. However, our results might indicate 
that preoperative anxious females requesting premedication with lorazepam might 
benefit from UGT2B15*2 genotyping because homozygous carriers show more 
postoperative anxiety reduction.
Study limitations
The results and application of the present study should be interpreted cautiously and 
within the context of the study methodology. Although we now have broader evidence 
that the UGT2B15 genotype is not an independent determinant for the clinical effects 
of lorazepam, there could be still an explanation for this finding. First, this might be 
explained by the single dosage of intravenous lorazepam in this study. Second, 
the dosage of lorazepam administered could be too low to be influenced by 
UGT2B15 genotype polymorphism. The very reason that we have refrained from 
administering a greater dosage was that it could provoke unwanted side effects 
such as drowsiness,4 which would lead to delayed recovery which is not suitable for 
patients undergoing same-day surgery. Third, we refrained from significance testing 
on differences between the patient categories because of an insufficient number in these 
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patient categories and to avoid multiple testing (Appendix 1). Fourth, patients with low 
preoperative anxiety scores could have biased our results because those patients do 
not have the ability to show significant reduction in anxiety. In addition, although the 
analysis was adjusted for type of surgery and type of anesthesia to control for possible 
confounding, any medications given perioperatively and postoperative side-effects (e.g. 
nausea, drowsiness and pain) could still have biased the results and should be therefore 
subjected to further research. Fifth, because we do not have pharmacokinetic data in 
the present study, we assume that lorazepam plasma concentration differences have 
played a role. The rationale for studying the clinical effects of lorazepam on the UGT2B15 
genotype was the known significant association between lorazepam pharmacokinetics 
and the UGT2B15 genotype.5 Furthermore, in clinical practice, lorazepam is administered 
because of its clinical effects especially from a patient perspective. Sixth, our findings 
may not be necessarily extrapolated to other ethnic groups because it is known that 
ethnic origin could influence pharmacogenetics.28 Our results are in line, however, with 
previous findings on other clinical effects of lorazepam according to UGT2B15 genotype 
polymorphisms found in Korean people.5 Furthermore, our study population has 
similar UGT2B15 genotype frequencies compared with previous Caucasian populations 
studied.29,30
Future perspectives
Although it is known that pharmacogenetics influence the clinical response to 
perioperative drugs, routine screening prior to pharmacotherapy is still not cost-
effective in clinical anesthesiology as we administer drugs to a large number of patients 
and frequently once only.31 It is recommended, however, that clinical studies evaluating 
drug response in anesthesiology include pharmacogenetic testing.31,32 Pharmacogenetic 
data obtained could be used, for example, for diagnostic purposes and risk stratification 
and could be of help to progress in new clinical studies in anesthesiology.31 
In case of premedication with lorazepam, we cannot recommend routine screening of 
UGT2B15 genotype at the moment. However, this study does define a population of 
clinical interest for future research. Future studies should be tailored to patients with 
high preoperative anxiety scores to gain more firm conclusions regarding the interaction 
between lorazepam and UGT2B15 genotype on postoperative anxiety.
CONCLUSION
UGT2B15 genotype influences postoperative anxiety levels in same-day surgery 
patients receiving lorazepam premedication. In patients with high preoperative 
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anxiety scores treated with lorazepam, anxiety reduction was greater in females 
with the homozygous UGT2B15*2 genotype compared to males with the same 
genotype polymorphism. To gain a deeper understanding in the clinical relevance of 
the interaction between lorazepam and UGT2B15 genotype on postoperative anxiety 
levels, future studies—especially randomized clinical controlled trials—focussing on 
patients with high preoperative anxiety scores would be required.
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APPENDIX 1 | Descriptive statistics of STAI-State distinguished by treatment condition, 
UGT2B15 genotype polymorphism, patient sex and preoperative anxiety score
Patient category Treat UGT Gender n Median SE
1. Lora wt/ht Male 38 -0.50 1.01
2. Lora hz Male 20 7.00 1.22
3. Plac wt/ht Male 59 4.00 0.76
4. Plac hz Male 20 4.00 1.64
5. Lora wt/ht Female 31 2.00 1.18
6. Lora hz Female 7 3.00 2.48
7. Plac wt/ht Female 24 4.00 1.12
8. Plac hz Female 8 6.50 1.46
1. Lora wt/ht Male 25 14.00 1.81
2. Lora hz Male 15 9.00 2.36
3. Plac wt/ht Male 23 13.00 1.64
4. Plac hz Male 5 18.00 2.65
5. Lora wt/ht Female 30 12.50 1.24
6. Lora hz Female 13 17.00 3.16
7. Plac wt/ht Female 34 18.00 1.46
8. Plac hz Female 11 12.00 3.05
STAI-State = State-Trait Anxiety Inventory, State part; white = patients with low preoperative anxiety scores; grey = 
patients with high preoperative anxiety scores; Treat, treatment condition: Plac = Placebo (NaCl 0.9%), Lora = lorazepam; 
UGT = UGT2B15 Genotype: wt/ht = wild type and heterozygous UGT2B15*2, hz = homozygous UGT2B15*2; n = number of 
patients; SE = standard error.
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ABSTRACT
Benzodiazepines are frequently used as a premedication. In day-case surgery, 
anaesthetists are reluctant to administer benzodiazepines preoperatively for reasons of 
delayed recovery. However, premedication with benzodiazepines might be beneficial 
regarding postoperative somatic symptoms/complaints (i.e. time to recovery and 
postoperative side effects) and psychological phenomena. A systematic review with 
meta-analysis was performed using all important search engines. Study methodological 
quality was assessed using risk of bias tables. Mean differences (MD) and odds ratios 
(OR) were used for continuous data (time to recovery and psychological phenomena) 
and categorical data (postoperative somatic symptoms) respectively. Random effects 
modelling was applied. Nineteen studies were included. Overall time to recovery was 
significantly delayed in patients receiving benzodiazepines (MD 1.75; 95% CI 0.82 to 
2.69) although time to discharge was not significantly affected. Postoperative side 
effects were significantly reduced in patients receiving benzodiazepines (OR 0.47; 95% 
CI 0.36 to 0.63). Regarding psychological outcome, only anxiety could be statistically 
analysed showing no statistical difference (MD 1.47; 95% CI -1.01 to 3.96). Although 
overall time to recovery was significantly prolonged by benzodiazepine premedication, 
withholding premedication in day-case surgery patients is not justified for such reason, 
as time to discharge was not negatively affected. Furthermore, benzodiazepines show 
to have beneficial effects on postoperative side effects. For firm conclusion regarding 
psychological phenomena, more research is needed. Anaesthetists should take into 
account this new evidence when they apply their premedication regime in day-case 
surgery.
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INTRODUCTION
Benzodiazepines are among the most prescribed drugs used for premedication.1 In a 
clinical setting, anaesthetists frequently administer benzodiazepines preoperatively as 
they have unique properties like anxiolysis – one of the main goals of premedication 
–, calming effects and anterograde amnesia as a favourable side effect profile.1 
Anaesthetists are reluctant to prescribe premedication (with benzodiazepines) in a day-
case setting as patients could be too somnolent postoperatively. Consequently, this 
may prolong their time to discharge which should be avoided, especially, in day-case 
surgery. However, a Cochrane Review could not support this hypothesis,2 although they 
did not focus specifically on benzodiazepine premedication. Furthermore, withholding 
premedication may not be justified as almost half of the patients in day-case surgery 
request something to relieve their stress and anxiety.3
In day-case surgery, patient’s somatic symptoms became of minor interest as 
perioperative morbidity and mortality are extremely low.4 Therefore, day-case surgery 
patients place higher priority on psychological phenomena rather than physical 
recovery in the postoperative period. Along with this, literature shows more attention 
for psychological aspects of perioperative care.5,6 Research evaluating benzodiazepine 
administration in day-case surgery is focussing on psychological phenomena including 
anxiety, fatigue, aggression and depressive moods.7
Preoperative benzodiazepine administration is mostly evaluated preoperatively. 
However, the reluctance of anaesthetists is based on potential postoperative concerns. 
Therefore, to determine whether benzodiazepine premedication in day-case surgery is 
appropriate, thorough research focussing on the postoperative period is needed.
To evaluate the effectiveness of benzodiazepine administration in day-case surgery, we 
conducted a systematic review with meta-analysis of randomised trials focussing on 
postoperative somatic symptoms/complaints and psychological phenomena. 
This systematic review and meta-analysis tested three related hypotheses:
1. In adult day-case surgery, benzodiazepines as a premedication do elongate time to 
recovery from general or regional anaesthesia;
2. Benzodiazepines as a premedication do beneficially affect postoperative somatic 
symptoms/complaints; and
3.  Benzodiazepines as a premedication do reduce postoperative psychological sequelae.
Mijderwijk.indd   71 28-10-2016   07:01:11
| 72 
| Chapter 4
METHODS
The Preferred Reporting Items for Systematic Review and Meta-Analyses guidelines were 
adhered to.8
Literature search
Literature search was performed in Embase, Medline OvidSP, ISI Web of Science, Scopus, 
Cochrane Central Register of Controlled Trials, PubMed Publisher, and Google Scholar, 
updated until January 2014. There were no language or publication date restrictions. 
Main key words for the search queries included day surgery, postoperative psychological 
aspect, somatic symptoms/complaints, and premedication. The full search is presented 
in Appendix 1.
Study selection
All randomised controlled trials including human adult patients undergoing day-
case surgery were included when they really tested premedication. We defined 
‘premedication tested’ as any medication given prior to induction of anaesthesia that 
was continued neither during the surgical procedure nor postoperatively. In addition, 
the intervention had to be tailored to the premedication itself. We excluded studies 
where no postoperative outcomes were assessed. Original articles written in English, 
German or French that included an abstract were maintained in the set in order to 
reduce language bias. Next, we excluded trials based on clinical anaesthetic and 
surgical selection criteria. Anaesthetic exclusion criteria concerned not undergoing 
general or regional anaesthesia. Surgical exclusion criteria included not undergoing 
day-case surgery or undergoing abortion, dental surgery or ophthalmology surgery. 
Also, trials testing non-benzodiazepines as a premedication were excluded. Finally, non-
randomised studies and studies with no placebo control (i.e. methodological criteria) 
were excluded.
Data extraction and management
Three authors (HM, SVB, RJS) independently analysed studies for inclusion in the analysis. 
Two authors (HM, SVB) independently assessed all included studies with respect to their 
quality. Data was extracted using a pre-set collection sheet. Authors were not blinded 
for information regarding the identified studies (e.g. journal, author, institution, date of 
publication), as it was previously shown that not blinding did not influence the results 
of meta-analysis.9 Disagreement among authors was resolved by consensus.
Included studies were reviewed for data on any of the following outcomes:
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1. Somatic symptoms/complaints—time to recovery, time to eye opening, time 
to first correct response (TCR), time to early recovery (i.e. discharge form the 
recovery room) and time to discharge; postoperative side effects, including, nausea, 
vomiting/emesis, dizziness, pain, headache and miscellaneous (coughing and 
double vision).
2. Psychological outcomes—anxiety, depression, fatigue and aggression.
All outcomes were eligible for assessment when they were measured up to the first 
postoperative day. 
FIGURE 1| Flow of information
(duplicates)
excluded n=31
excluded n=459
(no premedication tested, 
paediatrics, no postoperative 
outcomes assessed, article 
language non-
Englisch/French/German, no 
abstract available, non-original 
article)
excluded n=38
(non-general/regional anaesthesia, 
non day-case surgery, day-case 
surgery excluded)
excluded n=39
 (methodological criteria n=12, 
clinical criteria n=16, full article not 
retrieved n=3)
Embase n=213
included in systematic review/meta-
analysis n=19
combined literature search n=1094
included for title/abstract screening 
n=586
included after screening for 
title/abstract n=127
included for screening full article 
n=50
Google Scholar n=100
Pubmed Publisher n=0
included for screening full article 
n=89
Cochrane n=66
Scopus n=354
Web of Science n=60
Medline OvidSP n=301
(non-benzodiazepine 
premedication)
excluded n=508
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Quality assessment
The Cochrane Handbook of Systematic Reviews of Interventions was used to evaluate 
the risk of bias of each included study.10 Selection-, performance-, detection-, attrition-, 
reporting- and other biases are assessed in this risk of bias tool.
Statistical Analysis
Categorical outcome data were evaluated by odds ratios (OR) while continuous outcome 
data were evaluated using mean differences (MD). Random effects model was used 
for each outcome. Meta-regression was performed in order to evaluate heterogeneity 
among studies and included the following covariates: year of publication, quality 
assessment and the journal’s impact factor. Sensitivity analyses were performed in 
order to evaluate whether eliminating influential studies affect the results. Studies that 
exceed Cook’s distance 1/n were found influential. Funnel plots were used to graphically 
examining small study effects as an asymmetrical funnel shape may indicate publication 
bias.11 Inconsistency among studies was evaluated by means of the I2-statistic. An I2-
statistic of 25%, 50% and 75% were respectively defined as low, moderate and high 
inconsistency.12 We used Review Manager (RevMan) version 5.3 from the Cochrane 
Collaboration for analysis. Meta-regression was done in SPSS version 20.0 (IBM, NY, 
Armonk). Statistical significance was fixed at P < 0.05 (two-tailed).
RESULTS
Study selection and characteristics
The search was performed on 31 January 2014. After excluding duplicates (n = 508), 
586 studies were screened on the base of title/abstract. Based on the selection criteria, 
clinical criteria and studies that did use benzodiazepines as a premedication we excluded 
497 articles. Fifty full articles were reviewed accordingly. However, three articles could 
not be retrieved. We excluded 31 studies based on methodological and clinical criteria. 
Ultimately, 19 articles were eligible for systematic review/meta-analysis (Figure 1).7,13-30 
Table 1 shows the study characteristics. The risk of bias of the included studies is shown 
in Appendix 2. The risk of bias graph showing each risk of bias as percentages across all 
included studies is shown in Appendix 3. Appendix 4 shows the risk of bias scoring of 
the individual studies.
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Somatic symptoms/complaints—time to recovery
Twelve studies were included in meta-analysis with 1445 patients 
altogether.13,15,16,19,21-25,27,29,30 Applying random effects model resulted into Tau2 = 2.78, 
Chi2 = 69.73, df = 26, P < 0.01, I2 = 63%. Overall time to recovery was significantly 
delayed by benzodiazepines with 1.75 minutes (95% CI 0.82 – 2.69) (Figure 2a). Time to 
eye opening was significantly delayed with 1.47 minutes by benzodiazepines (95% CI 
0.51 – 2.42), but we could not find statistical significant differences regarding time to 
first correct response (P = 0.06), time to early recovery (P = 0.24) and time to discharge 
(P = 0.39), Figure 2a. Sensitivity analyses did not provide new insights. None of the 
covariates could explain the heterogeneity among the studies for time to eye opening, 
early recovery and discharge. However, time to first correct response (TCR) increased 
significantly in studies with a higher methodological quality (Appendix 5). All funnel 
plots of these studies were not considered asymmetrical (Appendix 6a).
In addition, Beechey et al., Hargreaves and Raybould et al. could not be subjected to meta-
analyses but did report on time to recovery.17,24,29,31 Beechey et al. found no difference 
in the time to awaken from anaesthesia.17,31 Hargreaves found that awakening from 
anaesthesia was significantly longer in the midazolam group compared to placebo and 
temazepam groups.24 Raybould et al. showed that the group receiving a benzodiazepine 
did not show significantly longer recovery times.29
Somatic symptoms/complaints—postoperative side effects
Seven studies were included in meta-analysis with 1530 patients 
altogether.14,16,17,23,26,28,30Results of random effects model yielded Tau2 = 0.00, Chi2 = 19.25, 
df = 24, P = 0.74, I2 = 0%. Overall postoperative side effects occurred significantly less in 
patients treated with benzodiazepines (OR 0.47, 95% CI 0.36 – 0.63) (Figure 2b).
Nausea (OR 0.34, 95% CI 0.21 – 0.55) and headache (OR 0.44, 95% CI 0.25 – 0.78) occurred 
significantly less in the patients treated with benzodiazepines. However, we could not 
find statistical significant differences regarding vomiting (P = 0.08), dizziness (P = 0.68) 
and the miscellaneous group (P = 0.21). Categorical data regarding pain showed no 
statistical significant difference (P = 0.86) as well as pain scored on a continuous scale 
(P = 0.55).
In addition, de Witte et al., Hargreaves and Kain et al. could not be subjected to meta-
analyse but did report postoperative side effects.19,24,25 De Witte et al. found no statistical 
difference in the incidence of nausea or vomiting and other side effects including 
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dizziness and headache.19 Hargreaves found no statistical difference in the incidence 
of minor side effects.24 However, nausea was found in 8 patients receiving temazepam, 
which was statistically significant when compared to the placebo group. Kain et al. found 
no significant difference regarding a postoperative pain score (Visual Analogue Score 
[VAS] >30) on discharge form the Post Anaesthesia Care Unit (PACU).25 Furthermore, 
undefined adverse effects were not significantly different in PACU.
Sensitivity analysis and meta-regression did not provide new insights (Appendix 5). 
Funnel plot for dizziness was asymmetrical suggesting publication bias; the other 
funnel plots were considered symmetrical (Appendix 6b).
Psychological outcomes
A total of 4 studies assessing anxiety were included in meta-analysis with 653 
patients.7,25,27,30 Random effects model yielded Tau2 = 3.96, Chi2 = 15.33, df = 3, P < 0.01, I2 
= 80%. Anxiety was not significantly affected (mean difference 1.47, 95% CI -1.01 – 3.96) 
(Figure 2c).
Ahmed et al., Bauer et al., Berendes et al., de Witte et al., Duggan et al. and Fredman et al. 
could not be subjected to meta-analysis but did report on anxiety.14,16,18-20,22 Ahmed et 
al. found no significant difference in patient’s anxiety levels.14 Bauer et al. did not found 
statistical significant difference in patient’s anxiety levels in PACU and at discharge from 
PACU.16 Berendes et al. found that clorazepate dipotassium had significant lower anxiety 
scores compared to placebo.18 No significant difference was found between midazolam 
and placebo. De Witte et al. found that all patients in the midazolam group reported 
a sufficient quality of anxiety reduction; 2 patients in the alprazolam group reported 
insufficient anxiety reduction and 1 patient did not know; 7 patients in the placebo 
group reported insufficient anxiety reduction and 3 patient did not know, which was 
statistically significant among groups.19 Duggan et al. found no significant difference 
in anxiety scores (VAS and State part of the State-Trait Anxiety Inventory (STAI-State)) 
at discharge.20Fredman et al. found that anxiety scores were unaffected during PACU 
admission.22
The studies by Kain et al. and Mijderwijk et al. measured anxiety beyond the first 
postoperative day.7,25 Kain et al. found a significant greater reduction in anxiety in 
the benzodiazepine group compared with placebo from 2-30 days after surgery.25 
Mijderwijk et al., on the seventh day after surgery, found significant greater reduction in 
anxiety measured by means of the Trait part of the State-Trait Anxiety Inventory (STAI-
Trait) and by means of the Hospital Anxiety and Depression Scale (HADS) in the placebo
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group, although no significant result was found regarding STAI-state.7 
None of the covariates enabled explaining heterogeneity among the studies (Appendix 
5). Sensitivity analyses did not provide new insights. The funnel plot was not considered 
asymmetrical (Appendix 6c).
Only the studies by Mijderwijk et al. and Oxorn et al. have reported about depression, 
fatigue and aggression.7,27 Oxorn et al. have reported results up to first postoperative 
day.27 They found no significant differences on depression and aggression while 
Mijderwijk et al. measured these outcomes beyond the first postoperative day.7Although 
no significant differences were found on depression, fatigue and trait aggression on the 
seventh day after surgery, yet they found a statistically significant result regarding state 
aggression.
DISCUSSION
Principal finding
The principal finding of this systematic review with meta-analysis is that overall 
benzodiazepines did unfavourably affect time to recovery, did reduce the incidence of 
postoperative side effects but they did not statistically significantly affect psychological 
outcomes. These findings will be discussed in further detail below.
Time to recovery
The overall test of significance showed that time to recovery is significantly prolonged 
in patients administered benzodiazepines preoperatively. However, only time to eye 
opening is significantly prolonged by 1.47 minutes in the benzodiazepine group. Time 
to early recovery and time to discharge were not affected by benzodiazepines. Although 
not statistically significant, benzodiazepines tend to prolong TCR. The articles that could 
not be subjected to meta-analysis are considered to have no influence.17,24,29
Considering all this, we agree with (some) anaesthetists that recovery time is prolonged 
by benzodiazepines but only at the first stage of recovery. Time to early recovery and 
time to discharge are clearly not affected by benzodiazepine premedication which is in 
line with a previous review.2 Therefore, withholding benzodiazepine premedication for 
reasons of delayed discharge time seems not justified in day-case surgery.
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FIGURE 2B | Forest plots for postoperative side effects (1/2) 
Regarding Raeder JC et al., postoperative n was determined proportionally and data regarding ‘nausea at home’ was ignored 
as this data is likely correlated with ‘nausea at recovery’.
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Postoperative side effects
The overall test of significance showed that premedication with benzodiazepines 
significantly reduced the incidence of postoperative side effects with 53%. When 
looking into further detail, benzodiazepine premedication clearly reduces the risk of 
postoperative headache (56%) and nausea (66%), and show a tendency to reduce the 
risk of vomiting. The risk of postoperative dizziness, pain and miscellaneous side effects 
was not statistically significantly affected by benzodiazepines. The articles not meeting 
the standards for this meta-analysis are considered to have no influence.19,24,25
After discharge from day-case surgery, headache, nausea and vomiting emerge 
with incidence rates of 27%, 17-21% and 5.7-8% respectively.32,33 Benzodiazepine 
premedication could be a favourable way to reduce these postoperative side effects, 
and, consequently, enhancing the quality of patients’ somatic recovery. We are fully 
aware that with regards to postoperative somatic symptoms/complaints, more factors 
could emerge in the postoperative period, such as sore throat and back pain.32,33 
Unfortunately, due to lack of data we could not test for these factors with regards to 
benzodiazepine premedication. This could be subject of further research.
Psychological phenomena
We were able to perform meta-analysis for anxiety, showing no statistical significant 
differences between benzodiazepine or placebo groups. With regards to the other 
psychological outcomes (i.e. depression, aggression and fatigue), meta-analysis 
could not be performed at all as they did not meet the eligibility criteria with regards 
to the time span. Therefore, the effects of premedication with benzodiazepines on 
psychological phenomena remain inconclusive. Given the shift towards psychological 
outcome in day-case surgery,5-7 we need more research on this topic. This should also be 
studied beyond the first postoperative day as recommend by others.32 Furthermore, we 
need more research on interventions in the preoperative period that could beneficially 
affect the postoperative period.34
Methodological strengths and weaknesses
The rationale for our extensive literature search was to get a solid understanding of the 
effects of benzodiazepine premedication in day-case surgery patients regarding somatic 
symptoms/complaints and psychological phenomena emerging in the postoperative 
period. By doing so, we minimized the risk of selection bias too. As a consequence, we 
had to evaluate many studies for eligibility. Selection bias was also minimized by not 
excluding studies based on their quality assessment. We tried to minimize language bias 
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by including articles not only written in English but also in German and France, when 
appropriate. This strategy seems justified as we included an article written in German.18 
However, potential language bias could not be ruled out. We were able to check the 
possible influence of the year of publication on the outcomes, as we did not have year of 
publication restrictions in our literature search. We used a pre-set standardized form for 
data-extraction and management. Risk of bias tables were used to evaluate the quality 
of each study, which was done by two authors individually. Discrepancies were resolved 
by consensus. Meta-regression was performed on each outcome individually. Meta-
regression was not always possible as numerical data was not always clearly provided or 
not provided. To deal with this, we systematically described the results of the outcomes 
of these studies.
Random effects model was performed for each meta-analysis when heterogeneity 
was present. For consistency’s sake, we also performed random effects model when 
heterogeneity was statistically not significant. Another justification for this analysis 
strategy is that judgements for heterogeneity in meta-analysis can be misleading when 
the number of included patients is insufficient.35 Thus we possibly could have under-
estimated heterogeneity and therefore we have applied random effects model even 
when heterogeneity was statistically insignificant.
The fact that heterogeneity is predominantly present in time to recovery and 
psychological phenomena while heterogeneity is nearly present in postoperative side 
effects suggests that the assessment sources may be different. With regards to time 
to recovery, in the majority of the studies it is unclear who actually measured time to 
recovery. However, in the study by De Witte et al. study nurses observed the patients 
in the recovery room.19 Likely, although not specifically stated, they assessed time to 
early recovery. Accordingly, interjudgement unreliability bias may have emerged and 
this could be the reason for the wide confidence intervals of this particular study. On 
the other hand, intrajudgement unreliability may have played a role when, for example, 
the pre-set definitions for specific time to recovery were not clear. Furthermore, next to 
these within study variation, in between study heterogeneity is possibly caused by intra- 
and/or interjudgement bias. Physicians, nurses or investigators may have alternately 
assessed time to recovery in patients, which is likely to induce bias.
The moderate inconsistency regarding dizziness can be caused by the vague definition of 
dizziness interpreted by patients. However, it was previously shown that heterogeneity 
might also be due to publication bias36 (i.e. small studies with expressive results are 
likely to be published) and in the case of dizziness publication bias has emerged.
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Heterogeneity can also be present due to conceptual concerns, especially in case of 
psychological outcomes. For example, anxiety itself can be considerably heterogeneous 
and reasons for heterogeneity can be difficult to clarify.37 Furthermore, heterogeneity 
among studies may always be due to change.11
In this study, we have focussed on a homogenous group of drugs used for premedication. 
As a consequence, we were able to perform meta-analysis and could draw conclusions 
from our results accordingly. Such a statistical synthesis was previously not feasible due 
to too many different premedication drugs.2 A total of eight different benzodiazepines, 
three different administration routes and different times of administration were 
nonetheless present in our meta-analysis. Unfortunately, it was methodologically 
statistically not feasible to evaluate this possible heterogeneity in our meta-regression. 
However, administration of benzodiazepines is characterized by high efficacy despite 
differences in route of administration and pharmacological properties.
CONCLUSION
This systematic review with meta-analysis provides new evidence for beneficial effects 
of premedication with benzodiazepines in day-case surgery. Benzodiazepine premedi-
cation does prolong time to recovery but only at the first stage of postoperative recov-
ery – time to discharge is not affected. Furthermore, benzodiazepines seem to reduce 
the incidence of postoperative side effects with 53%. However, effects on psychological 
outcomes remain inconclusive. It is recommended that future studies should also focus 
on other postoperative side effects, and on psychological phenomena.
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APPENDIX 1 | Complete literature search, 31 January 2014
Embase 213 210
Medline OvidSP 301 157
Web-of-science 60 26
Scopus 354 119
Cochrane 66 6
PubMed publisher 0 0
Google Scholar 100 68
Total 1094 586
Duplicates removed: 508
Embase 
(‘ambulatory surgery’/de OR (((ambul* OR day OR daycare OR daycase OR outpatient* 
OR office*) NEAR/3 (surg* OR operati*))):ab,ti) AND (‘psychological aspect’/de OR 
psychology/exp OR emotion/exp OR depression/exp OR fatigue/de OR exhaustion/
de OR stress/exp OR ‘adaptive behavior’/de OR ‘surgical stress’/de OR (psycholog* OR 
emotion* OR anxiet* OR fatigue OR exhaust* OR depress* OR perception* OR (somatic 
NEAR/3 (symptom* OR complain*)) OR ((mental OR preoperat* OR postoperat* OR 
perioperat* OR operative* OR surg*) NEXT/1 stress) OR (adapt* NEAR/3 behavio*) 
OR coping):ab,ti) AND (adult/exp OR ‘middle aged’/de OR aged/exp OR (adult* OR 
aged):ab,ti) AND (premedication/de OR benzodiazepine/de OR ‘anesthetic agent’/exp 
OR ‘antidepressant agent’/exp OR tranquilizer/exp OR (premedicat* OR pretreatment* 
OR (pre NEXT/1 (medicat* OR treatment* )) OR preanesthe* OR preanaesthe* OR 
anaesthetic* OR anesthetic* OR ((anxiet* OR antianxiet* OR ataract*) NEAR/3 (agent* 
OR drug*)) OR benzodiazepine* OR anxiolytic* OR tranquill* OR antidepress*):ab,ti) AND 
((random* OR factorial* OR crossover* OR (cross NEXT/1 over*) OR placebo* OR ((doubl* 
OR singl*) NEXT/1 blind*) OR assign* OR allocat* OR volunteer*):ab,ti OR ‘crossover 
procedure’/de OR ‘double-blind procedure’/de OR ‘randomized controlled trial’/de OR 
‘single-blind procedure’/de) NOT ([animals]/lim NOT [humans]/lim)
Medline OvidSP 
(“Ambulatory Surgical Procedures”/ OR (((ambul* OR day OR daycare OR daycase OR 
outpatient* OR office*) ADJ3 (surg* OR operati*))).ab,ti.) AND (exp psychology/ OR 
psychology.xs. OR exp emotions/ OR depression/ OR exp fatigue/ OR “Stress, 
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Psychological”/ OR “Adaptation, Psychological”/ OR “surgical stress”/ OR (psycholog* OR 
emotion* OR anxiet* OR fatigue OR exhaust* OR depress* OR perception* OR (somatic 
ADJ3 (symptom* OR complain*)) OR ((mental OR preoperat* OR postoperat* OR 
perioperat* OR operative* OR surg*) ADJ stress) OR (adapt* ADJ3 behavio*) OR coping).
ab,ti.) AND (exp adult/ OR (adult* OR aged).ab,ti.) AND (premedication/ OR “Preanesthetic 
Medication”/ OR exp benzodiazepines/ OR exp “anesthetics”/ OR exp “antidepressive 
agents”/ OR exp “Tranquilizing Agents”/ OR (premedicat* OR pretreatment* OR (pre 
ADJ (medicat* OR treatment* )) OR preanesthe* OR preanaesthe* OR premedicat* OR 
pretreatment* OR preanesthe* OR preanaesthe* OR anaesthetic* OR anesthetic* OR 
((anxiet* OR antianxiet* OR ataract*) ADJ3 (agent* OR drug*)) OR benzodiazepine* OR 
anxiolytic* OR tranquill* OR antidepress*).ab,ti.) AND (Clinical Trial.pt. OR randomized.
ab,ti. OR placebo.ab,ti. OR dt.fs. OR randomly.ab,ti. OR trial.ab,ti. OR groups.ab,ti. NOT 
(Animals/ NOT Humans/ ))
Cochrane 
((((ambul* OR day OR daycare OR daycase OR outpatient* OR office*) NEAR/3 (surg* 
OR operati*))):ab,ti) AND ((psycholog* OR emotion* OR anxiet* OR fatigue OR exhaust* 
OR depress* OR perception* OR (somatic NEAR/3 (symptom* OR complain*)) OR 
((mental OR preoperat* OR postoperat* OR perioperat* OR operative* OR surg*) NEXT/1 
stress) OR (adapt* NEAR/3 behavio*) OR coping):ab,ti) AND ((adult* OR aged):ab,ti) 
AND ((premedicat* OR pretreatment* OR (pre NEXT/1 (medicat* OR treatment* )) 
OR preanesthe* OR preanaesthe* OR anaesthetic* OR anesthetic* OR ((anxiet* OR 
antianxiet* OR ataract*) NEAR/3 (agent* OR drug*)) OR benzodiazepine* OR anxiolytic* 
OR tranquill* OR antidepress*):ab,ti)
Web-of-science 
TS=(((((ambul* OR day OR daycare OR daycase OR outpatient* OR office*) NEAR/3 (surg* 
OR operati*)))) AND ((psycholog* OR emotion* OR anxiet* OR fatigue OR exhaust* OR 
depress* OR perception* OR (somatic NEAR/3 (symptom* OR complain*)) OR ((mental 
OR preoperat* OR postoperat* OR perioperat* OR operative* OR surg*) NEXT/1 stress) 
OR (adapt* NEAR/3 behavio*) OR coping)) AND ((adult* OR aged)) AND ((premedicat* 
OR pretreatment* OR (pre NEXT/1 (medicat* OR treatment* )) OR preanesthe* OR 
preanaesthe* OR anaesthetic* OR anesthetic* OR ((anxiet* OR antianxiet* OR ataract*) 
NEAR/3 (agent* OR drug*)) OR benzodiazepine* OR anxiolytic* OR tranquill* OR 
antidepress*)) AND (random* OR factorial* OR crossover* OR (cross NEAR/1 over*) OR 
placebo* OR ((doubl* OR singl*) NEAR/1 blind*) OR assign* OR allocat* OR volunteer*))
Mijderwijk.indd   88 28-10-2016   07:01:11
89 |
Effectiveness of Benzodiazepine Premedication | 
4
Scopus 
TITLE-ABS-KEY(((((ambul* OR day OR daycare OR daycase OR outpatient* OR office*) W/3 
(surg* OR operati*)))) AND ((psycholog* OR emotion* OR anxiet* OR fatigue OR exhaust* 
OR depress* OR perception* OR (somatic W/3 (symptom* OR complain*)) OR ((mental 
OR preoperat* OR postoperat* OR perioperat* OR operative* OR surg*) PRE/1 stress) 
OR (adapt* W/3 behavio*) OR coping)) AND ((adult* OR aged)) AND ((premedicat* OR 
pretreatment* OR (pre PRE/1 (medicat* OR treatment* )) OR preanesthe* OR preanaesthe* 
OR anaesthetic* OR anesthetic* OR ((anxiet* OR antianxiet* OR ataract*) W/3 (agent* 
OR drug*)) OR benzodiazepine* OR anxiolytic* OR tranquill* OR antidepress*)) AND 
(random* OR factorial* OR crossover* OR (cross W/1 over*) OR placebo* OR ((doubl* OR 
singl*) W/1 blind*) OR assign* OR allocat* OR volunteer*))
PubMed publisher 
((((ambul*[tiab] OR day[tiab] OR daycare[tiab] OR daycase[tiab] OR outpatient*[tiab] 
OR office*[tiab]) AND (surger*[tiab] OR surgic*[tiab] OR operati*[tiab])))) AND 
((psycholog*[tiab] OR emotion*[tiab] OR anxiet*[tiab] OR fatigue[tiab] OR 
exhaust*[tiab] OR depress*[tiab] OR perception*[tiab] OR (somatic symptom*[tiab] 
OR somatic complain*[tiab] OR ((mental stress[tiab] OR preoperative stress[tiab] OR 
postoperative stress[tiab] OR perioperative stress[tiab] OR operative stress[tiab] OR 
surgical stress[tiab])) OR (adaptive behavio*[tiab]) OR coping)) AND ((adult*[tiab] OR 
aged[tiab])) AND ((premedicat*[tiab] OR pretreatment*[tiab] OR pre medicat*[tiab] OR 
pre treatment*[tiab] OR preanesthe*[tiab] OR preanaesthe*[tiab] OR anaesthetic*[tiab] 
OR anesthetic*[tiab] OR ((anxiet*[tiab] OR antianxiet*[tiab] OR ataract*[tiab]) AND 
(agent*[tiab] OR drug[tiab] OR drugs[tiab])) OR benzodiazepine*[tiab] OR anxiolytic*[tiab] 
OR tranquill*[tiab] OR antidepress*[tiab]) AND (random*[tiab] OR factorial*[tiab] OR 
crossover*[tiab] OR cross over*[tiab] OR placebo*[tiab] OR double blind*[tiab] OR single 
blind*[tiab] OR assign*[tiab] OR allocat*[tiab] OR volunteer*[tiab])) AND publisher[sb]
Google Scholar 
“ambulatory|day|daycare surgery|operation” 
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APPENDIX 3 | Summary risk of bias graph
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APPENDIX 4 | Individual risk of bias score
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APPENDIX 5 | Meta-regression
Covariate  b                95% CI
Lower bound Upper bound
Time to recovery
Time to eye opening
Year of publication -0.11 -0.28 0.06
Methodological quality 0.64 -0.08 1.36
Impact factor -0.19 -1.16 0.77
TCR
Year of publication -0.19 -0.75 0.37
Methodological quality 1.68 0.53 2.83
Impact factor 0.46 -3.30 4.22
Time to early recovery
Year of publication 0.37 -1.81 2.55
Methodological quality -1.27 -9.37 6.83
Impact factor -2.56 -12.66 7.54
Time to discharge
Year of publication 0.28 -0.85 1.42
Methodological quality 0.19 -11.91 12.29
Impact factor -0.18 -3.06 2.70
Postoperative side effects
Headache
Year of publication 0.08 -0.31 0.47
Methodological quality -0.86 -2.61 0.89
Impact factor -0.50 -1.12 0.11
Nausea
Year of publication -0.00 -0.05 0.05
Methodological quality -0.17 -0.58 0.25
Impact factor 0.20 -0.02 0.42
Vomiting
Year of publication 0.01 -0.08 0.09
Methodological quality 0.32 -0.15 0.80
Impact factor -0.17 -0.82 0.49
Dizziness
Year of publication -0.16 -0.49 0.16
Methodological quality 0.20 -1.31 1.71
Impact factor -0.47 -2.28 1.33
Pain
Year of publication NA NA NA
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APPENDIX 5 | Meta-regression (continued)
Covariate  b                95% CI
Lower bound Upper bound
Methodological quality NA NA NA
Impact factor NA NA NA
Miscellaneous
Year of publication NA NA NA
Methodological quality NA NA NA
Impact factor NA NA NA
Psychological outcome
Anxiety
Year of publication 0.12 -0.26 0.50
Methodological quality -1.01 -6.33 -4.32
Impact factor -0.20 -3.57 3.18
   B=regression coefficient; CI=confidence interval; TCR=time to first correct response; NA=not applicable.
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APPENDIX 6A | Funnel plots for time to recovery 
(time to eye opening)
APPENDIX 6A | Funnel plots for time to recovery 
(time to first correct response)
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APPENDIX 6A | Funnel plots for time to recovery 
(time to early recovery)
APPENDIX 6A | Funnel plots for time to recovery 
(time to discharge)
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APPENDIX 6B | Funnel plots for postoperative side effects                                                    
(headache) 
APPENDIX 6B | Funnel plots for postoperative side effects                                                    
(nausea)
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APPENDIX 6B | Funnel plots for postoperative side effects                                                    
(vomiting)
APPENDIX 6B | Funnel plots for postoperative side effects                                                    
(dizziness)
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APPENDIX 6B | Funnel plots for postoperative side effects                                                    
(pain)
APPENDIX 6B | Funnel plots for postoperative side effects                                                    
(pain, continuous)
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APPENDIX 6B | Funnel plots for postoperative side effects                                                    
(miscellaneous)
 
APPENDIX 6C | Funnel plots for psychological phenomena                                                    
(anxiety)
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ABSTRACT
Surgical procedures are increasingly carried out in a day-case setting. Along with 
this increase, psychological outcomes have become prominent. The objective was 
to evaluate the prognostic effects of sociodemographic, medical, and psychological 
variables assessed before day-case surgery on psychological outcomes after surgery in 
a prospective study. The study was carried out between October 2010 and September 
2011. We analyzed 398 mixed patients, from a RCT, undergoing day-case surgery at 
a university medical center. Structural Equation Modeling was used to jointly study 
candidate prognostic variables relating to sociodemographics (age, gender, nationality, 
marital status, having children, religion, educational level, employment), medical status 
(BMI, heart rate), and psychological status (anxiety, fatigue, aggression, depression, self-
esteem, self-efficacy), all assessed before surgery. We studied psychological outcomes 
on the seventh day after surgery, including anxiety (STAI-State/Trait, HADS-A), fatigue 
(MFI), depressive moods (HADS-D) and aggression regulation (STAS-State/Trait). The 
final prognostic model comprised the following prognostic variables: anxiety (STAI-
State/Trait, HADS-A), fatigue (MFI), depression (HADS-D), aggression (STAS-State/Trait), 
self-efficacy, gender and having children. The corresponding psychological variables as 
assessed at baseline were prominent – i.e. standardized regression coefficients ≥ 0.20 –, 
with the score on STAI-Trait being the strongest predictor overall. STAI-State (adjusted 
R2 = 0.44), STAI-Trait (0.66), HADS-A (0.45) and STAS-Trait (0.54) were best predicted. We 
provide a prognostic model that adequately predicts multiple outcomes in day-case 
surgery. Consequently, timely identification of vulnerable patients who may require 
additional medical or psychological preventive treatment becomes feasible.
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INTRODUCTION
Surgical procedures are increasingly carried out in a day-case setting.1,2 The patients’ 
perception of perioperative health in day-case surgery is currently not dominated by 
medical factors but by psychological factors3,4 including anxiety, depressive moods, 
aggression and feelings of fatigue.5 This shift calls for new research that provides 
prediction of these clinical outcomes to aid early clinical decision making, a task that, 
particularly, belongs to anesthesiologists’ preoperative assessment.6 
Prognostic models are statistical models that combine data from patients to predict 
clinical outcome.7 Such models based on data collected soon after presentation could in 
theory be used to aid early clinical decision making and allow more accurate counseling 
of patients.7 Conventionally, prognostic studies aim to find prognostic factors that 
accurately predict a single outcome variable.8 However, joint prediction of interrelated 
outcome variables, such as psychological outcome variables, has not yet been studied 
extensively. To that end, advanced statistical methodology like Structural Equation 
Modeling (SEM) is needed. SEM enables joint analyzes of several candidate prognostic 
factors on several outcome variables.9 SEM has been used in many research fields and is 
currently emerging in clinical medicine.10 However, in the field of anesthesiology it has 
been rarely used, although it was previously mentioned that this statistical methodology 
should be further established.11
We aimed to develop a prognostic model based on sociodemographic, medical, 
and psychological variables assessed just before day-case surgery on psychological 
outcomes after surgery using SEM.
METHODS
Study population and study design
This study is part of a larger double-blinded randomized controlled clinical trial, 
conducted at the Erasmus University Medical Center, comparing the effects of 
lorazepam and placebo in day-case surgery patients.5 However, the methods in 
this study have been adapted to address different objectives. We recruited patients 
from our day-case surgery department between October 2010 and September 
2011. We included all patients who were referred for day-case surgery and aged 
at least 18 years. Patients were excluded if they met one or more of the following 
criteria: insufficient command of the Dutch language; severe learning difficulties; 
or undergoing ophthalmology surgery, extracorporeal shock wave lithotripsy 
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(ESWL), endoscopy, Botox treatment, abortion, or chronic pain treatment. The latter 
procedures are generally considered to be minimally invasive. Most practitioners 
are of the opinion that these procedures do not require premedication. Finally, prior 
use of psychopharmaceuticals and contraindication to lorazepam use – according
to our national pharmacotherapeutic compass  – were also exclusion criteria. The 
study protocol was approved by the Medical Ethical Committee of Erasmus MC 
(Chairperson Prof. dr. H.W. Tilanus) and by the Netherlands Central Committee on 
Research involving Human Subjects (CCMO) and registered with EudraCT under 
number 2010-020332-19. The trial has also been registered under identification 
number NCT01441843 in the ClinicalTrials.gov protocol registration system. Written 
informed consent was obtained from all subjects. The time schedule for the current 
study is shown in Figure 1. 
FIGURE 1 | Timeline of the study
T0 = baseline assessment on the day of surgery (self-reported questionnaire); T1 = seventh postoperative day (self-reported 
questionnaire); STAI, State-Trait Anxiety Inventory; MFI, Multidimensional Fatigue Inventory; HADS, Hospital Anxiety and 
Depression Scale, STAS: State-Trait Anger Scale.
Outcome variables 
State-Trait Anxiety Inventory (STAI)
Anxiety was measured using the Dutch version of the STAI.12 The STAI consists of 
two 20-item scales. One scale measures how one feels in general (Trait anxiety), 
while the other measures how one feels at the present moment (State anxiety). All 
items are rated on a 4-point Likert scale, ranging from 1 (“not at all”) to 4 (“all the 
time”). Sum scores for both scales were calculated by adding the scores of all the 
items, theoretically ranging from 20 to 80. A higher score indicates a higher level 
of anxiety. STAI has been shown to have good validity, and the STAI-State and STAI-
Trait scales have similar reliability scores: Cronbach’s α > 0.80.12
Surgery
Demographic, 
clinical, STAI, 
MFI, HADS, 
STAS
HomeWard Operation area
Admission 
to the ward
Preoperative 
holding
Postoperative 
holding
Preparing and 
injection 
lorazepam or 
NaCl 0.9%
 STAI, MFI, 
HADS, STAS
T1
Discharge 
homeT0
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Multidimensional Fatigue Inventory (MFI)
Fatigue was measured using the Dutch version of the MFI,13 a 20-item questionnaire 
covering five scales: General fatigue, Physical fatigue, Mental fatigue, Reduced 
motivation, and Reduced activity. Each scale has four items and each item is rated 
on a 5-point Likert scale, ranging from one (“yes, that is true”) to five (“no, that is not 
true”). A sum score was calculated by adding the scores of all the items, theoretically 
ranging from 20 to 100. A higher score indicates a higher degree of fatigue. In the 
majority of cases, MFI has good validity and reliability, with Cronbach’s α exceeding 
0.80.13
Hospital Anxiety and Depression Scale (HADS)
Depressive moods were measured using a Dutch version of the HADS,14 which 
consists of two 7-item scales: one for anxiety (HADS-A) and one for depression 
(HADS-D). Each item comprises four answer alternatives and for each of the scales 
the total score theoretically ranges from 0 to 21. A higher score indicates a higher 
degree of either anxiety or depression. The HADS is known to have adequate validity 
and internal consistency in the Dutch population (Cronbach’s α = 0.8815). 
State-Trait Anger Scale (STAS)
Aggression regulation was assessed using the Dutch version of the STAS,16 which 
consists of two 10–item scales, one covering the State-aggression (how angry one 
feels at the moment) and one covering the Trait-aggression (how angry one feels in 
general). Each item is rated on a 4-point Likert scale, ranging from one (“not at all”) 
to four (“all the time”). The theoretical scores range from 10 to 40. A higher score 
indicates a higher degree of aggression. Both subscales have adequate validity; 
the STAS-State has good reliability (Cronbach’s α = 0.93), as does the STAS-Trait 
(Cronbach’s α = 0.88).16
Sociodemographic and medical prognostic variables
The sociodemographic variables we considered were gender, age, educational level, 
marital status, employment, religion, having children, and type of nationality (i.e. Dutch 
versus non-Dutch). The medical variables we considered were Body Mass Index (BMI) 
and preoperative heart rate (HR).
Mijderwijk.indd   119 28-10-2016   07:01:13
| 120 
| Chapter 5
Psychological prognostic variables
Baseline assessment of outcome variable
Baseline assessments of all psychological outcome variables were used as candidate 
prognostic variables.
Rosenberg Self-Esteem Scale (RSES)
Self-esteem was measured using the ten-item Dutch version of the RSES.17 Each item 
was rated on a 4-point Likert scale from 1 (“strongly agree”) to 4 (“strongly disagree”). 
The sum score theoretically ranges from 10 to 40. A higher score indicates a higher 
degree of self-esteem. RSES has good validity and reliability with a Cronbach’s α of 
0.87.17
General Self-Efficacy Scale (GSES)
Self-efficacy was measured using the Dutch version of the GSES.18 Each item is rated 
on a 4-point Likert scale. The scores of the ten items range from 1 (“not at all true”) 
to 4 (“exactly true”). Consequently, the theoretical sum score ranges from 10 to 40. A 
higher score indicates a higher degree of self-efficacy. Besides an adequate validity, 
GSES has a reliability of 0.85 (Cronbach’s α) in the Dutch population.19
Statistical analysis
We explored the relations between baseline assessments (T0, just before surgery) and 
outcome variables (T1, seventh day after surgery). We included sociodemographic, 
medical and psychological variables assessed at baseline in the model simultaneously. 
Predictor variables were entered for all outcomes in the model to allow for insight in 
the relative importance of each predictor. The analyses were guided by statistical and 
clinical-theoretical criteria. The first step was to analyze all predictor variables together 
with the seven outcome variables that were assessed on the seventh day after surgery. 
In the second step, we eliminated less-relevant predictor variables according to the 
backward elimination procedure (P-to-remove > 0.20 on at least four outcome variables) 
provided that there is no substantial loss of information (i.e. a decrease in P-value for 
model fit ≥ 0.10). Type of intervention as randomized was adjusted for.
Modeling was performed using the Maximum Likelihood (ML) as estimation method. As 
the distributions of the variables were considered non-normal, the final modeling was 
performed using the Maximum Likelihood for Robustness (MLR) as estimation method.
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The following measures were used to test for adequacy of the model fit:
1. Chi-square for model fit (low and non-significant values of the chi-square are desired; 
P-value > 0.05); 2. Chi-square/degrees of freedom ratio (a value < 2.0 was considered 
to be acceptable); 3. Comparative Fit Index (CFI), and Tucker-Lewis Index (TLI) (high 
values are desired (> 0.95);20,21 4. Root Mean Square Error of Approximation (RMSEA: a 
value < 0.05 indicates a close fit);22 and 5. Standardized Root Mean Squares of Residuals 
(SRMR: a value of < 0.08 indicates a reliable fit).23 After testing for goodness-of-fit, it was 
of particular clinical interest to calculate the percentages of explained variance for each 
outcome variable.
There was little missing data (< 5% for all variables), which were not included in the 
prognostic analysis. Bootstrapping was used for internal validation.24,25 Each subsample 
was a random sample with replacement from the full sample. We checked the internal 
validity of the prognostic model using 1000 bootstrap samples. Bias-corrected standard 
errors were estimated. For each predictor, we estimated the unstandardized regression 
coefficients, including the 95% bootstrapped confidence intervals, and standardized 
regression coefficients as effect estimates. 
We used SPSS version 20.0 (IBM Corp. Armonk, NY) and Mplus version 7 (Muthén and 
Muthén, Los Angeles, CA) for statistical analyzes. Estimates were regarded statistically 
significant if the two-sided P-value was < 0.05. 
RESULTS
We included 398 patients, who all completed measurement at baseline, while 383 (96%) 
completed measurement at follow-up. The study population had more males (56%) 
than females and most of the patients were Dutch (94%). The majority (60%) lived to-
gether with a partner, and approximately half of the patients had children. About two-
thirds reported being non-religious. 270 patients (68%) had a middle level of education, 
whereas lower but similar numbers of patients had low (n = 63) and high (n = 65) levels 
of education. Three-quarters of the patients were employed. The median age was 36.7 
years, the median BMI ((body weight in kilograms)/(body height in meters)2) was 24.6, 
and the median preoperative HR (beats per minute) was 69 (Table 1).
Mean anxiety scores (STAI-State, STAI-Trait and HADS-A) decreased after surgery, 
whereas the mean values for aggression scores (STAS-State and STAS-Trait) and 
depression scores (HADS-D) remained about the same over time (Table 2). Mean fatigue 
scores (MFI) increased postoperatively.
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TABLE 1 | General characteristics of the patients at baseline
Categorical n %
Type of intervention
     Verum (lorazepam) 198 49.7
     Placebo (NaCl 0.9%) 200 50.3
Gender 
     Female 174 43.7
     Male 224 56.3
Nationality
     Dutch 374 94.0
     Non-Dutch 24 6.0
Marital Statusa
     Single 158 39.7
     Together 240 60.3
Children
     Yes 206 51.8
     No 192 48.2
Religion
     Yes 128 32.2
     No 270 67.8
Educational levelb
     Low 63 15.8
     Middle-level 270 67.8
     High 65 16.3
Employment
     Yes 301 75.6
     No 97 24.4
Continuous                Percentiles
 n 25 50 75
Age  398 28.8 36.7 49.4
BMIc 398 22.4 24.6 27.7
Heart rated 396 62.0 69.0 78.0
a Single: unmarried, divorced, widow(er); Together: married, living together; b Low: no education, elementary school, pre-
paratory middle-level vocational education; Middle-level: middle-level vocational education, higher general continued 
education, higher vocational education; High: preparatory university education, university education; c Body Mass Index: 
body weight in kilogram)/(body height in meters)2; d Heart rate: beats per minute. 
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TABLE 2 | Descriptive of psychological variables
                               Baseline (T0)                             7th day after surgery (T1)
mean SD mean SD
STAI-State 38.1 9.4 30.3 8.9
STAI-Trait 33.5 8.1 30.5 8.7
HADS-A 4.7 3.1 2.9 2.9
MFI 41.6 13.1 48.5 17.0
STAS-State 10.2 1.2 10.6 2.5
STAS-Trait 13.4 3.6 13.1 3.6
HADS-D 3.0 2.4 2.8 2.9
RSES 33.5 4.4 NA NA
GSES 31.6 4.2 NA NA
Abbreviations: STAI-State, State-Trait Anxiety Inventory, State part; STAI-Trait, State-Trait Anxiety Inventory, Trait part; MFI, 
Multidimensional Fatigue Inventory; HADS-A, Hospital Anxiety and Depression Scale, Anxiety part; HADS-D, Hospital 
Anxiety and Depression Scale, Depression part; STAS-State, State-Trait Anger Scale, State part; STAS-Trait, State-Trait 
Anger Scale, Trait part; RSES, Rosenberg Self-Esteem Scale; GSES, General Self-Efficacy Scale; NA = not applicable. T0: n = 
398; T1: n = 383. 
Correlations between prognostic variables and outcomes over time
At T0 (baseline), the highest correlations were found between HADS-A and STAI-Trait 
(r = 0.66), and HADS-A and STAI-State (r = 0.66, Table 3). Also, STAI-Trait correlated 
substantially with STAI-State (r = 0.52), MFI (r = 0.54) and HADS-D (r = 0.55). At T1 (seventh 
day after surgery), the intercorrelations were substantial. The highest correlations were 
found between STAI-State and STAI-Trait (r = 0.76) and between STAI-State and HADS-A (r 
= 0.71).  STAI-Trait had a correlation of 0.71 with HADS-A. The intracorrelations over time 
of most of the psychological outcome variables varied from moderate to substantial: 
STAI-State (r = 0.42), STAI-Trait (r = 0.79), HADS-A (r = 0.59), MFI (r = 0.54), STAS-Trait (r 
= 0.68) and HADS-D (r = 0.55). STAS-State showed a correlation of only 0.16, however 
(Table 3). 
Prognostic potentialities of baseline variables
The final model comprised the following predictors: gender, having children, STAI-
State, STAI-Trait, HADS-A, MFI, STAS-State, STAS-Trait, HADS-D and GSES. Nationality, 
marital status, religion, educational level, employment, age, BMI, HR, RSES and type of 
intervention as randomized were fixed at zero. The performance measures all showed 
adequate values: using the MLR as the estimation method, the P-value for the chi-
square for model fit (98.99; df = 77) turned out to be just significant (P = 0.05), while 
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TABLE 4 | Prognostic performance of the baseline variables in the final model: 
                     explained variances
                    R2 Adjusted
A B C
Outcome variables 
Anxiety STAI-State 0.01 0.01 0.44
STAI-Trait 0.01 0.01 0.66
HADS-A 0.00 0.00 0.45
Fatigue MFI 0.02 0.02 0.31
Aggression STAS-State 0.01 0.01 0.15
STAS-Trait 0.01 0.01 0.54
Depression HADS-D 0.00 0.00 0.38
Abbreviations: STAI-State, State-Trait Anxiety Inventory, State part; STAI-Trait, State-Trait Anxiety Inventory, Trait part; MFI, 
Multidimensional Fatigue Inventory; HADS-A, Hospital Anxiety and Depression Scale, Anxiety part; HADS-D, Hospital 
Anxiety and Depression Scale, Depression part; STAS-State, State-Trait Anger Scale, State part; STAS-Trait, State-Trait Anger 
Scale, Trait part; GSES, General Self-Efficacy Scale.
A = Demographic variables assessed at baseline
B = Demographic and Medical variables assessed at baseline
C = Demographic, Medical, Psychological variables assessed at baseline
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the ML estimation method yielded a chi-square value of 97.36 (df = 77; P = 0.06). The 
chi-square/degrees of freedom ratio was 1.29. The comparative Fit Index (CFI) was 0.99, 
and Tucker-Lewis Index (TLI) 0.98. RMSEA was 0.03 (90% CI: 0.004 to 0.042). The SRMR 
was 0.02. The demographic variables had minor effects in the final model. Adding the 
medical variables did not affect the performance of the final model. In contrast, the 
prognostic potentialities of psychological baseline measurements were substantial. 
The adjusted explained variances (R2 adjusted) ranged from 0.15 for State aggression 
(STAS-State) to 0.66 for Trait anxiety (STAI-Trait). STAI-State, HADS-A, MFI, STAS-Trait and 
HADS-D showed R2 adjusted scores of 0.44, 0.45, 0.31, 0.54 and 0.38, respectively. In all, 
with the exception of aggression, the outcome variables were substantially predictable 
(Table 4). 
For each outcome variable on the seventh day after surgery (T1) we considered the 
important prognostic variables according to the standardized estimates (B), as shown in 
Table 5. We focused on standardized estimates with a value of ≥ 0.20 only (Figure 2). For 
STAI-State, baseline STAI-Trait was the most important predictor (B = 0.36), followed by 
MFI (B = 0.23). In contrast, the baseline assessment of STAI-State had no high prognostic 
impact. For STAI-Trait, only baseline STAI-Trait was important (B = 0.52). For HADS-A, 
baseline HADS-A had the highest prognostic effect (B = 0.41), followed by STAI-Trait 
(B = 0.27). For MFI, only baseline MFI was of high prognostic relevance (B = 0.50). For 
STAS-State, HADS-A had substantial prognostic effect (B = 0.24). In contrast, the baseline 
assessment of STAS-State had no high prognostic impact. For STAS-Trait, baseline STAS-
Trait dominated the prognostic variables (B = 0.57). STAI-Trait was also an important 
prognostic variable (B = 0.25). For HADS-D, two predictor variables were of prognostic 
importance: HADS-D (B = 0.36) and STAI-Trait (B = 0.26). The residuals of the outcomes 
were moderately interrelated (intercorrelations between 0.15 and 0.54).
DISCUSSION
We developed a prognostic model using sociodemographic, medical and psychological 
variables assessed just before day-case surgery that predicts multiple psychological 
outcomes after day-case surgery. Overall, apart from state aggression, the psychological 
outcome variables could be adequately predicted using the identified prognostic 
model. Sociodemographic and medical variables were of minor importance, with the 
exception of gender and having children. In contrast, the psychological variables as 
assessed at baseline were of prominent importance. 
This model is of interest for improving patients’ quality of recovery and is useful for 
preoperative decision making. Recently, prehabilitation programs have showed that 
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FIGURE 2 | Prognostic potentialities of the fi nal predictor variables distinguished by outcome 
variables
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optimal preoperative preparation leads to better postoperative outcomes.26 These 
programs improve postoperative outcomes by using preoperative interventions. 
Prehabilitation programs may differ for different surgical populations,27 and should be 
therefore tailored to the population of interest. One thing that should be developed 
in every single prehabilitation program is a preoperative prognostic model directed to 
vulnerable patients.26 The provided preoperative prognostic model in this study enables 
predicting, simultaneously, multiple outcomes of interest in day-case surgery by means 
of only one prognostic model. Vulnerable patients can be identified and guided in 
adequate follow-up accordingly, which will lead to better postoperative outcomes 
together with reduction of negative socio-economic effects. 
The model is also of interest for prognosis research dealing with psychological 
outcomes. First, from a clinical-theoretical perspective, the score on the STAI-Trait 
questionnaire showed to be a valuable prognostic variable for predicting almost all 
psychological outcome variables unless postoperative fatigue (B > 0.20). However, it 
was not powerful enough to replace the model. Sensitivity analysis that only included 
STAI-Trait as prognostic variable showed that only anxiety (STAI-State and STAI-Trait) as 
outcome variable was still adequately predicted, R2 equalled 0.37 and 0.62 respectively. 
Concerning aggression and depression, the reduction in R2 was considered too much, 
i.e. R2 percentage reduction of > 20%. That STAI-Trait was not an important variable for 
predicting fatigue (R2 < 0.20) is in line with earlier findings,28 but understanding why 
postoperative fatigue does not follow the mechanisms of other psychological factors 
requires further study. Christensen et al. have suggested that the mechanisms cannot 
be explained by psychological factors.29 However, more recently, it has been postulated 
that the underlying mechanism should be explained by psychological factors and mainly 
by its measurement itself.28 Our results support the latter. Second, from a statistical 
modeling perspective, here we have applied structural equation modeling (SEM), a 
strong statistical approach, to evaluate the joint potentialities of several variables in 
predicting several outcomes. This joint analysis is especially preferred as psychological 
outcome variables are likely to interact with one another,30 which is also observed in the 
present study. Next to this theoretical rationale of an integral analysis, SEM has a couple 
of additional advantages. SEM enables achieving a consistent set of predictors for all 
outcomes; and, accordingly, enables comparing the regression weights for the different 
outcome variables, which is difficult and time consuming when a conventional analysis 
was done (i.e. predicting each outcome individually). Furthermore, SEM tests if the 
prediction model represents adequately the data structure, with random fluctuation. 
Moreover, SEM gives insight in the related (residual) intercorrelations of the outcomes. 
When these residual intercorrelations would be high for some or all outcome variables 
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a principal component analysis or a partial least squares regression analysis would be 
indicated. This information would be missed in case of individual outcome analysis. It 
has to be noted that, ideally, a latent modeling approach seems indicated to analyze the 
joint prediction of observed variables. However, we have refrained from performing this 
approach as, in clinical practice, it is not plausible that the used measurements can be 
obtained without error. 
Future considerations
Of the psychological outcomes analyzed, the explained variances (R2) were substantially 
for the anxiety scales (STAI-State, STAI-Trait and HADS-A), the depression scale (HADS-D), 
the fatigue scale (MFI), and the trait component of aggression regulation (STAS-Trait). 
However, state aggression (STAS-State) was only moderately predictable. Although we 
found substantial explained variances as the criterion for assessing the performance 
of the individual outcomes in the current model, a number of variances still remain 
unexplained.
First, this could be due to the fallibility of the measurements. To assess such fallibility 
we evaluated the internal consistency of the measurements using Cronbach’s α, both 
at baseline and 1 week after surgery. According to the commonly accepted criteria,31 
we concluded that internal consistency was satisfactory for all measurements (for the 
majority of the used scales Cronbach’s α ≥ .85, four scales were in the range of 0.73 
to 0.79), except for HADS-D assessed at baseline (Cronbach’s α = 0.60). In this study 
we used two different measurements for anxiety and found the interrelationships of 
STAI and HADS-A to be non perfect, in line with previous research.32 This discrepancy 
suggests that the different instruments for anxiety have common and unique elements. 
Second, the model might be misspecified in principle, but we firmly believe that this 
possibility is not realistic. Third, the phenomenon of omitted variables may play a role 
in this study. Other unmeasured or as yet unknown variables may be of relevance, 
and consequently may, when added, enhance the prognostic performance of the 
model. While our study only comprises intrapersonal characteristics, interpersonal 
characteristics may also be important. For example, recent research has shown that 
negative dyadic coping (collaborative coping/dealing with stress within a couple) 
is associated with a higher degree of psychological distress.33 Positive dyadic coping 
seems to be effective in dealing with problems surrounding illness, especially in 
older couples.34 Such positive interpersonal variables could also help people cope in 
a perioperative setting. Environmental variables (e.g. living in suburbs), economic 
variables (e.g. economic crisis, being unemployed), and cultural variables could also be 
of interest. Adding such variables to our model may increase its prognostic performance. 
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Study limitations and study strengths
First, a limitation of this study was that the assessments were conducted at a single center, 
which means that further external validation is needed. Second, since we excluded 
patients who were taking psycho-pharmaceuticals and those with psychological 
disorders,5 we can assume that the level of psychological dysfunction after day-case 
surgery could well be higher. This might bias our findings negatively, or strengthen our 
findings. Third, since the majority of our study population was Dutch, different results 
may be obtained when considering broader nationalities or ethnical and sociocultural 
groups. 
Despite these limitations, the fact that our data were obtained in a RCT guarantees high 
quality of these data. Another strength of the study is the use of SEM. SEM appears to 
be a powerful approach that is suitable for conducting research on optimizing medical 
decision making using multiple outcome criteria. 
CONCLUSION
We provide a prognostic model, using a structural equation modeling framework, 
that adequately predicts multiple outcomes in day-case surgery. This enables 
timely identification of vulnerable patients who may require additional medical or 
psychological preventive treatment.
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IDENTIFY VULNERABLE PATIENTS 
IN AMBULATORY SURGERY: 
TOWARDS OPTIMAL 
MEDICAL DECISION-MAKING
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ABSTRACT
Ambulatory surgery patients are at risk of adverse psychological outcomes such as 
anxiety, aggression, fatigue, and depression. We developed and validated a clinical 
prediction model to identify patients who were vulnerable to these psychological 
outcome parameters. We prospectively assessed 383 mixed ambulatory surgery 
patients for psychological vulnerability, defined as the presence of anxiety (state/
trait), aggression (state/trait), fatigue, and depression seven days after surgery. Three 
psychological vulnerability categories were considered–i.e., none, one, or multiple 
poor scores, defined as a score exceeding one standard deviation above the mean for 
each single outcome according to normative data. The following determinants were 
assessed preoperatively: sociodemographic (age, sex, level of education, employment 
status, marital status, having children, religion, nationality), medical (heart rate and body 
mass index), and psychological variables (self-esteem and self-efficacy), in addition 
to anxiety, aggression, fatigue, and depression. A prediction model was constructed 
using ordinal polytomous logistic regression analysis, and bootstrapping was applied 
for internal validation. The ordinal c-index (ORC) quantified the discriminative ability of 
the model, in addition to measures for overall model performance (Nagelkerke’s R2). In 
this population, 137 (36%) patients were identified as being psychologically vulnerable 
after surgery for at least one of the psychological outcomes. The most parsimonious and 
optimal prediction model combined sociodemographic variables (level of education, 
having children, and nationality) with psychological variables (trait anxiety, state/trait 
aggression, fatigue, and depression). Model performance was promising: R2 = 30% and 
ORC = 0.76 after correction for optimism. This study identified a substantial group of 
vulnerable patients in ambulatory surgery. The proposed clinical prediction model 
could allow healthcare professionals the opportunity to identify vulnerable patients in 
ambulatory surgery, although additional modification and validation are needed.
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INTRODUCTION
Ambulatory surgery is increasing in the Western world in parallel with improved surgical 
safety due to advancements in anesthesia and surgical techniques. Perioperative 
morbidity and mortality in adult ambulatory surgery is less than 0.1%.1 Quality of 
life, along with endpoints like pain and transient loss of function, has become a more 
important clinical endpoint in ambulatory surgery, which is dominated by psychological 
outcome parameters such as anxiety, aggression, fatigue, and depression.2 Over the last 
decades, prediction research has been performed on somatic outcomes in ambulatory 
surgery patients,1,3-5 but prediction models tailored to psychological outcomes are 
lacking. Nevertheless, poor psychological outcomes in patients can have negative 
socioeconomic consequences due to prolonged convalescence that delays a return to 
normal activities and work.6-10
Accordingly, it is of clinical interest to predict which patients are at risk of psychological 
vulnerability after ambulatory surgery. Patients are considered vulnerable if they deviate 
substantially from the norm in terms of their psychological outcome parameters. If 
psychological vulnerability can be predicted before surgery, appropriate action could 
be taken as needed to improve outcomes after ambulatory surgery.
The objective of this study was to create and test a model that identifies psychologically 
vulnerable ambulatory surgery patients. Towards this end, we constructed and validated 
a clinical prediction model that included sociodemographic, medical, and psychological 
determinants.
METHODS
The study protocol was approved by the Medical Ethics Committee of Erasmus University 
Medical Center and by the Netherlands Central Committee on Research Involving 
Human Subjects. It was registered with EudraCT (#2010-020332-19). Written informed 
consent was obtained from all subjects.
Study population
This study comprises data from a larger randomized clinical trial published previously,2 
and parts of this Methods section were adapted to address the different objectives of 
the current study.
Briefly, 400 patients were recruited from our ambulatory surgery department during 
Mijderwijk.indd   139 28-10-2016   07:01:16
| 140 
| Chapter 6
October 2010 to September 2011. Inclusion criteria were patients who were at least 
18 yr of age and referred for ambulatory surgery. Exclusion criteria were patients who 
clearly had an insufficient command of the Dutch language or an intellectual disability, 
patients undergoing procedures generally considered less invasive (i.e., ophthalmology 
surgery, extracorporeal shock wave lithotripsy, endoscopy, Botox treatment, abortion, 
or chronic pain), those who previously used psychopharmaceuticals, and those with 
contraindications to the use of lorazepam. Patients were randomized to either the 
lorazepam group or the placebo (NaCl 0.9%) group in the original randomized-controlled 
trial (RCT). Healthcare professionals, patients, and researchers were all blinded to the 
medication given.
Procedure and intervention
All patients scheduled for ambulatory surgery received written information about 
the trial at least one week before surgery. A member of the research group enrolled 
patients after their admission to the ambulatory surgery centre and sought written 
informed consent. Patients who consented to participate completed a set of online 
questionnaires while waiting for surgery (T0). The study medication was then 
administered in the preoperative holding period. On the sixth day after surgery, one 
of the researchers telephoned the patients to remind them to complete the last set of 
online questionnaires the next day (T1).
Outcome variables
Anxiety was measured using the Dutch version of the State-Trait Anxiety Inventory 
(STAI).11 The STAI consists of two 20-item scales. One scale measures how people 
generally assess their feelings, i.e., trait anxiety (STAI-T), and the other scale measures 
how people assess their feelings at the present moment, i.e., state anxiety (STAI-S). Sum 
scores for both scales are calculated by summing the scores for the items. The theoretical 
range is from 20-80, with a higher score indicating a higher level of anxiety. The STAI has 
good validity, and the STAI-S and STAI-T scales have overall similar reliability scores, with 
Cronbach’s α > 0.80.11
Aggression regulation was assessed using the Dutch translated version of the State-
Trait Anger Scale (STAS),12 which consists of two ten-item scales. One scale measures 
state aggression, i.e., how people assess their anger intensity at the moment (STAS-S), 
and the other scale measures trait aggression, i.e., how people generally assess their 
anger intensity (STAS-T). Sum scores for both scales are calculated by summing the 
scores for the items. The theoretical range is from 10-40, with a higher score indicating a 
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higher level of aggression. Both subscales have adequate validity, and both the STAS-S 
and the STAS-T have good reliability scores, with Cronbach’s α values of 0.93 and 0.88, 
respectively.12
Fatigue was measured using the Dutch version of the Multidimensional Fatigue 
Inventory (MFI),13 a 20-item questionnaire that comprises five four-item scales: general 
fatigue, physical fatigue, mental fatigue, reduced motivation, and reduced activity. Sum 
scores are calculated by summing the scores for the items. The theoretical range is from 
20-100, with a higher score indicating a higher degree of fatigue. In the majority of 
cases, the MFI has good validity and reliability, with Cronbach’s α exceeding 0.80.13
Depressive moods were measured using a Dutch translated version of the Hospital 
Anxiety and Depression Scale (HADS),14 which consists of two seven-item scales. One 
scale measures anxiety (HADS-A), and the other scale measures depression (HADS-D). 
Sum scores for both scales are calculated by summing the scores on the items. The 
theoretical range is from 0-21, with a higher score indicating moods that are more 
depressive. The HADS has adequate validity and internal consistency in the Dutch 
population (Cronbach’s α = 0.88).15
All outcomes were assessed at T1 (postoperative day 7).
Determinants
The sociodemographic candidate determinants were sex, age, educational level, 
marital status, employment, religion, having children, and type of nationality. The 
medical candidate determinants were body mass index (BMI) and preoperative heart 
rate. Psychological candidate determinants included all baseline assessments of the 
psychological outcome variables, self-esteem, and self-efficacy.
Self-esteem was measured using the Dutch version of the Rosenberg Self-Esteem Scale 
(RSES).16 Sum scores are calculated by summing the scores on the items. The theoretical 
range is from 10-40, with a higher score indicating a higher degree of self-esteem. The 
RSES has good validity and reliability (Cronbach’s α = 0.87).16
Self-efficacy was measured using the Dutch version of the General Self-Efficacy Scale 
(GSES).17 Sum scores are calculated by summing the scores for the items. The theoretical 
range is from 10-40, with a higher score indicating a higher degree of self-esteem. 
The GSES has adequate validity and good reliability (Cronbach’s α = 0.85) in the Dutch 
population.18
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All determinants were assessed at T0 (preoperatively).
Definition of vulnerability
According to recent research in our field, use of constructed composite scales 
according to normative data is a practical way to screen for postoperative psychological 
outcomes.19 We used the 84th percentile cut-off as, to date, this is normally applied in 
clinical prediction studies to identify aberrant patients.20-22 Thus, likewise, patients in 
the present study were considered vulnerable after surgery if they scored a standard 
deviation (SD) of ≥1 above the mean in the normal population on the outcome variables. 
The mean (SD) norm scores were as follows: STAI-S, 34.8 (8.4); STAI-T, 36.9 (8.4); MFI, 41.1 
(16.1); STAS-S, 11.2 (3.1); STAS-T, 16.7 (4.0); HADS-A, 5.1 (3.6); and HADS-D, 3.4 (3.3).11,12,23,24 
The literature does not report norm scores for STAI and STAS, so these were obtained 
from the Dutch manual using the students’ category as the most appropriate reference 
group. Vulnerability was subsequently calculated on how many of the seven outcome 
parameters a patient scored in the vulnerability region. Consequently, vulnerability 
scores could range from 0 (not at all vulnerable) to 7 (vulnerable for all seven outcome 
variables). Patients were categorized as non-vulnerable (V0, vulnerability score 0), single 
vulnerable (V1, vulnerability score 1), and multiple vulnerable (V2, vulnerability score ≥ 
2).
Statistical analysis
Of the 400 patients enrolled in the original RCT, data from 398 patients were eligible 
for analysis.2 Of these, 383 patients completed the measurements on the seventh day 
after surgery. We calculated percentages and means as measures of a central tendency 
for determinants and outcome variables in these 383 patients. For continuous data, the 
standard deviation was presented as a measure of dispersion. Analyses were adjusted 
for the intervention as randomized together with the type of surgical specialty and the 
type of anesthesia.
Modelling strategy and validation
Ordered polytomous logistic regression analysis was used to develop the prediction 
model. All determinants were included in the model followed by a backward elimination 
procedure (P-to-remove > 0.20). Akaike’s Information Criterion was evaluated during 
the modelling procedure. The final model was subjected to bootstrapping (1,000 
times) for internal validation.25 The discriminative ability of the resulting prediction 
model was measured using the ordinal c-index (ORC).26 The ORC can be interpreted 
as the probability to rank cases correctly from two randomly selected categories. If a 
Mijderwijk.indd   142 28-10-2016   07:01:16
143 |
Prediction Model for Poor Psychological Outcome after Surgery | 
6
model orders patients randomly, the ORC is equal to 0.5; with perfect ordering, the 
ORC is equal to 1. Lorenz curves were constructed to visualize discrimination between 
the vulnerability categories.27 The Lorenz curve can well be used in clinical research to 
indicate discrimination between diseased and non-diseased states.28
Overall model performance was measured using Nagelkerke’s R2.29 All performance 
measures were corrected for optimism by bootstrapping (i.e., internal validation).25 We 
used SPSS version 20.0 (IBM Corp., Armonk, NY, USA) for statistical analyses. Performance 
measures were calculated in R version 3.0.1.30 Results were considered statistically 
significant if the two-sided P was < 0.05.
RESULTS
Patients
We found that 137 (36%) of the 383 ambulatory surgery patients were psychologically 
vulnerable, with 76 patients being single-domain vulnerable and 61 patients being 
multiple-domain vulnerable after surgery (Table 1). In the non-vulnerable group, 61% 
(n = 150) were male, whereas in both the single and multiple vulnerable groups, 50% 
were male. In all vulnerability categories, the majority of the patients had a middle-level 
education. Most patients were employed, and more than half of the patients lived with 
a partner. Patients of Dutch nationality dominated the study population (Table 2).
TABLE 1 | Vulnerability categories
Vulnerable points n %
None 246 64.2
One 76 19.8
Two 27 7.0
Three 10 2.6
Four 13 3.4
Five 5 1.3
Six 4 1.0
Seven 2 0.5
White, Non-vulnerable patients (V0); light gray, single vulnerable patients (V1); dark gray, multiple vulnerable patients (V3).
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TABLE 2 | Descriptions of baseline determinants distinghuished by vulnerability category
Baseline determinants                  Vulnerability categories
                  None (n=246)                   Single (n=76)                  Multiple (n=61)
Categorical variables n %   n %   n %
Sex (male) 150 61.0   38 50.0   31 50.8
Education                
  Middle 162 65.9   54 71.1   43 70.5
  High 47 19.1   11 14.5   5 8.2
Employment (having) 193 78.5   57 75.0   39 63.9
Marital Status (together) 158 64.2   43 56.6   34 55.7
Children (yes) 124 50.4   35 46.1   40 65.6
Religion (yes) 74 30.1   24 31.6   26 42.6
Nationality (Dutch) 233 94.7   69 90.8   57 93.4
Continuous variables Mean SD   Mean SD   Mean SD
Age 40.0 14.3   38.4 12.8   39.8 12.3
BMI 25.1 4.2   25.4 4.1   25.8 4.0
Heart rate 70 13   72 13   71 13
STAI-S (20–80)* 35.7 8.8   40.7 9.6   43.3 8.9
STAI-T (20–80)* 30.9 6.2   35.4 7.7   41.8 9.2
STAS-S (10–40)* 10.1 0.7   10.3 1.4   10.5 2.2
STAS-T (10–40)* 12.7 2.9   14.0 3.7   15.6 4.8
MFI (20–100)* 36.8 10.6   48.2 12.4   52.0 13.5
HADS-A (0–21)* 3.8 2.5   5.5 3.3   7.1 3.6
HADS-D (0–21)* 2.4 1.9   3.3 2.3   5.3 3.1
RSES (10–40)* 34.4 3.9   32.8 4.5   30.9 5.1
GSES (10–40)* 32.0 4.1   30.9 4.2   30.9 4.2
Observed values, assessed at baseline. BMI, body mass index; STAI-S, State-Trait Anxiety Inventory, State part; STAI-T, Sta-
te-Trait Anxiety Inventory, Trait part; STAS-S, State-Trait Anger Scale, State part; STAS-T, State-Trait Anger Scale, Trait part 
MFI, Multidimensional Fatigue Inventory; HADS-A, Hospital Anxiety and Depression Scale, Anxiety part; HADS-D, Hospital 
Anxiety and Depression Scale, Depression part; RSES, Rosenberg Self-Esteem Scale; GSES, General Self-Efficacy Scale. *(xx-
xx) reflects the score range for that particular measurement. SD, standard deviation.
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TABLE 3 | Univariate and multivariable odds ratios
                           Univariate Multivariable
  OR* (95% CI) OR*(95% CIb)
Categorical variables        
Sex 1.50  (0.99 to 2.27)    
Education        
   Middle 0.81  (0.46 to 1.42) 1.73  (0.88 to 4.24)
   High 0.44  (0.20 to 0.94) 1.92  (0.74 to 6.18)
Employment 0.56  (0.35 to 0.89)    
Marital Status 0.72  (0.47 to 1.10)    
Children 1.35  (0.89 to 2.04) 1.97  (1.13 to 3.63)
Religion 1.45  (0.94 to 2.24)    
Nationality 0.78  (0.35 to 1.77) 2.40  (0.76 to 9.89)
Continuous variables        
Age 1.00  (0.98 to 1.01)    
BMI 1.03  (0.98 to 1.08)    
Heart rate 1.01  (1.00 to 1.03)    
STAI-S 1.07  (1.05 to 1.10)    
STAI-T 1.15  (1.11 to 1.18) 1.08  (1.03 to 1.15)
STAS-S 1.21  (1.01 to 1.45) 1.19  (0.89 to 1.62)
STAS-T 1.17  (1.10 to 1.24) 1.06  (0.97 to 1.14)
MFI 1.09  (1.07 to 1.11) 1.06  (1.03 to 1.09)
HADS-A 1.31  (1.21 to 1.40)    
HADS-D 1.43  (1.30 to 1.57) 1.17  (1.01 to 1.36)
RSES 0.87  (0.83 to 0.91)    
GSES 0.95  (0.90 to 1.00)    
Estimated values are adjusted for type of intervention as randomized, type of surgical specialty, and type of anesthesia. 
Multivariable model’s OR (95% CIb) for type of intervention as randomized (0=placebo, 1=lorazepam) is 1.47 (0.88 to 2.52). 
Used method: ordered polytomous logistic regression analysis; link function: logit. BMI, body mass index; STAI-S, 
State-Trait Anxiety Inventory, State part; STAI-T, State-Trait Anxiety Inventory, Trait part; STAS-S, State-Trait Anger Scale, 
State part; STAS-T, State-Trait Anger Scale, Trait part; MFI, Multidimensional Fatigue Inventory; HADS-A, Hospital Anxiety 
and Depression Scale, Anxiety part; HADS-D, Hospital Anxiety and Depression Scale, Depression part; RSES, Rosenberg 
Self-Esteem Scale; GSES, General Self-Efficacy Scale. *OR, odds ratio; The ORs of psychological instruments are per unit 
increase in the score. CI, confidence interval. CIb, 1000 times bootstrapped confidence interval.
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The mean range of values for age (38.4-40.0) yr, BMI (25.1-25.8) kg*m-2, and preoperative 
heart rate (70-72) beats*min-1 were nearly equally distributed in the three vulnerability 
categories. As expected, preoperative anxiety, aggression, fatigue, and depression 
scores were lowest in the non-vulnerable group and highest in the multiple vulnerable 
group. Similarly, the self-esteem and self-efficacy scores were worse in the multiple 
vulnerable group (Table 2).
Univariate and multivariable analyses
Table 3 presents the univariate and multivariable odds ratios (ORs) of the candidate 
determinants in the clinical prediction model. We focused on the ORs of the determinants 
in the multivariable prediction model. The level of education was an important predictor 
for vulnerability (OR for a middle-level education, 1.73; 95% confidence interval [CI], 
0.88 to 4.24; OR for a high-level education, 1.92; 95% CI, 0.74 to 6.18). Other Important 
sociodemographic predictors were having children (OR, 1.97; 95% CI, 1.13 to 3.63) and 
Dutch nationality (OR, 2.40; 95% CI, 0.76 to 9.89).
None of the medical determinants were relevant in the multivariable model. In contrast, 
various psychological determinants were important predictors of psychological 
vulnerability. Higher anxiety, aggression, fatigue, and depression scores seemed to be 
associated with a higher risk of psychological vulnerability after surgery (Table 3).
Model performance
The overall model performance was good (Nagelkerke’s R2, 41%; 30% after correction for 
optimism). The discriminative ability of the final prediction model was also promising, 
with an ORC of 0.80 (0.76 after correction or optimism). The Figure illustrates the 
practical use of the prediction model. If we aim to correctly identify 50% of those who 
are vulnerable, we correctly label about 90% of the non-vulnerable patients as being 
non-vulnerable (Figure 1).
DISCUSSION
Study results indicated that, based on the scores for the four psychological outcome 
parameters (i.e., anxiety, aggression, fatigue, and depression), more than one-third of 
our study population showed poor psychological outcomes one week after ambulatory 
surgery. We constructed and validated a clinical prediction model to identify these 
vulnerable patients. The final prediction model combined sociodemographic (i.e., level 
of education, having children, and nationality) and psychological determinants (i.e., 
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trait anxiety, state/trait aggression, fatigue, and depression) and had promising overall 
performance and discriminative ability.
FIGURE 1| Lorenz curves for 383 patients enrolled in a randomized-controlled trial
The graphs show the relation between the cumulative proportion of patients who are classified as non-vulnerable while 
they are vulnerable (y-axis, Figure A) vs classified as non-vulnerable among the non-vulnerable patients. Figure B) classifica-
tion as non-vulnerable or as scoring only one vulnerable outcome vs multiple vulnerability.
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Model considerations
We developed a multivariable model with nine independent variables, four of which had 
statistically significant ORs. Interestingly, with respect to the psychological determinants, 
STAI-T (trait anxiety) was the only one of the three anxiety questionnaires (i.e., STAI-S, 
STAI-T, and HADS-A) included in the final prediction model. This suggests that these 
tests assess not only common elements but also unique elements. Furthermore, it is 
known that STAI-T assesses negative affectivity next to anxiety.31
With respect to the sociodemographic determinants, we found that level of education 
was somewhat paradoxically related to vulnerability. Specifically, in univariate analysis, 
patients with a low level of education were more likely to be vulnerable. In contrast, more 
highly educated patients were more likely to be vulnerable in the multivariable analysis. 
To exclude the possibility that this was a statistical artefact due to high correlation 
between determinants (i.e., multicollinearity), the variance inflation factor (VIF) 
should be evaluated. The VIF quantifies the degree to which multicollinearity among 
the determinants degrades the precision of estimate coefficients.32 Multicollinearity 
negatively affects the results and the reliability of the regression estimates.32 Generally, 
a VIF value exceeding 4.0 is considered to threaten valid statistical inferences. We 
therefore checked the multicollinearity, but we found that the VIF did not exceed 2.1. 
Further analyses suggested that the change in the impact of education on psychological 
vulnerability emerged when, in addition to demographic variables, trait anxiety was 
included in the prediction model. This effect was not found in analyses with the other 
psychological variables. One possible explanation is that patients with low levels of 
education are masking (i.e., giving socially desirable answers about) their anxiety, which 
is considered as ‘‘social desirability’’ in the psychological literature.33,34 Alternatively, they 
may recognize their feelings of anxiety to a lesser degree –i.e., using denial as a defence 
mechanism. This latter psychological adjustment is well known in, for example, cancer 
research.35 Furthermore, it could be that a spurious correlation emerged and that more 
educated patients really did have more anxiety. We emphasize that these results could 
be due to statistically random fluctuations.
Likewise, type of nationality turned out to be paradoxically in the analysis. Interpretations 
should be cautious as the Dutch nationality highly dominated the study population –i.e., 
our study population consisted of only 24 non-Dutch patients, making our estimate of 
this effect quite unstable.
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Future considerations
As one-third of our study patients showed poor psychological outcome, more 
attention should be paid to psychological outcome parameters as clinical endpoints. 
Furthermore, to improve the quality of care in ambulatory surgery and to avoid 
negative socioeconomic effects,6-10 patients who are vulnerable according to these 
psychological outcome parameters should be prepared adequately before surgery. This 
is a task that could be managed by anesthesiology departments, since preoperative 
risk assessment is a specific task of anesthesiologists, and optimizing treatment can 
enhance postoperative recovery.36,37
One method of preparing vulnerable patients could be treatment with premedication. 
Nevertheless, from previous studies, we know that solitary treatment with premedication, 
e.g., administration of benzodiazepines prior to surgery, is insufficient to improve the 
quality of recovery,2,38,39 although more research is needed to clarify the effectiveness 
of premedication with benzodiazepines on psychological outcomes in ambulatory 
surgery.40 Consequently, non-drug treatments, such as psychological preparation, seem 
more appropriate. In ambulatory surgery, preoperative psychological preparation could 
include several approaches,41 including written, video, and/or visit information.41 In 
particular, video information would provide the patient with a better understanding of 
the medical intervention.42,43
These methods could be implemented within, for example, a multimodal prehabilitation 
program that has physical, nutritional, and psychological aspects. The prehabilitation 
programs could enhance postoperative recovery using preoperative interventions 
tailored to the population of interest.44-47 Because ambulatory surgical procedures are 
planned well in advance, a prehabilitation program could be considered to treat these 
vulnerable patients. Currently, however, there is a lack of prehabilitation programs for 
ambulatory surgery.
Such methods could also be adjusted and tailored to the postoperative period and 
perhaps incorporated into the rehabilitation program. Rehabilitation programs are 
multimodal programs that predominantly intervene in the postoperative period to 
enhance postoperative outcome.48 Such programs have been shown to be effective 
in different surgical populations.48-50 It has also been suggested that rehabilitation 
programs should be reserved for patients who require postoperative care after the 
prehabilitation program.47
If these multidisciplinary prehabilitation and rehabilitation programs are implemented, 
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anesthesiologists should play a prominent role in their management.51 Development 
of a risk stratification model is highly recommended so that the program could be 
tailored to different sets of patients.44 Using our prediction model, risk stratification 
for the ambulatory population may become feasible, and stratification could guide 
decision-making. Presumably, patients identified as single-domain vulnerable would 
need a different treatment plan than those identified as multiple-domain vulnerable. 
The Appendix illustrates the clinical application of the constructed clinical prediction 
model for two clinical cases.
There should be further investigation as regards the clinical importance of these 
findings in terms of the identified vulnerabilities. Additional research is also needed 
to investigate which treatment is required for vulnerable patients; furthermore, a cost-
effectiveness analysis should be performed.
Using this prediction model requires some effort, and therefore, future studies could 
be tailored to minimize this effort. Future studies could also investigate whether 
determinants associated with ‘‘bad’’ habits (e.g., smoking, alcohol and drug usage, 
excessive eating, sedentary lifestyle, etc.) are manifestations of psychological 
vulnerability. It would also be interesting to investigate the influence of interpersonal 
variables, since previous research shows that these variables are also important care 
characteristics.52 In addition, preoperative mental health screening could be considered, 
especially with regard to more severe (surgical) populations. One essential step is to 
acquire external validation for our model in independent sets of patients, which may 
indicate the need for modifications.32
Study limitations and strengths
Our study has some limitations. First, 15 patients were not analyzed due to lack of 
outcome data. These patients could be vulnerable and therefore unable to complete 
the measurements one week after surgery. Second, in the original RCT, patients were 
excluded due to use of psychopharmaceuticals or because they were undergoing 
certain surgical procedures, e.g., abortion, which were stressful for these patients.2 It 
is plausible that these patients may be more susceptible to the psychological events 
that could be elicited by a surgical procedure. Therefore, we expect that the actual 
percentage of vulnerable patients in ambulatory surgery may be higher than 36%. This 
does not imply that the final prediction model should be changed accordingly. Finally, 
this was a single-centre study, and the generalizability of the model needs to be studied.
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The main strength of our study is that it uses high-quality data from a randomized trial. 
In addition, we internally validated our prediction model. Detection of vulnerability was 
based on tests that are all psychometrically validated in psychomedical fields. Therefore, we do 
not assume that we have necessarily underdiagnosed vulnerability in this surgical population.
CONCLUSION
This study identified a substantial group of vulnerable patients in ambulatory surgery. 
The proposed clinical prediction model is a first step in predicting poor psychological 
outcome after ambulatory surgery, although additional modification and validation are 
needed. The model could allow healthcare professionals, especially anesthesiologists, 
the opportunity to identify vulnerable patients in ambulatory surgery who would 
benefit from specific interventions.
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APPENDIX 1
 In this manuscript, we constructed the following clinical prediction model:
Y = β0 + βEduc1 × Educ1 + βEduc2 × Educ2 + βChildren × Children + βNationlaity × Nationality + βSTAI-T 
× STAI-T + βSTAS-S×STAS-S + βSTAS-T ×STAS-T + βMFI ×MFI + βHADS-D ×HADS-D
β0 = 10.223 (threshold 0) or 11.823 (threshold 1)
βeduc1 = 0.546; βeduc2 = 0.653; βChildren = 0.676; βNationality = 0.876; βSTAI-T = 0.078; βSTAS-S = 0.177; 
βSTAS-T = 0.059; βMFI = 0.057; βHADS-D = 0.153
Application clinical prediction model – Case 1
Miss X, born at 01-02-1970 in Rotterdam where she has been living. She has been mar-
ried and gave birth to two children. She completed primary school only. Preoperatively, 
she showed the following results on the questionnaires:
STAI-S  25
STAI-T  23
STAS-S  12
STAS-T  10
MFI  30
HADS-A    3
HADS-D    5
GSES  35
RSES  35
Her estimated risk of being non-vulnerable, single-vulnerable and multiple vulnerable 
equals 84%, 12% and 4% respectively.
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Application clinical prediction model – Case 2
Mr Y, born at 03-04-1972 in Rotterdam where he has been living. This single man has 
no children. He graduated from university and works as a lawyer. Preoperatively, he 
showed the following results on the questionnaires:
STAI-S  40
STAI-T  45
STAS-S  17
STAS-T  12
MFI  40
HADS-A  12
HADS-D  10
GSES  15
RSES  20
His estimated risk of being non-vulnerable, single-vulnerable and multiple vulnerable 
equals 9%, 23% and 68% respectively.
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ABSTRACT
Postoperative fatigue is common following surgery, however its etiology is still unknown. 
The most common theory to date is of psychological nature assuming that anxiety and 
depression are closely related to fatigue. Although these factors are indeed strongly 
interrelated, direction of causality is currently not determined which is necessary 
for proper treatment. We tried to unravel the direction of these pathways using an 
appropriate statistical methodology in order to find a target for treatment or prevention. 
Structural equation modeling was used to unravel the pathways among fatigue, 
anxiety, and depression in 398 mixed adult patients undergoing day-case surgery. 
Assessments took place preoperatively and postoperatively. Fatigue was measured 
using the Multidimensional Fatigue Inventory, whereas anxiety and depression were 
measured using the Hospital Anxiety and Depression Scale. Standardized regression 
coefficients (B) were used as measures of relative importance. The most optimal path 
model showed that preoperative fatigue substantially predicted postoperative fatigue 
(B = 0.54, P = 0.00), and that preoperative anxiety and depression were unimportant in 
predicting postoperative fatigue. Furthermore, at each single measurement moment 
fatigue significantly predicted anxiety and depression rather than vice versa. The model 
fit was adequate: χ2 16.10, df 9, P = 0.06, CFI 0.991, TLI 0.979, SRMR 0.029, RMSEA 0.045.
In the day-case surgery population postoperative fatigue is likely induced via 
preoperative fatigue, and not a consequence of anxiety and depression. If an 
intervention for postoperative fatigue is considered, preoperative treatment tailored to 
reduce preoperative fatigue could be strategy of choice.
Mijderwijk.indd   160 28-10-2016   07:01:17
161 |
Potential Pathways leading to Postoperative Fatigue  | 
7
INTRODUCTION
Postoperative fatigue is a widespread problem in nowadays society. Postoperative fatigue 
considerably negatively affects the physical and psychosocial condition of patients.1 
Furthermore, it also leads to unwanted economic effects because postoperative fatigue 
could prolong the convalescence period delaying return to normal daily activities.1,2 
Postoperative fatigue seems to emerge substantially among patients undergoing a 
broad range of surgical procedures including major abdominal, gynaecological, cardiac 
surgery, and even after minor surgery.3 The incidence of postoperative fatigue varies 
among these different types of surgery, and at specific time points in the convalescence 
period which may accumulate up to 92%.3 To cope with this, most patients complain 
with their general practitioner or with their surgeon. Hence, numerous studies have 
aimed to find the underlying cause of postoperative fatigue but the etiology remains 
inconclusive. These studies resulted in two different theories, namely a physiological 
and a psychological theory. The physiological theory assumes that postoperative fatigue 
originates from the surgical response to trauma.4 The psychological theory – most 
commonly accepted to date – assumes that anxiety and depression are misinterpreted 
as fatigue in the postoperative period.5 In day-case surgery the latter theory is most likely 
because the surgical response to trauma is minimized by the nature of the procedures, 
use of minimal invasive surgical techniques, and advanced anesthetic techniques 
using short acting drugs. Furthermore, fatigue, anxiety, and depression are strongly 
interrelated in the postoperative period.5-7 However, the direction of causality between 
these phenomena is not yet determined.7,8 If we would be able to unravel the directions 
of the pathways between fatigue on the one hand and anxiety and depression on the 
other hand, patient treatment could be more directed to the primary cause. For this 
purpose, appropriate statistical methodology, such as structural equation modeling 
(SEM), was previously proposed.8 This method has been shown to be a suitable statistical 
method to unravel potential clinical pathways.9,10
The objective of this study was to unravel the directions of the pathways between 
fatigue on the one hand and anxiety and depression on the other hand in a day-case 
population using SEM. Secondly, the objective was to find a target for treatment in order 
to prevent postoperative fatigue according to the identified pathway.
METHODS
This study used data from a larger randomized placebo-controlled clinical trial 
evaluating the postoperative effectiveness of preoperative administered lorazepam.11 
The study protocol was approved by the Medical Ethics Committee of Erasmus MC and 
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by the Netherlands Central Committee on Research Involving Human Subjects (CCMO). 
It was registered with EudraCT (#2010-020332-19). The original trial was also registered 
in the ClinicalTrials.gov protocol registration system (#NCT01441843). Written informed 
consent was obtained from all subjects. In order to address the different objectives of 
this paper, we have adapted parts of the methods section.
Study population
Consecutive adult patients undergoing day-case surgery at the Erasmus University 
Medical Center, Rotterdam, The Netherlands, were invited to participate in this study. 
Patients were excluded if they clearly had an insufficient command of the Dutch language 
or intellectual disability, or were undergoing ophthalmology surgery, extracorporeal 
shock wave lithotripsy, endoscopy, botulinum toxin A treatment, abortion or chronic 
pain treatment. Furthermore, preceding use of psychopharmaca or any contraindication 
to lorazepam use served as exclusion criteria.
Study design
Measurements were performed preoperatively on the day of surgery (T0) and 
postoperatively at the seventh day after surgery (T1).
Study measures
Fatigue was measured with the Dutch version of the Multidimensional Fatigue Inventory 
(MFI), a 20-item questionnaire covering five scales (4 items): General fatigue, Physical 
fatigue, Mental fatigue, Reduced motivation and Reduced activity.12 Sum scores were 
calculated, which theoretically could range from 20 to 100. A higher score indicates 
a higher degree of fatigue. MFI has a promising validity and a good reliability in the 
majority of cases (Cronbach’s α > 0.80).12
Anxiety and depression were measured by a Dutch translated version of the Hospital 
Anxiety and Depression Scale (HADS), which consists of two 7-item scales, i.e. one for 
anxiety (HADS-A) and one for depression (HADS-D).13 For each scale the sum score 
was calculated which theoretically could range from 0 to 21. A higher score indicates 
a higher degree of anxiety and/or depressive moods. In the Dutch population, HADS 
is known to have a good validity and high internal consistency (Cronbach’s α = 0.88).14
Analysis
We used SEM to unravel the directions of the pathways among fatigue on the one 
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hand and anxiety and depression on the other hand.15 It is desirable to have a minimal 
subject:parameter ratio of 10:1.15 This study clearly fulfils this criterion. We used 
maximum likelihood estimation during the model generation procedure.
Unravelling the pathways among fatigue, anxiety and depression
In the day-case surgery population it is difficult to hypothesize a path model because 
research on fatigue, anxiety, and depression is scarce. Therefore we used a more 
explorative way to unravel the pathways: we evaluated all possible models.15 According 
to the three study measures of interest, eight pathways (23) are possible at each single 
measurement moment (lag 0). Consequently, we evaluated 64 (23 times 23) models in 
total. In these model evaluations, the pathways from fatigue to anxiety and depression 
and vice versa across time (lag 1) were left free, meaning that they were estimated. 
Autoregressions of the study measures across time were always estimated. Figure 1 
shows the structure of the hypothesized models.
In the next step, at lag 1, we evaluated whether it was statistically allowed to restrict 
the pathways from preoperative fatigue to postoperative anxiety and postoperative 
depression; and the pathways from preoperative anxiety and preoperative depression 
to postoperative fatigue in order to find the most parsimonious model. 
We want to emphasize that anxiety and depression were empirically measured 
separately – hence this is symbolized as a square in the Figure. However, according to 
the study objective (i.e. to unravel the directions of the pathways between fatigue on 
the one hand and anxiety and depression on the other hand), anxiety and depression 
are jointly related to fatigue – hence this is symbolized as a rectangle in the Figure. 
Accordingly, if a pathway runs from preoperative anxiety to postoperative fatigue the 
pathway starting with preoperative depression also runs to postoperative fatigue and 
vice versa. Thus, if the pathway from preoperative anxiety to postoperative fatigue was 
restricted, the pathway starting with preoperative depression running to postoperative 
fatigue was also restricted.
The pathways between anxiety and depression at lag 1 were left free, because these 
pathways were not of interest according to the study aim. Next to identification of the 
most plausible model, rivalling models were evaluated.
The most plausible model was then adjusted for type of intervention as randomized to 
control for possible confounding and subjected to bootstrapping using 1000 samples 
with replacement for internal validation;16 95% bias-corrected bootstrap confidence 
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intervals were calculated for unstandardized regression coeffi  cients. The fi nal model 
was estimated with the MLR estimation method (i.e. maximum likelihood estimation 
with robust standard errors). Standardized regression coeffi  cients (B) were used as 
estimates of relative importance (theoretical range, -1.0 to 1.0). Eff ect sizes can be 
reasonably estimated in combination with signifi cance testing, which also takes into 
account sample size and intercorrelations among variables. Explained variances of 
study measures are presented.
FIGURE 1 | Hypothesized path models for one measurement moment (lag 0):
A. anxiety on fatigue; depression on fatigue; depression on anxiety
B. anxiety on fatigue; depression on fatigue; anxiety on depression
C. anxiety on fatigue; fatigue on depression; depression on anxiety
D. anxiety on fatigue; fatigue on depression; anxiety on depression
E. fatigue on anxiety; depression on fatigue; depression on anxiety
F. fatigue on anxiety; depression on fatigue; anxiety on depression
G. fatigue on anxiety; fatigue on depression; depression on anxiety
H. fatigue on anxiety; fatigue on depression; anxiety on depression
Bold is shown in the fi gure. 
Model fi t
The following measures were used to test for adequacy of the model fi t: 
Χ2 for model fi t (low and non-signifi cant values of the χ2 are desired; P-value > 0.05); χ2/
df ratio (a value <2.0 was considered to be acceptable); information criteria including 
Akaike (AIC), Bayesian (BIC), sample-size adjusted BIC; Comparative Fit Index (CFI), and 
Tucker-Lewis Index (TLI). High values are desired (> 0.95);17,18 Root Mean Square Error 
of Approximation (RMSEA: a value <0.05 indicates a close fi t);19 and Standardized Root 
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preoperative 
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Mean Squares of Residuals (SRMR: a value of <0.08 indicates a reliable fit).20
We used SPSS version 20.0 (IBM Corp. Armonk, NY) and Mplus version 7 (Muthén and 
Muthén, Los Angeles, CA) for statistical analyses. Estimates were regarded statistically 
significant if the two-sided P-value was <0.05.
RESULTS
The study population consisted of 224 males and 174 females. The mean age equalled 
39.4 years with a standard deviation of 13.6. More sociodemographic and clinical 
characteristics of the patients can be found elsewhere.11
Analysis
According to the measures for adequacy of the model fit, the results of the 64 models 
were inconclusive. Following parsimonious modeling, we decided to keep the pathways 
equal at lag 0 (i.e. at T0 and T1). This step maintained an adequate fitting model. The 
remaining eight models were further evaluated showing that the pathway from fatigue 
to anxiety and depression was most plausible according to the measures for adequacy 
of the model fit. At lag 1, it was statistically allowed to fix the pathways from preoperative 
fatigue to postoperative anxiety, and preoperative fatigue to postoperative depression 
at 0.00. It was also statistically allowed to fix the pathways from preoperative anxiety 
to postoperative fatigue, and preoperative depression to postoperative fatigue at 0.00. 
As the pathway between anxiety and depression was ambiguous at lag 0, all rivalling 
models were evaluated. None of the models has been found better fitting the data than 
the alternatives. Therefore, we decided to intercorrelate anxiety and depression at lag 
0.15 The final model is presented in Figure 2. The model fit was promising χ2 16.10, df 9, 
P-value 0.06, χ2 /df 1.79, AIC 13233.66, BIC 13329.34, sBIC 13253.18, CFI 0.991, TLI 0.979, 
SRMR 0.029, RMSEA 0.045.
Standardized regression coefficients (B) of the study measures are shown in Table 1. Bs among 
fatigue, anxiety and depression showed a range from 0.28 to 0.54. Autoregressions coefficients 
for fatigue, anxiety and depression were 0.54, 0.42 and 0.41 respectively. 95% Bias-corrected 
bootstrap intervals of the unstandardized regression coefficients can also be found in Table 1.
Mijderwijk.indd   165 28-10-2016   07:01:17
| 166 
| Chapter 7
TABLE 1 | Regression coefficients and explained variances according to the model
Study measure B‡ β¶ 95% CIb
# R2§
Preoperative
Anxiety ON 0.17
  Fatigue 0.42 0.10 0.08 to 0.12
Depression ON 0.23
  Fatigue 0.48 0.09 0.07 to 0.11
Anxiety WITH
  Depression 0.35 2.10 1.45 to 2.87
Postoperative
Fatigue ON 0.30
  Fatigue† 0.54 0.71 0.58 to 0.82
  Anxiety Fixed at 0.00
  Depression Fixed at 0.00
Anxiety ON 0.45
  Fatigue† Fixed at 0.00
  Fatigue‡ 0.28 0.05 0.03 to 0.07
  Anxiety 0.42 0.39 0.28 to 0.50
  Depression 0.19 0.23 0.11 to 0.35
Depression ON 0.48
  Fatigue† Fixed at 0.00
  Fatigue‡ 0.45 0.08 0.06 to 0.09
  Anxiety 0.02 0.02 -0.06 to 0.11
  Depression 0.41 0.49 0.37 to 0.62
Anxiety WITH
  Depression 0.42 1.89 1.32 to 2.65
Analysis adjusted for type of intervention as randomized. †Preoperative fatigue; ‡Postoperative fatigue; ‡Standardized 
regression coefficient; ¶unstandardized regression coefficient; #1000 times bootstrapped 95% confidence interval; 
§Explained variances.
DISCUSSION
The principal finding of this study was that postoperative fatigue is likely induced by 
the presence of preoperative fatigue. The role of preoperative anxiety and depression 
on postoperative fatigue may be questioned. This finding is in line with recent research 
in other sets of patients showing that fatigue is a primary phenomenon rather than a 
consequence of anxiety and depression.21,22
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FIGURE 2 | Most parsimonious path model including standardized regression coeffi  cients
The pathways that have been fi xed at 0.00 are omitted in the fi gure.
Explained variances (R2) are estimated for each study measure (Table 1). Postoperative 
fatigue was substantially predictable (R2 = 0.30). Overall, explained variances of the fi nal 
model were substantial, range 0.17 to 0.48 (Table 1).
The second observation was that our data structure showed that the role of anxiety and 
depression with regards to fatigue is also questioned when these variables are measured 
simultaneously at one measurement moment (i.e. lag 0). Although conclusions with 
regards to directionality should be drawn with caution by the absence of a temporal 
relation, recent research performing path modeling on simultaneous measurements 
also showed results supporting the hypothesis that fatigue is a cause and not a 
consequence of anxiety and depression.22 Furthermore, in support of our model, others 
have showed that, although in a diff erent patient sample, improving fatigue results in 
less anxiety and depression.23
At fi rst sight our fi ndings seem to contradict with the suggested psychological theory 
of postoperative fatigue by Salmon and Hall as mentioned in the introduction.5 This 
theory states that postoperative fatigue is the result of misinterpretation of anxiety 
and depression in the postoperative surgical ward in inpatients. However, in day-case 
surgery, patients are admitted and discharged on the day of surgery. So, the medical 
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context may explain our deviant findings.
The next step could be to find and perform an appropriate intervention to treat 
postoperative fatigue in day-case surgical patients when needed. Many pre-, per- 
and postoperative interventions for postoperative fatigue have been designed, 
conducted, and reviewed systematically.24 This review showed that improved analgesia 
could only significantly attenuate postoperative fatigue. A possible reason for the 
lack of significance of many interventions could be the wrong target of intervening. 
Structural equation modeling (SEM) has been shown to be able to indicate a target for 
intervention in order to treat fatigue after a medical process.21 The corollary according 
to our SEM model is that we should focus on treating preoperative fatigue when we aim 
for prevention of postoperative fatigue. This could well be feasible in day-case surgery 
because all procedures are planned admissions, meaning that the prehabiliation period 
is sufficient to intervene. Surgical prehabilitation is the period of time from diagnosis 
to the surgical intervention in which the preoperative status of the patient can be 
optimized. Recently, it has been shown that prehabilitation programs are effective 
in enhancing postoperative recovery, and that this method is superior to the more 
conventional approach to intervene in postoperative period – i.e rehabilitation.25 The 
content of prehabilitation programs may differ and should be adjusted to the specific 
requested health issue.26
When we aim to reduce preoperative fatigue, multimodal treatment seems 
indicated because it is known that fatigue has a multifactorial nature.12,27 Multimodal 
prehabilitation programs could be a suitable framework to achieve this. Moreover, 
multimodal prehabilitation programs – with physical, nutritional, and psychological 
aspects – are more effective than unimodal programs.25,28  These existing programs 
could be further optimized and tailored to reduce preoperative fatigue when other 
aspects are considered too. For example, a brief psychological relaxation treatment 
starting preoperatively was shown to be effective in reducing postoperative fatigue.29 
We also know that cognitive behavioural therapy is an established treatment regarding 
a broad range of fatigue syndromes.30 This therapy could well be effective when it is 
tailored to preoperative fatigue specifically.
Pharmacological therapy could also be of interest. We know that pharmaca acting 
at (the precursor of ) the neurotransmitter 5-hydroxytryptamine could be of interest 
as this is likely to be involved in the process of fatigue, anxiety and depression.31-33 
However, regarding the former, it was shown that this process was more pronounced 
in major surgery,33 making this treatment likely less suitable for day-case surgery 
patients. Preoperative pharmacological treatment (i.e. premedication) is a frequently 
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used tool to prepare patients for the upcoming surgery and to improve postoperative 
outcome. In day-case surgery, however, premedication is administered on the day of 
the surgical procedure and is therefore not in time to address preoperative fatigue. 
Furthermore, previous research showed that premedication is not strong enough to 
affect postoperative fatigue positively.11 On the other hand, a recent meta-analysis 
showed that more profound research is needed for firm conclusion about the effect of 
premedication on postoperative fatigue in day-case surgery.34 
Recommendations for future research
This study is a first approach to unravel the directions of the pathways among 
fatigue, anxiety, and depression in day-case surgery using SEM. Although the fit of 
the identified model was adequate, our results should be confirmed in other sets of 
patients. Modifications in the identified model might be necessary. Furthermore, 
directionality between simultaneously measured study measures should be confirmed 
using a longitudinal design including pre- and postoperative measurements. Although 
prognostic research has been done in day-case surgery,35 further work is increasingly 
needed to determine which patients are vulnerable (i.e. have aberrant levels of 
preoperative fatigue). Prognostic models and preoperative risk evaluations have to 
be performed to indicate which patients need additional treatment and potentially 
prehabilitation programs.25 Cost-effectiveness analysis may be of incremental value. 
Furthermore, future research should be tailored to find predictors of preoperative 
fatigue instead of postoperative fatigue.
Strengths and limitations
In this work we relied on a specific statistical modeling generation technique. This non-
hypothesis driven method is a strength of this study in that it allows unravelling clinical 
pathways in an efficient way. Furthermore, we evaluated rivalling models that could 
fit the data in order to avoid confirmation bias.36 Nevertheless, decisions during the 
modeling procedure are a matter of judgement, and theoretically other models could 
be statistically tested. External validation in another (day-case) surgery population is 
recommended. Hence, the generalizability of the present results should be made with 
caution especially in a non-day-case surgery population.
CONCLUSION
In conclusion, in day-case surgery postoperative fatigue is likely induced via preoperative 
fatigue. The role of anxiety and depression on postoperative fatigue may be questioned. 
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If an intervention for postoperative fatigue is considered, preoperative treatment 
embedded in a prehabilitation program framework tailored to reduce preoperative 
fatigue seems to be the strategy of choice. Ultimately, this will lead to reduction of 
physical, psychosocial, and economic burden.
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Day-case surgery is continuously progressing. Due to anesthetic and surgical 
advancements, outcome measurements have been shifted towards more patient 
centered outcomes like quality of recovery dominated by psychological phenomena. 
The aim of the present thesis was to evaluate the effectiveness of the most performed 
medical preparation prior to surgery (i.e. premedication) on these patient centered 
outcomes. Furthermore, in this thesis we attempted to identify vulnerable patients after 
day-case surgery according to these patient centered outcomes, and to give tools to 
predict them accurately which could lead to (more) tailored interventions. This chapter 
discusses the results together with its implications for clinical practice. Furthermore, 
future prospects will be outlined.
1.1 In retrospect
It was found that premedication with lorazepam was not strong enough to enhance 
quality of recovery and psychological phenomena including anxiety, feelings of fatigue, 
depression and aggression seven days after day-case surgery when compared to 
placebo. However, lorazepam might postpone the decrease in anxiety and aggression 
after day-case surgery (Chapter 2). An additional pharmacogenetic study showed that 
lorazepam premedication might be beneficial to some patient groups nonetheless. 
Particularly female patients with high preoperative anxiety scores might probably benefit 
from lorazepam premedication when they are homozygous carriers of the UGT2B15*2 
genotype (Chapter 3). On the other hand, systematic review and meta-analysis showed 
that psychological phenomena are not yet adequately addressed with regards to 
benzodiazepine premedication to date. Benzodiazepine premedication did show to 
have beneficial effects on postoperative side-effects such as nausea. Furthermore, time 
to discharge was not negatively affected after benzodiazepine premedication (Chapter 4).
Criteria for vulnerable patients were constructed. Subsequently, vulnerable patients 
were identified and predicted by means of prognostic modeling techniques (Chapter 
5 and 6). It was found that roughly one third of the study population was vulnerable 
according to the constructed definition of vulnerability which was based on scores from 
the normal population (Chapter 6). 
As the etiology of postoperative fatigue is still unknown, structural equation modeling 
was performed to take a first step in unravelling the preoperative and postoperative 
pathways between fatigue on the one hand and anxiety and depression on the other 
hand. Postoperative fatigue was predominantly induced by preoperative fatigue and, 
likely, not a consequence of anxiety and depression (Chapter 7).
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1.1.1 Part 1: Premedication with lorazepam and other benzodiazepines
Randomized controlled clinical trials (RCTs) are, nowadays, the preferred method to 
evaluate the effectiveness of medical treatment. Researchers have critically discussed 
this framework however. Next to the time consuming efforts and costs, external validity 
is discussed in the literature.1,2
The Consolidated Standards of Reporting Trials (CONSORT) statement is mainly 
focussed on aspects that cover internal validation.1,3 Although after the introduction 
of the CONSORT statement in 1996 trial reporting improved,4,5 there are still trials 
published that lack providing important methodological content.6 The performed RCT 
described in Chapter 2 is in accordance with the CONSORT statement. Despite the fact 
that several modifications have been made over the years,3,4,7 it still might benefit from 
further modifications. For example, treatment adherence is not specifically included 
in this checklist but is an important element of research quality.8 The study by Zhang 
et al showed that treatment adherence is not always given in published RCTs which 
could lead to different interpretation of study results.8 Previous RCTs in the field, i.e. 
testing benzodiazepine premedication, used oral dosages and lacked information 
about treatment adherence.9-11 Also, the RCT described in Chapter 2 did not report on 
treatment adherence. However, as the study medication was administered intravenously, 
treatment adherence equalled 100%. 
Difficulties with internal validation will resonate in external validation. RCTs that are 
carried out at a single center – such as the one presented in this work – have less 
generalizability than multi-centered RCTs. Furthermore, patient selection creates a more 
homogeneous study population which limits generalizability too. In our case, Dutch 
patients with no history of preceding use of psychopharmaceuticals dominated the 
study population that might have biased the results of our patient related outcomes. 
However, still, external validity is a matter of judgement.12 
The conclusions drawn from a single RCT should be interpreted cautiously as false 
negative results may be present.12,13 A recent RCT in inpatient surgery also found no 
beneficial effect of lorazepam premedication on patient experience and patient quality 
of recovery at the first postoperative day.14 Although that study did not evaluate 
lorazepam premedication beyond the first postoperative day like we did, the combined 
findings may suggest a lack of benefit with routine use of lorazepam as premedication. 
However, it might not be justified to withhold premedication routinely as it may be 
possible that subgroups of (vulnerable) patients could benefit from premedication. The 
relative wide confidence intervals of the outcome parameters in the presented RCT in 
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Chapter 2 might indicate a heterogeneous response to premedication with lorazepam.
Meta-analysis of performed RCTs will give more robust results and therefore more 
firm conclusions.12 However, it was not possible to make conclusive remarks with 
respect to the effectiveness of premedication with benzodiazepines on psychological 
outcome in our meta-analysis of RCTs in Chapter 4. Due to an insufficient number of 
trials examining the effect of benzodiazepines on psychological outcomes in day-case 
surgery, it was not allowed to make proper conclusions. With respect to postoperative 
side effects, we found beneficial results, and the results showed that time to discharge 
was not negatively affected after benzodiazepine premedication. Recently, two studies 
presenting systematic review and meta-analysis also showed a decrease in postoperative 
side-effects, i.c. post-operative nausea and vomiting.15,16 These studies lacked the ability 
to generalize their results since they studied the perioperative use of midazolam only. 
Furthermore, the study population included mixed surgical patients. Nonetheless, 
available evidence increasingly suggests positive effects on post-operative side-effects 
without affecting time to discharge after premedication with benzodiazepines.
The main assumption made in the derived pharmacogenetic study, described in Chapter 
3, included the achieved plasma level of lorazepam in patients. The rationale of this 
study was based upon previous profound research by Chung et al showing significant 
different plasma concentration of lorazepam according to UGT2B15 genotype.17 Thus, 
in our work, plasma levels of lorazepam were not assessed which makes the effect site 
concentration – effect relationship a matter of debate. The results of this study were 
complex: anxiety differences significantly depended on a highest order interaction 
between premedication (lorazepam yes/no), UGT2B15 genotype status, patient gender, 
and preoperative level of anxiety. Although higher order interactions are mathematically 
correct, clinical interpretation is challenging as the outcome is explained by the 
combination of multiple variables. Visualisation can help the reader to understand the 
result, however sacrifices may be needed (i.c. dichotomization of a continuous variable). 
As significant lower order interactions are less relevant than higher order interactions,18 
higher order interactions should not be ignored for reasons of complexity.
1.1.2 Part 2: Identifying vulnerable patients
Prognostic modeling could facilitate health care professionals to aid medical decision 
making. We performed two studies using preoperative data in order to identify 
vulnerable patients in the postoperative period.
In Chapter 5, a prognostic model was constructed predicting multiple psychological 
outcomes simultaneously one week after day-case surgery. Clinically, a patient is more 
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than one outcome variable, especially when psychological phenomena are considered 
as outcome – these variables are likely intercorrelated. Statistically, when these 
outcomes are considered, the most appropriate and efficient way of analysing includes 
a joint analysis instead of running separate multivariable regressions. To achieve 
this, a structural equation modeling framework could be useful.19 The constructed 
prognostic model (Chapter 5) showed substantial explained variances, but was still 
imperfect. Omitted and unknown variables could play a role, for example interpersonal 
variables. Model misspecification could have emerged. Furthermore, fallibility of the 
measurements is an option. We have refrained from correcting for measurement errors 
in the analyses, as this would make our study less suitable for use in clinical practice.
Although the scores of the psychological phenomena were not that high, sufficient 
variation c.q. heterogeneity was found. Chapter 6 showed that 36% of our day-case 
surgery population was vulnerable after the surgery according to constructed cut-off 
scores (a patient was vulnerable when the score for an outcome exceeded one standard 
deviation above the mean according to normative scores). The creation of one single 
outcome including three vulnerability categories allowed us to use conventional 
statistical regression modeling (i.c. ordinal logistic regression modeling).20 The proposed 
model showed a promising discriminative ability and model performance. Although 
the constructed composite scale (i.e. none-, single- and multiple vulnerable) enabled 
to classify patients for vulnerability and to predict them adequately, the costs for such a 
classification is loss of information.20 The model selection was performed by backward 
elimination of determinants to find the most parsimonious model.21 In our analysis 
strategy P-to-remove equalled 0.20. However others have used less stringent P-values 
especially in small data sets.20,21 The latter strategy will allow more predictor variables in 
the final model.
In Chapter 5 it is suggested that postoperative fatigue behaves differently when 
compared to the other psychological phenomena including anxiety, depression and 
aggression. This is imaginable as researchers have suggested several theories about the 
underlying causal structure. Some believe that the underlying structure is of somatic 
nature,22 while others believe it should be explained in a psychological way.23 Although 
the truth will lie somewhere in the middle,24 the psychological theory of Salmon and 
Hall is still leading this field.25-27 This theory states that anxiety and depression are 
misinterpreted as fatigue (i.e. somatisation) but the directionality assumed is never 
solved.25,27 In Chapter 7 a path analysis was executed to unravel directionality among 
these phenomena. Path modeling is a specific feature of structural equation modeling 
(SEM) which can be used to unravel directionalities of clinical pathways in complex 
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entities.19,28 The most plausible model showed that fatigue likely induces anxiety and 
depression rather than vice versa. With regards to the theory of Salmon and Hall the 
difference could be explained by the medical context: day-case surgery patients are less 
hospitalised than the patients where the theory of Salmon and Hall is based on.
In this work SEM was performed on longitudinal data as well as on cross-sectional 
information, i.e. simultaneous measurements assessed at the same measurement 
moment. The temporal design in longitudinal data allows to make statistical judgement 
on directionality.19 By definition temporal precedence cannot be demonstrated in cross-
sectional data and inference about directionality is complicated therefore. However, 
SEM has also been performed on cross-sectional data to guide medical decision-
making.28,29 When study measures are assessed cross-sectionally and directionality is 
suggested, the researcher should provide a valid rationale.19 Although the conclusion 
in Chapter 7 is reluctant about directionality among fatigue, anxiety and depression 
when measured simultaneously, these pathways were presented in the model diagram 
as previous research has shown similar results with respect to these phenomena, and 
empirical tested therapies have directed into such a structure.29,30
Prior to the analysis there was no hypothetical construct concerning the direction 
of the pathways among fatigue, anxiety and depression within our day-case surgery 
study population. The three possibilities to deal with such a research question include 
defining a structural equation model without directionality, define and test all possible 
models, or include reciprocal effects in the defining model.19 In the work presented 
all possible models were tested. As expected, equivalent models exist (i.e. different 
models fit the data structure equally well).19 As we did not succeed to find a preferred 
pathway, it was decided to keep the pathways on the cross-sectional data similar (i.e. 
the preoperative and postoperative pathways were kept equal) as statistically it was not 
possible to choose one above the other. This limits claims about directionality. Causality 
(i.e. true directionality) can only be claimed when 1) the identified model is replicated in 
other independent study samples, 2) (near) equivalent models are definitely ruled out, 
and 3) empirical studies have demonstrated evidence for manipulable variables in the 
model and accurate prediction of effect of interventions.19,31 These issues were beyond 
the scope of the current thesis and were not addressed therefore.
1.2 In prospect
Although there is variation in the progress of day-case surgery worldwide,32 it has 
been estimated that 80% of elective surgical procedures will be carried out as day-case 
surgery.33 In some parts of the world this percentage has already been achieved.32 It 
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is expected that the increase of day-case surgery will continue since more and more 
complex surgical procedures are being carried out in a day-case setting. For example, 
craniotomies for brain tumour resection have recently been performed on a day-case 
base.34,35 In addition, the worldwide population continues to expand together with 
aging.36,37 As a consequence, the incidence of vulnerable patients undergoing day-case 
surgery will likely increase substantially. To preserve the medical and socio-economic 
success of day-case surgery, adequate care should be present for these vulnerable 
patients.
1.2.1 Part 1: Premedication with lorazepam and other benzodiazepines
To gain more insight in the role of lorazepam on psychological outcomes in the day-case 
surgery population, new randomized controlled clinical trials should be designed and 
conducted to improve generalizability. This is of incremental importance. It is widely 
known that the response to drugs can show wide variability among patients.38 Including 
other biological-, cultural- and environmental factors will give more insight in possible 
variability in drug response.38 Day-case surgery patients with other disease states such 
as abortion or brain tumour resection were not in the scope of this thesis. These patient 
groups could respond differently to premedication with lorazepam due to aberrant 
psychological and physiological processes altered by the underlying disease. With 
respect to cultural- and environmental factors, exploring lifestyle diversity could be of 
additional value. For example, the clearance of lorazepam – and other drugs primarily 
metabolized by uridine 5’-diphosphate-glucuronosyltransferases – has been found to 
be significantly higher in obese.39,40 
Next to genetic factors affecting lorazepam metabolizing enzymes, the focus of future 
studies could also be the variability of lorazepam at the receptor site. Premedication (i.c. 
lorazepam) is regularly administered once, and, accordingly, the clinical effect is more 
dependent on the premedication distribution than on the premedication elimination.41 
The entry of drugs into the brain is controlled by the blood-brain-barrier (BBB) and the 
blood-cerebrospinal fluid barrier. Exploration of the latter is at a beginning stage.42 
Although several pathways exist for crossing the BBB, benzodiazepines cross the BBB 
predominantly via diffusion.42,43 Furthermore, at the epithelial cells in the BBB, the 
apically located P-glycoprotein transporter controls drug entry over the BBB by pumping 
substrates out of cells.44 P-glycoprotein is the most extensively studied active drug 
efflux transporter. One of the reasons for its popularity is the wide variety of substrates 
involved which also includes lorazepam.42 Modifications in P-glycoprotein activity 
could probably result in different clinical effects of lorazepam premedication. On the 
one hand genetic disruptions such as gene polymorphisms are known that could affect 
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P-glycoprotein activity. For example, in 24% of the Caucasian population homozygosity 
occurs for an allele that is correlated with reduced P-glycoprotein activity.45 On the other 
hand, chemical possibilities such as co-administration modifying P-glycoprotein activity 
could also be an option to investigate in order to obtain better therapeutic efficacy 
with lorazepam premedication. Literature shows heterogeneous results with respect 
to the effectiveness of co-administration that is able to inhibit P-glycoprotein (e.g. 
quinidine),46-48 i.e. co-administration does not always provide the expected enhanced 
effect of drugs that are P-glycoprotein substrates. One of the hypotheses includes the 
role of lipophility of the drug. It is suggested that the more lipophilic the drug, the less 
pronounced efflux via P-glycoprotein.42,49 This should be taken into account when co-
administration modifying P-glycoprotein is considered. Among the benzodiazepines, 
lorazepam has a moderate lipophility.50,51
Another way to improve the clinical efficacy of lorazepam premedication is to improve 
its affinity to the GABAA receptor complex after its entrance to the CNS. Several 
modifications in the GABAA receptor have shown interesting results with respect to 
benzodiazepine sensitivity.52-55 It remains to be explored whether these modifications 
can be applied to lorazepam. 
Future studies could also analyse other benzodiazepines as premedication prior to 
day-case surgery. In accordance with the aging population it is advised to administer 
benzodiazepines that undergo Phase II metabolism only such as oxazepam and 
temazepam, as these have no active metabolites and substantial drug interactions 
are rare.42 Furthermore, administration of benzodiazepine premedication should be 
considered carefully since it is known that it also may cause, for example, agitation and 
delirium.56-58 The most optimal (benzodiazepine) premedication will likely be different 
for different sets of (vulnerable) patients. 
1.2.2 Part 2: Identifying vulnerable patients
In this thesis the focus was on the relationships among variables by using a variable 
centered approach. Adding statistical methodologies that take into account a patient-
centered approach could be helpful to identify vulnerable patients in the growing 
heterogeneous day-case surgery population – more elderly, and more complex surgery 
will be more and more exposed to day-case surgery in the near future. Such statistical 
methodology aims to group (non) vulnerable patients into various sets of patients that 
each have their own unique characteristics. Thus, the focus here is on relationships 
among patients.59 A couple of the most used methods that integrate variable-centered 
and person-centered include latent class analysis, latent transition analysis, latent class 
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growth analysis, and (general) growth mixture modeling. The description and purpose 
of these statistical methodologies are well described elsewhere.59 Thus, in short, these 
methods try to cluster patients from a heterogeneous population into (latent) classes 
that represent a homogeneous subpopulation that has its own set of parameter values.59 
This may enable a tailored treatment approach to such a subpopulation.
Furthermore, in addition to well-known model modifications in prognostic modeling 
such as including other determinants and replication of the model in other sets of 
patients,20 prognostic modeling in day-case surgery patients could especially benefit 
from additional measurement moments. For example, adding distal outcomes (i.e. long 
term outcomes) that cover rehabilitation success such as returning to normal daily 
activities, returning to work, etcetera. Multiple preoperative measurements would also 
help to understand the preoperative period in (vulnerable) patients and to create more 
time for appropriate interventions if needed. More preoperative and postoperative 
measurements will also help to confirm the direction of the pathways between fatigue 
on the one hand and anxiety and depression on the other hand. If future research 
could confirm the found perioperative pathway from fatigue to anxiety and depression 
(Chapter 7), prognostic studies could be simplified according to parsimonious modeling 
by focussing particularly on reducing preoperative fatigue.
The definition of a vulnerable patient is a matter of judgement. Therefore we have 
chosen to create and validate a prognostic model that was not restricted to a cutoff point 
of vulnerability (Chapter 5). Subsequently, the vulnerability threshold of an individual 
patient is for the discretion of the health care professional. Many criteria could be used. 
One possibility is described in Chapter 6: a patient is considered vulnerable when the 
score is more than one standard deviation away from the mean according to the normal 
population. Subsequently, decision making with respect to treatment options for these 
vulnerable patients becomes feasible.
Further studies could be subjected to evaluate different decision rules in combination 
with possible treatments. In day-case surgery, decision rules that take into account 
multiple outcomes seem indicated. Some methods that may be of interest are well 
described elsewhere.60,61 When decision rules are validated they might be incorporated 
in expert (critiquing) systems. These systems provide a computer-based advice to the 
physician for clinical decision making.62 Such a computer program was previously 
applied in anesthesiology for risk assessment.62 Although the clinical utility needs 
further exploration, these programs have shown potential as a tool for prevention.63
The decision to offer a vulnerable patient a treatment, and especially which kind of 
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treatment is of particular clinical interest but still not investigated in day-case surgery 
patients. According to the identified vulnerable patients in Chapter 6, it is likely that 
single vulnerable patients need a different treatment plan than multiple vulnerable 
patients.
Intervening preoperatively is currently of increasing interest. Synthesis of evidence 
has shown promising results on postoperative outcomes.64 These programs are called 
‘prehabilitation programs’. These programs seem superior to rehabilitation programs 
– programs that intervene in the postoperative period, especially when they use a 
multimodal framework.64 The prehabilitation time frame in day-case surgery includes 
the preoperative period from the moment of the medical diagnosis until the moment 
of the surgical intervention. Since the surgical procedures are electively planned in 
day-case surgery, a prehabilitation program should be able to perform. Moreover, 
the study presented in Chapter 6 showed that one-third of our day-case population 
show vulnerable features with respect to psychological outcome parameters showing 
the need to improve these postoperative outcomes. Nevertheless, currently, no 
evidence-based prehabilitation program – or rehabilitation program or a combination 
of the two – does exist for the day-case surgery population. But, if a prehabilitation 
program is desired, who will lead its development, implementation, and evaluation? 
Since multimodal prehabilitation programs focussing on physical, nutritional and 
psychological aspects seem more effective,64,65 a multidisciplinary team including, 
for example, the anesthesiologist, the surgeon and the psychologist will be needed. 
Furthermore, it is likely that a beneficial and cost-effective prehabilitation program 
in day-case surgery may differ according to the postoperative outcomes of interest 
and health care settings.66 For example, if reducing postoperative fatigue is intended, 
it might be reasonable to focus on reducing preoperative fatigue as this might lower 
fatigue, anxiety and depression postoperatively (Chapter 7). Subsequently, for example, 
the constructed prediction models in the current thesis may not fully apply and new 
prediction models tailored to preoperative fatigue need to be designed by statisticians. 
Furthermore, treatment options will likely change and more tailored to the primary 
phenomenon. In the case of fatigue, psychological relaxation therapies and cognitive 
behavioural therapy have shown potential in reducing fatigue.67,68 Accordingly, 
psychological professionals are needed to perform or teach these treatments which 
should be evaluated in well-conducted studies. When the objective is to adjust patients’ 
lifestyle to reduce body weight to make, for example, lorazepam premedication more 
effective, a dietician and/or physiotherapist is likely desired. 
So, who should coordinate a prehabilitation program in day-case surgery in order 
Mijderwijk.indd   187 28-10-2016   07:01:18
| 188 
| Chapter 8
to prevent vulnerability after surgery? I would suggest the anesthesiologist. Risk 
assessment and managing multidisciplinary teams perioperatively are skills that are 
predominantly dedicated to anesthesiologists.69,70 Furthermore, it was previously 
recommended that, in day-case surgery, “anesthesiologists should take the lead in 
studying the impact of post discharge symptoms and advocating for our patient’s best 
care, even if it involves care beyond our traditional period of involvement”.71 However, 
as the daily clinical practice of a medical doctor is quite busy, tasks may be delegated to 
trained and dedicated day-case surgery nurses as soon as their role is well described in 
protocols. This corresponds with the concept of the start of day-case surgery, more than 
a 100 years ago.72,73
1.3 Concluding remarks
This thesis aimed to evaluate the effects of premedication with benzodiazepines, in 
particular lorazepam, on the quality of recovery of day-case surgery which is dominated 
by psychological outcome parameters nowadays. The studies reveal that, in general, 
patients undergoing day-case surgery have no additional benefit with benzodiazepine 
premedication with respect to these outcome parameters, although future studies 
are needed to make more firm conclusions. The studies also reveal that lorazepam 
premedication might be beneficial in subgroups of day-case surgery patients. 
Furthermore, benzodiazepine premedication has beneficial effects on postoperative 
side-effects and does not negatively affect time to discharge. This thesis also illustrates 
that the application of novel statistical methodologies can help in unravelling the 
pathways among variables, and can lead to adequate identification of vulnerable 
patients paving the way for optimal medical decision making in day-case surgery.
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Chapter 1 is a general introduction about the concept of day-case surgery, the 
preoperative evaluation, and possible preparation of patients for the surgical procedure 
with specific attention to premedication with benzodiazepines, in particular lorazepam. 
Furthermore, postoperative evaluation and statistical modeling is outlined.
Chapter 2 presents a randomized placebo controlled clinical trial that was undertaken 
to assess the effectiveness of premedication with lorazepam on the quality of recovery 
and psychological phenomena including anxiety, feelings of fatigue, depression 
and aggression up to seven days after day-case surgery. The results showed that 
premedication with lorazepam did not improve quality of recovery. Furthermore, it was 
found that the postoperative decrease in anxiety was lower in the lorazepam group, and 
that the postoperative aggression scores were slightly increased in this group.
Chapter 3 concerns a derived pharmacogenetic study evaluating patient variability 
in anxiolytic effect after premedication with lorazepam according to the UGT2B15 
genotype. It was found that the UGT2B15 genotype polymorphism influences 
postoperative anxiety levels. This clinical effect was also depended on the interaction 
with patient gender and the preoperative anxiety score. Further exploration showed that 
high preoperative anxious females with genetically reduced lorazepam glucuronidation 
(UGT2B15*2 homozygotes) had more anxiety reduction than males with the same 
genotype.
Chapter 4 reviews the effectiveness of premedication with benzodiazepines on 
postoperative somatic symptoms/complaints and psychological phenomena in 
day-case surgery by means of a systematic literature review with meta-analysis of 
randomized placebo controlled clinical trials. Benzodiazepines showed to have 
favourable effects on postoperative somatic symptoms/complaints such as nausea. 
Regarding psychological phenomena, only anxiety could be subjected to meta-analysis 
showing no statistical difference. More research is needed to make firm conclusions 
on psychological outcomes. Furthermore, this review concluded that the reluctance 
of some anesthesiologists to administer benzodiazepine premedication in day-case 
setting is not justified for reasons of delayed recovery – time to discharge was not 
negatively affect after benzodiazepine premedication.
Chapter 5 describes the results of a prognostic model using preoperative data including 
sociodemographic, medial and psychological determinants in order to predict multiple 
psychological outcomes jointly one week after day-case surgery. Apart from state 
aggression the psychological outcomes could be adequately predicted using the 
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identified model. Sociodemographic and medical variables were of minor importance, 
with the exception of gender and having children. In contrast, the psychological 
variables as assessed at baseline were of prominent importance. 
Chapter 6 defines a definition of a vulnerable patient with respect to psychological 
outcomes one week after the surgical procedure based on scores from the normal 
population. Roughly one third of the study population was identified as being 
vulnerable. Subsequently, a prediction model was constructed using preoperative data 
that was able to predict adequately vulnerability in day-case surgery patients.
Chapter 7 describes a study aimed to unravel potential pathways leading to 
postoperative fatigue based on a theory assuming that anxiety and depression are 
closely related to fatigue. Using a structural equation modeling framework, it was 
suggested that postoperative fatigue is likely induced via preoperative fatigue and not 
a consequence of anxiety and depression.
Chapter 8 includes the general discussion. The results and methodological 
considerations of this thesis are discussed. Furthermore, clinical implications and 
recommendations for future research are given. 
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Hoofdstuk 1 is een algemene introductie over het concept van operaties in 
dagbehandeling. De preoperatieve evaluatie en mogelijke voorbereidingen voor 
patiënten met betrekking tot de chirurgische ingreep worden besproken. De aandacht 
gaat hierbij uit naar premedicatie met benzodiazepines, in het bijzonder lorazepam. 
Verder is de postoperatieve evaluatie en het statistisch modelleren uiteengezet.
Hoofdstuk 2 betreft een gerandomiseerde placebo gecontroleerde klinische trial dat 
was uitgevoerd om de effectiviteit van premedicatie met lorazepam te meten tot zeven 
dagen na de operatie op de kwaliteit van het herstel en op de volgende psychologische 
verschijnselen: angst, gevoelens van vermoeidheid, depressie en agressie. De 
resultaten toonden aan dat premedicatie met lorazepam niet de kwaliteit van het 
herstel verbeterde. Tevens bleek dat de postoperatieve angstreductie lager was in de 
lorazepam groep en dat de postoperatieve agressiescores subtiel waren toegenomen 
in deze groep.
Hoofdstuk 3 betreft een afgeleide farmacogenetische studie dat de variabiliteit 
tussen patiënten in anxiolytisch effect na premedicatie met lorazepam evalueerde 
met betrekking tot het UGT2B15 genotype. Het bleek dat het UGT2B15 genotype 
polymorfisme de postoperatieve angstscores beïnvloedde. Het klinische effect hing 
ook af van de interactie tussen het geslacht van de patiënt en de preoperatieve 
angstscore. Verdere exploratie toonde aan dat preoperatief hoog angstige vrouwen 
met genetisch gereduceerde lorazepam glucuronidatie (UGT2B15*2 homozygoten) 
meer angstreductie hadden dan mannen met hetzelfde genotype.
Hoofdstuk 4 bespreekt de effectiviteit van premedicatie met benzodiazepines op 
postoperatieve somatische symptomen/klachten en psychologische verschijnselen 
bij operaties in dagbehandeling door middel van een systematische literatuurstudie 
en meta-analsye van gerandomiseerde placebo gecontroleerde klinische trials. 
Benzodiazepines bleken gunstige effecten te hebben op postoperatieve somatische 
symptomen/klachten zoals misselijkheid. Met betrekking tot de psychologische 
verschijnselen was het enkel mogelijk om angst te onderzoeken in een meta-analyse. 
Er bleek geen statisch verschil te zijn. Meer onderzoek is nodig om meer gefundeerde 
conclusies te trekken over psychologische uitkomstmaten. Verder concludeerde 
deze literatuurstudie dat de terughoudendheid van sommige anesthesiologen om 
premedicatie met benzodiazepines toe te dienen bij operaties in dagbehandeling 
niet gerechtvaardigd is op basis van gedachten dat dit een vertraagd herstel geeft 
– het tijdstip van ontslag werd niet negatief beïnvloed na premedicatie met een 
benzodiazepine.
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Hoofdstuk 5 beschrijft de resultaten van een prognostisch model dat gebruik maakte van 
preoperatieve data welke bestond uit sociodemografische, medische en psychologische 
determinanten om zo meerdere psychologische uitkomstmaten, die een week na de 
operatie in dagbehandeling waren gemeten, gezamelijk te voorspellen. Behalve de 
situationele agressie konden de psychologische uitkomstmaten goed worden voorspeld 
wanneer gebruik werd gemaakt van het geïndentificeerde model. Met uitzondering 
van geslacht en het al dan niet hebben van kinderen waren de sociaaldemografische en 
medische variabelen van ondergeschikt belang. De psychologische variabelen die op 
baseline werden gemeten, waren daarentegen van prominent belang.
Hoofdstuk 6 geeft een definitie van een kwetsbare patiënt met betrekking tot 
psychologische uitkomsten een week na de operatie in dagbehandeling. Dit was 
gebaseerd was op scores van de normale populatie. Ongeveer een derde van de 
studiepopulatie werd geïndentificeerd als kwetsbaar. Vervolgens werd op basis van 
preoperatieve data een voorspellend model geconstrueerd dat in staat was om op een 
adequate manier de kwetsbaarheid van deze patiënten te voorspellen.
Hoofdstuk 7 beschrijft een studie die gericht was op het ontrafelen van potentiële 
paden die leiden naar postoperatieve vermoeidheid. De studie was gebaseerd op een 
theorie die ervan uitgaat dat angst en depressie nauw verwant zijn met vermoeidheid. 
Met behulp van een Structural Equation Modelling framework werd gesuggereerd dat 
postoperatieve vermoeidheid waarschijnlijk geïnduceerd wordt via preoperatieve 
vermoeidheid en dat dit niet een gevolg is van angst of depressie.
Hoofdstuk 8 bevat de algemene discussie. De resultaten en methodologische 
overwegingen van dit proefschrift worden bediscussieerd. Verder worden klinische 
implicaties en aanbevelingen voor verder onderzoek gegeven.
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Tijdens mijn studie geneeskunde raakte ik al snel klinisch betrokken bij de afdeling 
anesthesiologie. Naast mijn studie wilde ik mij ook graag op wetenschappelijk gebied 
ontwikkelen. Toen ik, in het kader van de master Clinical Research, de mogelijkheid 
kreeg om, op dezelfde afdeling anesthesiologie, een gerandomiseerd, dubbelblind, 
placebo-gecontroleerd onderzoek op te zetten en uit te voeren, heb ik geen moment 
getwijfeld om dit project te starten. Ik wist destijds nog niet dat het zou uitgroeien tot 
een promotietraject. Ik ben altijd vastberaden geweest om dit project van het begin tot 
en met het einde te voltooien. Ik ben zeer dankbaar dat ik door dit proces heb mogen 
gaan. Vele mensen zijn op mijn pad gekomen en hebben mij hierin geholpen. Dit 
proefschrift is daarom niet compleet zonder dankwoord en daar wil ik dan ook graag 
mee besluiten.
Allereerst mijn promotor, prof. dr. R.J. Stolker. Het project was al enige tijd aan de gang 
toen ik voor het eerst een ‘officiële’ afspraak met u had. Naast het feit dat het gesprek 
zeer informatief en opbouwend was, was het ook gezellig. Ik vond het bijzonder 
dat u alle tijd voor mij nam. Echter dit bleek geen uitzondering te zijn, want op alle 
afspraken die volgden nam u uitgebreid de tijd om mijn werk te bespreken. Altijd 
lagen mijn stukken al klaar, volledig voorzien van correcties, suggesties en overige 
feedback. Ik kreeg van u veel vrijheid om mijn gedachten te verwerken. U overwoog 
ze grondig en schaafde ze bij waardoor ik in de juiste richting bleef gaan. U was altijd 
positief, gaf perspectief en motiveerde enorm als het tegen zat. Het feit dat u een zeer 
gepassioneerde en betrokken promotor bent, werd nog maar eens duidelijk toen 
u uitgebreid participeerde in het analyseren van de studies voor het systematische 
review met meta-analyse. Daarnaast bent u altijd de spin in het web geweest in deze 
multidisciplinaire onderzoeksgroep. Dank ook voor het feit dat u betrokken wilt zijn in 
het verwezenlijken van mijn klinische ambitie. Ik hoop van harte dat we in de toekomst 
op zowel persoonlijk als op professioneel vlak contact zullen blijven houden. Ik vind het 
een eer om bij u te mogen promoveren. 
Copromotor, dr. M. Klimek. Als ik terugkijk is het erg bijzonder om te zien wat voor weg 
wij hebben gelopen. Na één meeloopdag op de OK nodigde u mij uit om te solliciteren 
in het PACU studententeam, waar ik jaren met zeer veel plezier heb mogen werken. 
Daarnaast gaf u mij de mogelijkheid om een RCT op te zetten en uit te voeren onder 
uw directe supervisie. Ik ben u hier buitengewoon dankbaar voor. U gaf me veel ruimte 
om mijzelf te ontplooien en voorzag mij van alle faciliteiten om onderzoek te kunnen 
doen. U was altijd bereikbaar en gaf gevraagd en ongevraagd waardevolle adviezen. 
Daarnaast stond u mij altijd direct bij op de ‘werkvloer’ als dat nodig was. Van dichtbij 
heb ik mogen leren van uw klinisch en wetenschappelijk redeneren en het omgaan 
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met en oplossen van tegenslagen. Onder andere door uw mentorschap heb ik een MSc 
in Clinical Research en KNAW Akademie Assistentschap succesvol kunnen afronden 
waar ik u tot op de dag van vandaag dankbaar voor ben. Uw betrokkenheid was verder 
zichtbaar door het feit dat u bij iedere presentatie van het onderzoek aanwezig was. 
Dank dat u altijd bereid bent om mee te denken en te helpen mijn klinische carriere 
vorm te geven. Daarnaast waardeer ik ook de vriendschap buiten de werksfeer en hoop 
deze nog lang te kunnen onderhouden. 
Copromotor, dr. H.J. Duivenvoorden. Ik ben zeer dankbaar dat u één van mijn 
leermeesters bent geworden. Tijdens onze eerste afspraken over het opzetten van de 
RCT bleek – achteraf gezien – al dat u een ras wetenschapper bent. U trok het onderzoek 
in een breder perspectief en stippelde al snel een promotie-traject uit, wat uiteindelijk 
mede heeft geleid tot dit huidige werk. Ik kon toen nog niet voorzien hoe belangrijk u 
was voor de fundering en uitvoering van dit project. Op vele gebieden heb ik ongekend 
veel van u mogen leren, in het bijzonder over methodologie en het bedenken en 
uitvoeren van statistische analyses. Ontelbare keren bent u naar de onderzoekskamer 
afgereisd om samen met mij data te analyseren, ideeën uit te werken, al mijn vragen 
te beantwoorden en ga zo maar door. Dat u een ras wetenschapper bent bleek nog 
maar eens toen u na uw pensioen gewoon door wilde gaan met het begeleiden van 
het onderzoek. Ik bewonder uw wetenschapsfilosofie. Uitspraken als “houd het simpel, 
maar niet simplistisch” en “de patiënt is meer dan een uitkomstvariabele” zullen mij 
altijd bijblijven. Graag wil ik u ook bedanken voor uw persoonlijke adviezen omtrent 
het begrenzen van onderzoek in mijn privéleven. Ik hoop met u dit goede contact te 
kunnen onderhouden. 
Prof. dr. E.W. Steyerberg, prof. dr. T. van Gelder en prof. dr. L.P.H.J. Aarts, dank voor 
uw bereidheid om plaats te nemen in de leescommissie en zo dit proefschrift op zijn 
wetenschappelijke waarde te beoordelen. Prof. dr. E.W. Steyerberg dank voor uw 
coaching en stimulatie gedurende een deel van dit project. Ik kon altijd laagdrempelig 
bij u aankloppen voor vragen.
Prof. dr. H.J.M. Verhagen, prof. dr. J. Passchier en prof. dr. B. Preckel, dank voor uw 
bereidheid om in de grote commissie plaats te nemen om van gedachten te willen 
wisselen over de inhoud van mijn proefschrift.
Het personeel van de chirurgische dagbehandeling van het Erasmus MC onder 
leiding van Joleen Smit wil ik bedanken voor de bereidheid om mee te werken met dit 
project. Zonder jullie welwillendheid had dit project nooit uitgevoerd kunnen worden. 
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In het bijzonder wil ik Jeanette den Hollander en Henk van Welzen bedanken. 
Jullie waren mijn steun en toeverlaat op respectievelijk de verpleegafdeling en de 
preoperatieve holding van de chirurgische dagbehandeling. Door jullie enthousiasme 
en gedrevenheid heeft het onderzoek op de juiste manier kunnen plaatsvinden. Dank 
voor het meedenken en de vele gouden tips op de afdeling. Daarnaast waren de 
wedstrijden naar SPARTA Rotterdam altijd bijzonder gezellig.
Stefan van Beek, collega, zwager en vriend. In het begin heb ik getwijfeld om je te 
betrekken bij de PACU en bij dit project, gezien onze familieband. Echter toen ik de 
knoop had doorgehakt, heb ik nooit meer getwijfeld. We kunnen goed privé en werk 
gescheiden houden en het is soms juist prettig om korte lijntjes te hebben. Je bent 
bereid om hard te werken en hebt goede ideeën. We kunnen goed gestructureerd 
samenwerken en mede daarom is de RCT goed verlopen. Het is mooi om te zien dat het 
vervolg op dit project onder jouw hoede valt en ik ben blij dat ik je hier bij kan helpen. 
Ik hoop dat we in de toekomst nog veel samen mogen werken! Ik ben dankbaar dat je 
mijn zwager én paranimf bent. 
Ko Hagoort, bedankt voor uw tijd in het reviewen van de eerste manuscripten en 
presentaties op de Engelse taal. 
Een aantal mensen hebben een specifiek deel van dit project mogelijk gemaakt. Prof. 
dr. Ron van Schaik wil ik bedanken voor het mogelijk maken en het faciliteren van de 
analyses naar het UGT2B15 genotype. Tevens wil ik u danken voor uw wetenschappelijke 
bijdrage aan het desbetreffende manuscript. Ik dank dr. Frank Grüne voor de hulp bij 
het opzetten van dit project en de gezellige doch informatieve ontmoetingen in de 
wandelgangen. Drs. Esther Pluijms wil ik bedanken voor het bereid zijn voor het 
vervullen van de functie onafhankelijke arts voor patiënten als zij vragen hadden over 
dit project. Wichor Bramer ben ik veel dank verschuldigd voor de hulp bij het vinden 
van de juiste literatuur voor de systematische review en meta-analyse. Daan Nieboer 
dank ik voor de hulp bij statistische analyses in het programma R. 
Bart ten Brinke, bedankt dat je op deze bijzondere dag naast me wilt staan als paranimf. 
Het voelt goed dat je naast me staat gezien onze vriendschap die we sinds de aanvang 
van de studie geneeskunde hebben. De mooiste periode was ongetwijfeld de jaren dat 
we huisgenoten waren. Je had altijd tijd voor een ‘bakkie’ en een goed gesprek over de 
zin en onzin van het leven. Ik wens je veel succes met je opleiding tot orthopeed. 
Maarten voor de Poorte, Mr. Artist, we kennen elkaar al jaren en hebben al veel samen 
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meegemaakt. Het is nooit saai dankzij jouw creatieve brein. Gaaf dat je de cover en de 
covers van de hoofdstukken – en het verhaal erachter – hebt willen ontwerpen. De cover 
heeft, nu jij hem hebt ontworpen, voor mij een extra dimensie. De vele telefoontjes 
hierover mag je bij mij declareren. 
Mijn familie wil ik graag bedanken. Mijn broer Matteo en zussen Margrit & Antoinet 
dank ik voor de warme band die we samen hebben. Als ‘oudste broer’ ben ik hier erg 
blij mee. In het bijzonder wil ik mijn ouders noemen. Jullie weten als geen ander wat 
dit project allemaal heeft gekost. Lieve ma, van jongs af aan heeft u alles op zij gezet 
voor ons en voor mij. Altijd was u voor ons thuis en creeërde u rust zodat een ieder 
thuis kon studeren. U cijferde zichzelf altijd weg en plaatste ons in het middelpunt – 
bewonderingswaardig. Dank voor al uw support. Beste pa, dank voor de bijzondere 
relatie die we hebben. We kunnen erg goed samen praten en werken. Dank voor de 
vele gesprekken en vaderlijke adviezen als ik ergens tegen op zag of wat dan ook. Uw 
christelijke kaders zijn mij altijd tot steun en helpen mij om verder te gaan.
Als laatste wil ik mijn lieve vrouw, Marieke, bedanken voor haar onvoorwaardelijke 
steun tijdens deze periode. We leerden elkaar kennen toen dit project net was gestart. 
Zoals je hebt gemerkt was dit project voor mij niet altijd een makkelijke periode en voor 
jou een belasting die je er gratis bij kreeg. Als gevolg wilde je eigenlijk pas trouwen als 
“dat onderzoek” allemaal achter de rug was. Gelukkig trouwden we eerder en zijn we 
al weer twee jaar gelukkig getrouwd. Dankzij jou heb ik de moed erin gehouden. Jouw 
positieve karakter, scherpe blik, relativeringsvermogen en praktische hulp zijn leidend 
geweest in de voltooiing van dit proefschrift. Je bent zonder meer het beste wat mij is 
overkomen.
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Hendrik-Jan (Herjan) Mijderwijk was born on December 22nd, 1988 in Driebruggen, the 
Netherlands. After graduating from secondary school (Gymnasium, Nature&Health, 
Willem van Oranje College, Waalwijk) in 2007, he started his medical training at the 
Erasmus University Medical Center in Rotterdam. Next to following the ordinary study 
of medicine, he also started a Master of Science (MSc) program in Clinical Research at 
the Netherlands Institute of Health Sciences in 2009. During this program he received 
training particularly in epidemiology and biostatistics. In 2011 he attended the Graduate 
Summer Institute of Epidemiology and Biostatistics at the Johns Hopkins Bloomberg 
School of Public Health, Baltimore, Maryland, USA. In the context of his MSc he started 
with the design and conduction of a Randomized Placebo Controlled Clinical Trial at 
the Day-Case Surgery department of the Erasmus MC in close collaboration and under 
the supervision of Prof. dr. R.J. Stolker, dr. M. Klimek, and dr. H.J. Duivenvoorden. Data 
collection and data analysis from patients treated at the Day-Case Surgery department 
formed the basis of the current thesis. In 2012 an MSc degree in Clinical Research was 
obtained. He was awarded a Royal Netherlands Academy of Arts and Sciences (KNAW) 
Academy Assistantship and a KNAW Research Traffic Grant for his scientific work. The 
latter was used, together with a grant from the Stichting Prof. Michael-van Vloten 
Fonds, for a clinical neurosurgical internship at the National Hospital for Neurology and 
Neurosurgery, London, UK in 2014. Subsequently, in the same year, he obtained cum 
laude his medical degree. From that point on he works as a medical doctor aiming for 
a training position in Neurosurgery. He became a registered epidemiologist in 2015. 
Besides his medical studies and work he continued his scientific research that has led 
to this PhD candidacy and this thesis entitled: Medical Decision Making in Day-Case 
Surgery.
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DE COVER
De cover toont een onopgeloste Rubik’s 
Cube toegepast op dit proefschrift.
Wetenschappelijk onderzoek begint met 
een onopgelost vraagstuk. Om tot een 
oplossing te komen moet er, net als bij 
een Rubik’s Cube, veel worden gepoogd, 
gewikt en gewogen. Perspectieven kunnen 
gaandeweg veranderen. Soms moet 
worden teruggedraaid om een andere 
route in te slaan. Eén passende zijde leidt 
nog niet tot een opgeloste Rubik’s Cube. 
De oplossing van een wetenschappelijk 
vraagstuk vereist vaak ook een passende 
multidimensionale benadering.
De toegepaste Rubik’s Cube in dit 
proefschrift bevat zes afbeeldingen 
die de inhoud van het proefschrift 
representeren. Aan het begin staan alle 
zijden nog door elkaar. Echter, gedurende 
het project wordt steeds duidelijker 
hoe de hoofdstukken zich tot elkaar 
verhouden. De Rubik’s Cube lost zich 
meer en meer op, maar is bewust nog niet 
voltooid. Dit proefschrift is dan afgerond, 
de volledige oplossing is nog niet daar. 
Gelukkig, want:
       
 
It is not knowledge, but the act of learning,
not possession but the act of getting there,
which grants the greatest enjoyment.
                                                    - Carl Friedrich Gauss (1777 - 1855)
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